mrsn_Current_Folio

0001558370-18-009290.txt : 20181113 0001558370-18-009290.hdr.sgml : 20181113 20181113171423 ACCESSION NUMBER: 0001558370-18-009290 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181113 DATE AS OF CHANGE: 20181113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mersana Therapeutics, Inc. CENTRAL INDEX KEY: 0001442836 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38129 FILM NUMBER: 181179067 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-498-0020 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC DATE OF NAME CHANGE: 20080813 10-Q 1 mrsn-20180930x10q.htm 10-Q mrsn_Current_Folio_10Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10‑Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-38129

Mersana Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		04‑3562403
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

840 Memorial Drive Cambridge, MA 02139

(Address of principal executive offices)

(Zip Code)

(617) 498‑0020

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐ No ☒.

There were 23,182,472 shares of Common Stock ($0.0001 par value per share) outstanding as of November 12, 2018.

Table of Contents

Unless otherwise stated or the context requires otherwise, all references to “us,” “our,” “we,” the “Company” and similar designations in this Quarterly Report on Form 10-Q refer to Mersana Therapeutics, Inc. and its consolidated subsidiary, Mersana Securities Corp.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward‑looking statements. Forward‑looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. The words “anticipate,” “believe,” “estimate,” “expect,” “goal,” “intend,” “may,” “seek,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “possible,” “could,” “should,” “continue,” “contemplate” or the negative of these terms or other similar expressions are intended to identify forward‑looking statements, although not all forward‑looking statements contain these identifying words.

These forward‑looking statements include, among other things, statements about:

the initiation, cost, timing, progress and results of our current and future research and development activities, preclinical studies and clinical trials;

the potential benefits of strategic partnership agreements and our ability to enter into selective strategic partnership arrangements;

the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates;

our ability to quickly and efficiently identify and develop additional product candidates;

our ability to advance any product candidate into, and successfully complete, clinical trials;

our intellectual property position, including with respect to our trade secrets; and

our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected cash resources and our need for additional financing.

We may not actually achieve the plans, intentions or expectations disclosed in our forward‑looking statements, and you should not place undue reliance on our forward‑looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward‑looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in the “Risk Factors” section, that we believe could cause actual results or events to differ materially from the forward‑looking statements that we make. Our forward‑looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

The forward‑looking statements contained herein represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments may cause our views to change. However, although we may elect to update these forward‑looking statements at some point in the future, we have no current intention of doing so, except to the extent required by applicable law. You should, therefore, not rely on these forward‑looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

Table of Contents

TABLE OF CONTENTS


	Page
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)
Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017	4
Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2018 and 2017	5
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017	6
Notes to Condensed Consolidated Financial Statements	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3. Quantitative and Qualitative Disclosures About Market Risk	37
Item 4. Controls and Procedures	37
PART II - OTHER INFORMATION	38
Item 1. Legal Proceedings	38
Item 1A. Risk Factors	38
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	39
Item 6. Exhibits	40
Signatures	41

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Mersana Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share data)


	September 30,		December 31,
	2018		2017
Assets
Current assets:
Cash and cash equivalents	$	61,604	$	26,591
Short-term marketable securities		24,455		88,143
Accounts receivable		586		784
Prepaid expenses and other current assets		3,404		2,025
Total current assets		90,049		117,543
Property and equipment, net		2,525		2,319
Long-term marketable securities		—		10,482
Other assets		1,804		371
Total assets	$	94,378	$	130,715
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	6,729	$	3,070
Accrued expenses		10,512		6,944
Deferred rent		48		232
Deferred revenue		14,151		21,635
Total current liabilities		31,440		31,881
Deferred rent, net of current portion		328		67
Deferred revenue, net of current portion		32,756		28,773
Total liabilities		64,524		60,721
Commitments (Note 9)
Stockholders' equity
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively		—		—
Common stock, $0.0001 par value; 175,000,000 shares authorized; 23,160,875 and 22,765,017 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively		3		3
Additional paid-in capital		171,627		168,018
Accumulated other comprehensive loss		(42)		(149)
Accumulated deficit		(141,734)		(97,878)
Total stockholders’ equity		29,854		69,994
Total liabilities and stockholders’ equity	$	94,378	$	130,715

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Mersana Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share and per share data)


	Three months ended				Nine months ended
	September 30,				September 30,
		2018		2017		2018		2017

Collaboration revenue	$	2,151	$	6,267	$	9,405	$	14,284
Operating expenses:
Research and development		15,180		11,412		40,098		32,145
General and administrative		4,380		2,905		12,181		7,406
Total operating expenses		19,560		14,317		52,279		39,551
Other income:
Interest income		340		318		1,049		527
Total other income		340		318		1,049		527
Net loss		(17,069)		(7,732)		(41,825)		(24,740)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities		48		(6)		107		(15)
Comprehensive loss	$	(17,021)	$	(7,738)	$	(41,718)	$	(24,755)
Net loss attributable to common stockholders — basic and diluted	$	(17,069)	$	(7,732)	$	(41,825)	$	(24,740)
Net loss per share attributable to common stockholders — basic and diluted	$	(0.74)	$	(0.35)	$	(1.82)	$	(2.94)
Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted		23,152,019		22,242,129		22,979,516		8,407,541

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Mersana Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)


	Nine months ended
	September 30,
	2018		2017
Cash flows from operating activities
Net loss	$	(41,825)	$	(24,740)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		907		673
Loss on disposal of fixed assets		20		—
Net amortization of premiums and discounts on investments		(288)		(118)
Stock-based compensation		2,756		990
Change in deferred rent		77		(115)
Changes in operating assets and liabilities:
Accounts receivable		198		320
Prepaid expenses and other current assets		(1,379)		(1,791)
Other assets		(1,433)		47
Accounts payable		3,619		1,112
Accrued expenses		3,568		1,132
Deferred revenue		(5,532)		(9,193)
Net cash used in operating activities		(39,312)		(31,683)

Cash flows from investing activities
Maturities of marketable securities		74,565		25,320
Purchase of property and equipment		(1,093)		(433)
Purchase of marketable securities		—		(111,321)
Net cash provided by (used in) investing activities		73,472		(86,434)

Cash flows from financing activities
Net proceeds from initial public offering		—		67,420
Net proceeds from issuance of common stock upon partial exercise of overallotment		—		725
Proceeds from exercise of stock options		853		431
Net cash provided by financing activities		853		68,576

Increase (decrease) in cash, cash equivalents and restricted cash		35,013		(49,541)
Cash, cash equivalents and restricted cash, beginning of period		26,962		100,668
Cash, cash equivalents and restricted cash, end of period	$	61,975	$	51,127

Supplemental disclosures of non-cash activities:
Conversion of preferred stock to common stock upon closing of initial public offering	$	—	$	94,450
Purchases of property and equipment included in accounts payable and accrued expenses	$	75	$	82
Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606	$	2,031	$	—

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements

(unaudited)

(in thousands, except share and per share data)

1. Nature of business and basis of presentation

Mersana Therapeutics, Inc. is a clinical stage company located in Cambridge, Massachusetts. The Company is advancing a proprietary pipeline of targeted oncology therapeutics leveraging multiple proprietary platforms, including its Dolaflexin® antibody drug conjugate (ADC) platform. The Company’s first product candidate, XMT-1522, an ADC designed to address a much broader population of patients with HER2-antigen expressing tumors than served by currently approved HER2 therapies, is currently in a Phase 1 dose escalation study. The Company’s second clinical stage product candidate, XMT-1536, an ADC targeting NaPi2b, an antigen broadly expressed in certain types of cancer, is also in a Phase 1 dose escalation study. In addition, the Company has established a strategic partnership with Takeda Pharmaceutical Company Limited (Takeda) under which Takeda obtained rights to XMT‑1522 outside of the United States and Canada. The Company has also established strategic research and development partnerships with Takeda and Merck KGaA for the development and commercialization of additional ADC product candidates against a limited number of targets selected by the Company’s partners based on the Company’s Dolaflexin platform. The Company has other earlier stage platforms, including Dolasynthen and Alkymer and is developing an ADC platform for immuno-oncology indications.

The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.

On September 17, 2018, the Company announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold that had been imposed on the Phase 1 study of XMT-1522 that was announced on July 19, 2018. As part of its plan to resume dosing in the study, the Company made changes to the study protocol, including a once-every-four-week dosing regimen, increased monitoring and exclusion of patients with advanced hepatic impairment. The partial clinical hold, the protocol changes and the approval process for the protocol changes have resulted in a change in the expected timeline for clinical results for XMT-1522. Selection of a recommended Phase 2 dose is expected in mid-2019.

On July 3, 2017, the Company completed an initial public offering (IPO), in which the Company issued and sold 5,000,000 shares of its common stock at a public offering price of $15.00 per share, for aggregate gross proceeds of $75,000. The Company received $67,420 in net proceeds after deducting $7,580 of underwriting discounts and commissions and offering costs. On August 2, 2017, the Company issued and sold 51,977 shares of common stock at $15.00 per share for gross proceeds of $780 upon the partial exercise of the underwriters’ overallotment option. The Company received net proceeds of $725 after deducting $55 in underwriting discounts and commissions.

In connection with preparing for the IPO, the Company effected a 1-for-4.5 reverse stock split of the Company’s common stock. The reverse stock split became effective on June 15, 2017. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. All share and per share amounts in the financial statements and the notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.

The Company has incurred net losses since inception. The Company’s net loss was $41,825 for the nine months ended September 30, 2018 and $38,707 for the year ended December 31, 2017. The Company expects to continue to incur operating losses for at least the next several years. As of September 30, 2018, the Company had an accumulated deficit of $141,734. The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. The Company’s net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company’s stockholders' deficit and working capital. The Company believes that its existing cash, cash equivalents and marketable

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

securities as of September 30, 2018, will enable it to fund its current operating plan for at least the next twelve months, which the Company expects will allow it to achieve initial clinical data readouts for its two clinical stage development programs, select recommended Phase 2 doses and continue to advance its earlier assets.

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2017 and the notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 28, 2018.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of September 30, 2018, the results of its operations for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017. Such adjustments are of a normal and recurring nature, other than the adjustments associated with the adoption of ASC Topic 606, Revenue from Contracts with Customers (Topic 606). The results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results for the year ending December 31, 2018, or for any future period.

Effective January 1, 2018, the Company adopted the requirements of Topic 606 using the modified retrospective method as discussed below in Note 2: Summary of Significant Accounting Policies. All 2018 amounts and disclosures set forth in this Quarterly Report on Form 10-Q reflect these changes.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include those of the Company and its subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.

Use of Estimates

The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, management’s judgments with respect to the performance obligations and estimated selling prices within its revenue arrangements, accrued expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.

The Company utilized significant estimates and assumptions in determining the fair value of its common stock prior to the Company’s IPO. The Company has utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately‑Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company's chief operating decision-maker, the Company's chief executive officer, view the Company's operations and manage its business as a single operating segment, which is the business of discovering and developing ADCs.

Research and Development

The Company expenses all costs incurred in performing research and development activities. Research and development expenses include salaries and benefits, materials and supplies, preclinical expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. Costs of certain development activities, such as manufacturing, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs associated with collaboration agreements are included in research and development expense.

Revenue Recognition

Effective January 1, 2018, the Company adopted the provisions of Topic 606, using the modified retrospective transition method. Under this method, the Company recorded the cumulative effect of initially applying the new standard to all contracts in process as of the date of adoption. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.

The adoption of the new revenue recognition guidance resulted in increases of $2,031 in deferred revenue and accumulated deficit as of January 1, 2018. For the three months ended September 30, 2018, revenue increased by $2, net loss decreased by $2 and basic and diluted net loss per share decreased by $0.00, based on revenue recognition under Topic 606 as compared to the Company’s prior revenue recognition methodology under ASC 605 Revenue Recognition. For the nine months ended September 30, 2018, revenue decreased by $570, net loss increased by $570 and basic and diluted net loss per share increased by $0.02, based on revenue recognition under Topic 606 as compared to the Company’s prior revenue recognition methodology under ASC 605 Revenue Recognition. These changes were primarily caused by the differences in determining and allocating transaction price under Topic 606.

The Company enters into collaboration agreements which are within the scope of Topic 606, under which the Company licenses rights to its technology and certain of the Company’s product candidates and performs research and development services for third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.

The promised good or services in the Company’s arrangement typically consist of license rights to the Company’s intellectual property and research and development services. The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised good or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.

The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include both fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method better predicts the amount expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services or any significant difference is due to factors other than financing; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.

The Company’s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is not probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are not included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company’s collaboration arrangements.

The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.

For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.

The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30 day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.

Collaborative Arrangements

The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808, Collaborative Arrangements (ASC 808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company considers the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.

Fair Value Measurements

Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820 Fair Value Measurement (ASC 820) establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

Level 1—Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2—Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level 3—Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.

The following amounts were presented as cash, cash equivalents and restricted cash:


	Nine months ended				Nine months ended
	September 30, 2018				September 30, 2017
	Beginning		End		Beginning		End
	of period		of period		of period		of period
Cash and cash equivalents	$	26,591	$	61,604	$	100,297	$	50,756
Restricted cash included in other assets		371		371		371		371
Total cash, cash equivalents and restricted cash per statement of cash flows	$	26,962	$	61,975	$	100,668	$	51,127

Marketable Securities

Short-term marketable securities consist of investments with maturities greater than three months and less than one year from the balance sheet date. Long-term marketable securities consist of investments with maturities greater than one year that are not expected to be used to fund current operations. The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Amortization and accretion of discounts and premiums are recorded as interest income within other income. Unrealized gains and losses on available-for-sale securities are included in other comprehensive loss as a component of stockholders’ equity until realized.

Other Assets

The Company recorded other assets of $1,804 and $371 as of September 30, 2018 and December 31, 2017, respectively. The September 30, 2018 amount is comprised of restricted cash of $371 held as security deposits for a standby letter of credit related to a facility lease and a corporate credit card program and $1,433 held by a service provider. The December 31, 2017 amount is comprised of restricted cash.

Accounting for Stock-based Compensation

The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation—Stock Compensation (ASC 718). ASC 718 requires all stock-based payments to employees and directors to be recognized as expense in the statements of operations based on their grant date fair values. Expense related to stock awards to non-employees is required to be recognized in the statement of operations based on the awards' vesting date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model.

The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate and (iv) the expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the IPO and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.

There were significant judgments and estimates inherent in the determination of the fair value of our common stock prior to the closing of the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an IPO or sale.

In the first quarter of 2017, the Company made an accounting policy election to recognize forfeitures as they occur upon adoption of guidance per ASU No. 2016-09. The adoption of this ASU did not have a material impact on the Company's financial statements.

Net Loss per Share

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods.

For purposes of the diluted net loss per share calculation, convertible preferred stock, warrants to purchase common stock and options to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):


	Three months ended		Nine months ended
	September 30,		September 30,
	2018	2017	2018	2017
Warrants	110,365	129,491	110,365	129,491
Stock options	3,670,680	3,205,714	3,670,680	3,205,714
	3,781,045	3,335,205	3,781,045	3,335,205

Patent Costs

The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations.

Income Taxes

The Company accounts for income taxes using the liability method. The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

Comprehensive Income (Loss)

Comprehensive income (loss) is comprised of net loss and other comprehensive income (loss). For the three and nine months ended September 30, 2018 and 2017, other comprehensive loss consisted of unrealized gain (loss) on marketable securities.

Concentration of Credit Risk and Off-Balance Sheet Risk

The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. Cash, cash equivalents, and marketable securities are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk.

Recently Issued Accounting Pronouncements

In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments (ASU No. 2016-01) related to the recording of financial assets and financial liabilities. Under the amended guidance, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) are to be measured at fair value with changes in fair value recognized in net income (loss). However, an entity has the option to measure equity investments without readily determinable fair values either (i) at fair value or (ii) at cost, adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative will be recognized in net income (loss). The amended guidance became effective January 1, 2018. The Company adopted the new standard effective January 1, 2018. Based on the Company’s current investment holdings, the adoption of this new standard did not have a material impact on its consolidated financial position or results of operations.

In February 2016, the FASB issued ASU No. 2016-02, Leases (ASU No. 2016-02), which will replace the existing guidance in ASC 840, Leases. The updated standard aims to increase transparency and comparability among organizations by requiring lessees to recognize lease assets and lease liabilities on the balance sheet and requiring disclosure of key information about leasing arrangements. This standard is effective for the Company in the fiscal year beginning after December 15, 2018, but early adoption is permissible. The Company is currently evaluating the potential impact that ASU No. 2016-02 may have on its financial position and results of operations.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of contingent consideration payments made after a business combination and several other clarifications not currently applicable to the Company. The new standard also clarifies that an entity should determine each separately identifiable source or use within cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The Company adopted the new standard effective January 1, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated statement of cash flows.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows: Restricted Cash (ASU No. 2016-18). The amendments in this update require that amounts generally described as restricted cash and restricted cash equivalents be included within cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The Company adopted the new standard effective January 1, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated statement of cash flows.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting. This guidance is intended to provide clarity and reduce diversity in practice as to when changes to the terms or conditions of share-based payments are accounted for as modifications. Under this new guidance, entities will apply modification accounting if the fair value, vesting conditions or classification of the award changes. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2017-09 is to be adopted prospectively to an award modified on or after the adoption date. The Company adopted the new standard effective January 1, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated statement of cash flows.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808):Clarifying the Interaction between Topic 808 and Topic 606. The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-18 is to be adopted retrospectively to the date of initial application of Topic 606. The Company is currently evaluating the potential impact that ASU No. 2018-18 may have on its financial position and results of operations.

3. Collaboration agreements

Takeda XMT-1522 strategic partnership

In January 2016, the Company entered into a Development Collaboration and Commercial License Agreement with Takeda through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc. for the development and commercialization of XMT-1522 (the XMT-1522 Agreement). Under the XMT-1522 Agreement, Takeda was granted the exclusive right to commercialize XMT-1522 outside of the United States and Canada. Under the XMT-1522 Agreement, the Company is responsible for conducting certain Phase 1 development activities for XMT-1522, including the ongoing Phase 1 clinical study, at its own expense. Takeda has the option to conduct Phase 1 development activities at its own expense within its territory. The parties agreed to collaborate on the further development of XMT-1522 in accordance with a global development plan (Post-Phase 1 Development). The parties agreed to share equally all clinical stage manufacturing costs and any Post-Phase 1 Development costs incurred in the performance of activities for the purpose of obtaining regulatory approval in either the United States or Canada and in certain other major markets in the rest of the world. Each party will be responsible for all Post-Phase 1 Development costs incurred in the performance of activities solely for the purpose of obtaining regulatory approval in such party's territory. Each party may conduct independent development of XMT-1522, subject to certain restrictions.

The Company received an upfront payment of $26,500 upon execution of the XMT-1522 Agreement. In addition, the Company was entitled to a milestone payment of $20,000 upon achievement of the IND Clearance Date (as defined therein). The Company achieved the IND Clearance Date in October 2016.

In addition to the milestone payment upon achievement of the IND Clearance Date, the Company is entitled to receive future development, regulatory and commercial milestones of up to $288,000, consisting of $87,000 of development milestones, $128,000 of regulatory milestones and $73,000 of commercial milestones, as well as royalties in the low to mid teens on net sales of XMT-1522 in Takeda’s territory during the applicable royalty term. There are development milestones payable upon the achievement of nine separate events: the initiation of Phase 2 clinical trials and Phase 3 clinical trials for four separate specified patient populations and the initiation of a Phase 3 clinical trial for one additional unspecified patient population. There are 14 regulatory milestones, which are payable upon regulatory submissions, regulatory approvals and pricing approvals, as applicable, for the U.S., European Union and Japanese markets for up to four separate patient populations and multiple label indications. In addition, a regulatory milestone is payable upon the receipt of regulatory and pricing approval in two specified markets other than the United States, the European Union or

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

Japan. There are three individual commercial milestones, which are payable upon the attainment of certain thresholds for annual net sales. The next potential milestone the Company will be eligible to receive is a development milestone of $12,000 related to the initiation of a Phase 2 clinical trial.

The XMT-1522 Agreement expires upon the expiration of the royalty term for XMT-1522, after which time, Takeda will have a perpetual, royalty-free license. However, Takeda may terminate the XMT-1522 Agreement in its entirety for convenience upon 30 days' prior written notice at any time up to the initiation of the first Phase 2 clinical study of XMT-1522 or upon 90 days' prior written notice following the initiation of the first Phase 2 clinical study of XMT-1522. Each party may terminate the XMT-1522 Agreement in its entirety upon bankruptcy or similar proceedings of the other party and in its entirety or on a country-by-country basis upon an uncured material breach of the agreement by the other party. Following termination, XMT-1522 will revert to the Company for further development and commercialization.

Takeda strategic research and development partnership

In March 2014, the Company entered into a Research Collaboration and Commercial License Agreement with Takeda through Takeda’s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (the 2014 Agreement). The 2014 Agreement was amended in January 2015 and amended and restated in January 2016 (the 2016 Restated Agreement). The agreements initially provided Takeda with the right to develop ADCs directed to a total of seven exclusive targets, designated by Takeda, over a specified period of time. Takeda will be responsible for the product development and marketing of any products resulting from this collaboration. To date, the Company has received $24,800 in non-refundable upfront fees, technology access fees or option exercise fees.

For the two targets initially under the 2014 Agreement, the Company initially granted a research license upon designation of a target. To receive a development and commercialization license for these designated targets, Takeda was required to pay an additional option exercise fee of $1,300. For the remaining five targets, the Company grants a research, development and commercialization license upon the designation of a target.

For each designated target, the Company and Takeda develop research plans to evaluate Takeda's antibodies as ADCs incorporating the Company's technology. The Company receives service fees for its efforts under the research plans. The goal of the research plans is to provide Takeda with sufficient information to formally nominate a development candidate and begin Investigational New Drug Application (IND), enabling studies or cease development on the designated target.

As of September 30, 2018, Takeda had designated four targets and received development and commercialization licenses for the first, third and fourth designated targets and a research license for the second designated target. Takeda has limited replacement rights for two designated targets, subject to certain contractual restrictions. Takeda is required to pay $500 to utilize the second limited replacement right.

As of September 30, 2018, if products are successfully developed and commercialized, the Company would be entitled to receive aggregate milestones of up to $474,750 for all eligible designated targets consisting of $50,250 in development milestones, $153,000 in regulatory milestones, and $271,500 in commercial milestones. The total milestones payable on each of the remaining eligible three targets are $158,250. There are four individual development milestones per target, which are payable upon the filing of an IND application and the initiation of Phase 1 through Phase 3 clinical trials. There are eight individual regulatory milestones per target. These are payable upon regulatory submissions, regulatory approvals and pricing approvals, as applicable, for the U.S., European Union and Japanese markets and regulatory approvals for both a second and third indication. There are six individual commercial milestones, which are payable upon the first commercial sale in each of the U.S., European Union and Japanese markets and upon the attainment of three separate defined thresholds for annual net sales. The next potential milestone payment the Company will be eligible to receive is a development milestone of $750 related to the filing of an IND. The Company is also entitled to receive royalties on product sales, if any, during the applicable royalty term. Royalties payable on the remaining designated targets are in the mid to high single digits.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

The Company may elect to exercise an option to co-develop and co-commercialize one product incorporating either Takeda's fifth, sixth or seventh target in the United States for a payment of $15,000. If the Company elects to exercise the option to co-develop and co-commercialize a product, the Company will share in 50% of the profits related to the United States. The Company will be responsible for 50% of costs incurred specifically for the United States and 30% of global development costs. Any costs incurred specifically for a foreign country will be borne 100% by Takeda. If the Company elects to co-develop and co-commercialize a product, certain regulatory milestones and royalties related to the United States for that target would not be paid by Takeda.

Unless earlier terminated, the 2016 Restated Agreement will expire upon the expiration of the last royalty term for a product under the agreement, after which time, Takeda will have a perpetual, royalty-free license. Except with respect to the target antigen of a product for which the Company exercised its option to co-develop and co-commercialize in the United States, Takeda may terminate the 2016 Restated Agreement in its entirety or with respect to any target for convenience upon 45 days' prior written notice. Each party may terminate the 2016 Restated Agreement in its entirety upon bankruptcy or similar proceedings of the other party or upon an uncured material breach of the agreement by the other party. However, if such breach only relates to one target, the agreement may only be terminated with respect to such target.

Accounting Analysis

For periods prior to January 1, 2018, the Company applied the provisions of ASC 605 in accounting for these arrangements. Refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 28, 2018 for the accounting analysis under these provisions.

Under ASC 605 and Topic 606, the Company has concluded that the 2016 Restated Agreement and the XMT-1522 Agreement should be accounted for as one arrangement due in part because the agreements are with the same party and were negotiated and executed contemporaneously. Further, in applying the contract modification practical expedient, the Company has aggregated the effect of all modifications through the initial date of application of Topic 606 for the purposes of (i) identifying the satisfied and unsatisfied performance obligations, (ii) determining the transaction price and (iii) allocating the transaction price to the satisfied and unsatisfied performance obligations.

The performance obligations and the allocated transaction price as of the date of initial application of Topic 606 are as follows:


	Allocated
Performance obligations	Transaction Price
XMT-1522 license and research services	$	49,828
Joint research committee services for XMT-1522		449
Exclusive license to the first designated target and research services		6,611
Research license to the second designated target and research services		1,017
Material right related to the exclusive license to the second designated target		526
Exclusive license to the third designated target and research services		4,974
Exclusive license to the fourth designated target and research services		3,678
Material right related to the license to the fifth designated target and research services		3,506
Material right related to the license to the sixth designated target and research services		3,506
Material right to license to the seventh designated target and research services		3,506
Material right related to first replacement right for a designated target		3,506
Material right related to the second replacement right to a designated target		3,116
Rights to future technological improvements		1,750
Joint research committee services		150
	$	86,123

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

The Company has concluded the license related to each of the designated targets is not distinct from the research services performed related to each of the designated targets as Takeda cannot obtain the benefit of the license without the related research services. Each license to a designated target and the related services performance obligation is considered distinct from every other license to a designated target and related services performance obligation as each research plan is pursued independent of the any other research plans for other designated targets. Further, the material rights provided in the agreement provide Takeda incremental rights for either no additional consideration or for additional fees that contain a significant discount. The material rights are distinct from the other performance obligations in the arrangement as they are options in the contract and are not required for Takeda to obtain the benefit of the other promised goods or services in the arrangement.

Similarly, the Company concluded that the XMT-1522 license and the related research and development services, including the Phase 1 development and the transfer certain materials and know how related to the Company's manufacturing processes are one performance obligation. The license to the Company's intellectual property is not distinct from the research and related development services that the Company is obligated to perform. Takeda would not have the ability to realize the value of the license without the Company performing the related services.

The Company has concluded that the Post-Phase 1 Development activities under the XMT-1522 Agreement represent joint operating activities in which both parties are active participants and of which both parties are exposed to significant risks and rewards that are dependent on the commercial success of the activities. Accordingly, the Company is accounting for the Post-Phase 1 Development activities in accordance with ASC 808 and they are not considered revenue elements under Topic 606. For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company was billed approximately $2,210, $924, $5,013 and $1,719, respectively, from Takeda representing the Company's share of Post-Phase 1 Development costs incurred by Takeda. These amounts have been reflected as research and development costs in the consolidated statement of operations. The Company did not perform any Post-Phase 1 Development activities or incur any associated costs prior to January 1, 2018. During the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company billed Takeda $1,165, $0, $2,959 and $0, respectively, related to ASC 808 costs.

As of the date of initial application of Topic 606, the total transaction price for the 2016 Restated Agreement and the XMT-1522 Agreement was $86,123, which included approximately $14,023 of fees associated with research and development activities which had been or were expected to be provided. The Company utilizes the expected value approach to estimate the amount of consideration related to the fees associated with development and research services. The Company utilizes the most likely amount approach to estimate any development and regulatory milestone payments to be received. As of the date of initial application of Topic 606, there were no milestone payments, which had not been received, included in the estimated transaction price. The Company considered the stage of development and the remaining risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Takeda. The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be achieved. The Company has determined that any commercial milestones and sales based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. In the third quarter of 2018, the Company revised its estimate for fees associated with research and development activities under the XMT-1522 Agreement to $9,755. The revised total transaction price for the 2016 Restated Agreement and the XMT-1522 Agreement is $86,429.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

rights received and any fees payable upon exercise of the associated option, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology or exercise the option. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees.

The Company will recognize revenue related to the performance obligations, which include research licenses or an exclusive development and commercialization license and the related research services, over the estimated period of the research and development services using a proportional performance model. The Company measures proportional performance based on the costs incurred relative to the total estimated costs of the research. To the extent that the Company receives fees for the research services as they are performed, these amounts are recorded as deferred revenue. Revenue related to material rights will be recognized when the option is exercised, unless there are additional research services that the Company is required to perform related to the designated target (in which case revenue will be recognized based on the proportional performance model) or at the time the option right lapses. To the extent that the Company receives a fee upon exercise of the option, such amounts are recorded as deferred revenue. Revenue related to the material rights related to replacement rights will be recognized over the research term of the replacement target once the replacement right is exercised or at the time the right lapses unused. To the extent that the Company receives a fee upon exercise of the replacement right, such amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the performance period (which in the case of the joint research committee services approximates the time and cost incurred), which is expected to be ten years and six years, respectively. The Company will reassess the estimated remaining term at each subsequent reporting period.

For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company recorded total revenue of $82, $5,768, $4,697 and $12,052, respectively, related to its efforts under the 2016 Restated Agreement and the XMT-1522 Agreement. Included in accounts receivable as of September 30, 2018 and December 31, 2017 was $32 and $454, respectively, related to the Takeda agreements. Included in accounts payable as of September 30, 2018 was $530 related to the Takeda agreements. During the quarter ended September 30, 2018, the Company revised its estimate of the total costs to complete research services under the 2016 Restated Agreement and the XMT-1522 Agreement, which changed the total consideration to be received under the agreements and the amount of revenue recognized in the three months and nine months ended September 30, 2018. The Company recognized approximately $1,380 less for the three months and nine months ended September 30, 2018 as a result of the Company’s change in estimate. The change in estimate increased the net loss by $1,380 for the three months and nine months ended September 30, 2018, or $0.06 per common share.

As of September 30, 2018, the Company had $41,104 of deferred revenue related to the Takeda agreements that will be recognized over the remaining performance periods for the applicable obligations.

Takeda invested $10,000 as part of the Company’s IPO.

Merck KGaA

In June 2014, the Company entered into a Collaboration and Commercial License Agreement with Merck KGaA (the Merck KGaA Agreement). Upon the execution of the agreement, Merck KGaA paid the Company a nonrefundable technology access fee of $12,000 for the right to develop ADCs directed to six exclusive targets over a specified period of time. No additional fees are due when a target is designated and the commercial license to the target is granted. Merck KGaA will be responsible for the product development and marketing of any products resulting from this collaboration. All six targets were designated prior to 2018.

Under the terms of the agreement, the Company and Merck KGaA develop research plans to evaluate Merck KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives fees for its efforts under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to formally nominate a development candidate and begin IND-enabling studies or cease development on the designated target.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

In addition to the payments received for research and development activities performed on behalf of Merck KGaA, the Company is also eligible to receive up to a total of $780,000 in future milestones related to all targets under the agreement, plus low to mid single digit royalties on the commercial sales of any resulting products during the applicable royalty term. The total milestones are categorized as follows: development milestones—$84,000; regulatory milestones—$264,000; and sales milestones—$432,000. There are six individual development milestones per target, payable upon the completion of various activities from the delivery of ADCs meeting defined specifications, through the dosing in a Phase 3 clinical trial. There are five regulatory milestones, which are payable upon regulatory approvals for a first indication in each of the U.S., European Union and Japanese markets and regulatory approvals for both a second and a third indication in the United States. There are three individual commercial milestones, which are payable upon the attainment of certain defined thresholds for annual net sales.

Prior to 2018, the Company had received $3,000 related to development milestones under the agreement. There have been no additional milestone payments in the nine months ended September 30, 2018. The next potential milestone payment the Company will be eligible to receive will be a development milestone of $500 on Merck KGaA's designation of a preclinical development candidate for any target. Revenue will be recognized upon achievement of the milestone. The Company and Merck KGaA may also enter into a future supply agreement to provide clinical study material should Merck KGaA pursue clinical development of any candidates nominated under the agreement.

Unless earlier terminated, the agreement will expire upon the expiration of the last royalty term for a product under the agreement, after which time, Merck KGaA will have a perpetual, royalty-free license, or if Merck KGaA does not designate any ADC product candidates produced by the Company under the agreement as preclinical development candidates, upon the expiration of the last to expire research program. Merck KGaA may terminate the agreement in its entirety or with respect to any target for convenience upon 60 days' prior written notice. Each party may terminate the Merck KGaA Agreement in its entirety upon bankruptcy or similar proceedings of the other party or upon an uncured material breach of the agreement by the other party. However, if such breach only relates to one target, the agreement may only be terminated with respect to such target.

In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the Merck KGaA Supply Agreement). Under the terms of the agreement, the Company will provide Merck KGaA preclinical non-GMP ADC Drug Substance and clinical GMP Drug Substance for use in clinical trials associated with one of the antibodies designated under the Merck KGaA Agreement. The Company receives fees for its efforts under the Merck KGaA Supply Agreement and reimbursement equal to the supply cost.

Accounting Analysis

For periods prior to January 1, 2018, the Company applied the provisions of ASC 605 in accounting for this arrangement. Refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 28, 2018 for the accounting analysis under these provisions.

By applying the contract modification practical expedient, the Company has aggregated the effect of all modifications through the initial date of application of Topic 606 for the purposes of (i) identifying the satisfied and unsatisfied performance obligations, (ii) determining the transaction price and (iii) allocating the transaction price to the satisfied and unsatisfied performance obligations.

The Company identified the following performance obligations under the agreement: (i) exclusive license and research services for six designated targets, (ii) rights to future technological improvements and (iii) participation of project team leaders and providing joint research committee services.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

every other license for a designated target and related services performance obligation as each research plan is pursued independent of every other research plans for other designated targets.

As of the date of initial application of Topic 606, the total transaction price for the Merck KGaA Agreement was $22,875, which included approximately $7,875 fees for research and development activities which have been or were expected to be received and $3,000 of milestone payments previously earned. The Company utilizes the expected value approach to estimate the amount of consideration related to the payment of fees associated with development and research services. The Company utilizes the most likely amount approach to estimate any development and regulatory milestone payments to be received. As of the date of initial application of Topic 606, there were no milestones payments that had not already been received, included in the estimated transaction price. The Company considered the stage of development and the remaining risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Merck KGaA. The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be achieved. The Company has determined that any commercial milestones and sales based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. For each of the three and nine months ended September 30, 2018, the transaction price decreased $805 to $22,070 due to a decrease in fees for research and development activities expected to be received, as the Company revised its estimate for fees associated with research and development activities under the Merck KGaA Agreement in the third quarter of 2018 to $7,070. The revised total transaction price for the Merck KGaA Agreement is $22,070.

The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation or in the case of certain variable consideration to one or more performance obligations. The estimated standalone selling prices for performance obligations, that include a license and research services, were developed using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an estimated market rate for research services. The estimated standalone selling price of the licenses was established based on comparable transactions. The estimated standalone selling price for the rights to future technological improvements was developed based on the estimated selling prices of a license or rights received, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees.

The transaction price of $22,875 was allocated to the performance obligations as follows: approximately $4,226 for each of the license and corresponding research and development services units of account for the first and second designated targets; $3,439 for each of the license and corresponding research and development services units of account for the third, fourth, fifth and sixth designated target; $425 for rights to future technological improvements; and $242 for joint research committee services.

The Company is recognizing revenue related to the exclusive license and research and development services performance obligation over the estimated period of the research and development services using a proportional performance model. The Company measures proportional performance based on the costs incurred relative to the total costs expected to be incurred. To the extent that the Company receives fees for the research services as they are preformed, these amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the performance period (which in the case of the joint research committee services approximate the time and cost incurred each period), which are 10 and 5 years, respectively. The Company is continuing to reassess the estimated remaining term at each subsequent reporting period.

During the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company recorded revenue of $1,482, $499, $2,426 and $2,107, respectively, related to its efforts under the collaboration agreement. Included in accounts receivable as of September 30, 2018 and December 31, 2017 was $163 and $330, respectively, related to the Merck KGaA Agreement.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

As of September 30, 2018, the Company had recorded $5,480 in deferred revenue related to the Merck KGaA Agreement that will be recognized over the remaining performance period.

Summary of Contract Assets and Liabilities

The following table presents changes in the balances of our contract assets and liabilities during the three and nine months ended September 30, 2018:


	Balance at
	Beginning						Balance at
	of Period		Additions		Deductions		End of Period
Three months ended September 30, 2018
Contract assets	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	48,208	$	849	$	2,151	$	46,906


	Balance at
	Beginning						Balance at
	of Period		Additions		Deductions		End of Period
Nine months ended September 30, 2018
Contract assets	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	52,439	$	2,373	$	7,906	$	46,906

The impact of the adoption of the new revenue recognition guidance is reflected within the beginning of period balance.

During the three months and nine months ended September 30, 2018, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods:


	Three months ended		Nine months ended
	September 30, 2018		September 30, 2018
Revenue recognized in the period from:
Amounts included in the contract liability at the beginning of the period	$	1,760	$	7,515
Performance obligations satisfied in previous periods	$	—	$	—

Other Revenue

The Company has provided limited services for a collaboration partner, Asana BioSciences. For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company recorded revenue of $587, $0, $782 and $125, respectively, related to these services. In addition, during the nine months ended September 30, 2018, the Company recognized revenue of $1,500 related to a milestone achieved upon the completion of a GLP toxicology study by Asana BioSciences. The next potential milestone the Company is eligible to receive is $2,500 upon dosing the fifth patient in a Phase 1 clinical study by Asana BioSciences. Included in accounts receivable as of September 30, 2018 was $391 related to the Asana agreement.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

4. Fair value measurements

The following table presents information about the Company's assets and liabilities regularly measured and carried at a fair value and indicates the level within fair value hierarchy of the valuation techniques utilized to determine such value as of September 30, 2018 and December 31, 2017:


					Significant
			Quoted Prices		Other		Significant
			in Active		Observable		Unobservable
	Fair		Markets		Inputs		Inputs
	Value		(Level 1)		(Level 2)		(Level 3)
September 30, 2018
Cash and cash equivalents	$	61,604	$	61,604	$	—	$	—
Marketable securities:
U.S. Treasuries		24,455		24,455		—		—
	$	86,059	$	86,059	$	—	$	—


					Significant
			Quoted Prices		Other		Significant
			in Active		Observable		Unobservable
	Fair		Markets		Inputs		Inputs
	Value		(Level 1)		(Level 2)		(Level 3)
December 31, 2017
Cash and cash equivalents	$	26,591	$	26,591	$	—	$	—
Marketable securities:
U.S. Treasuries		62,640		62,640		—		—
Commercial paper		24,931		—		24,931		—
Corporate bonds		11,054		—		11,054		—
	$	125,216	$	89,231	$	35,985	$	—

There were no changes in valuation techniques or transfers between fair value measurement levels during the nine months ended September 30, 2018 and 2017. As of September 30, 2018 and December 31, 2017, cash and cash equivalents were comprised of cash and money market funds.

5. Marketable securities

The following table summarizes marketable securities held at September 30, 2018 and December 31, 2017:


			Gross		Gross
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
September 30, 2018
U.S. Treasuries	$	24,497	$	—	$	(42)	$	24,455
	$	24,497	$	—	$	(42)	$	24,455


			Gross		Gross
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
December 31, 2017
U.S. Treasuries	$	62,777	$	—	$	(137)	$	62,640
Commercial paper		24,931		—		—		24,931
Corporate bonds		11,066		—		(12)		11,054
	$	98,774	$	—	$	(149)	$	98,625

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

As of September 30, 2018, the Company held 7 securities that were in an unrealized loss position. The aggregate fair value of securities held by the Company in an unrealized loss position for less than 12 months at September 30, 2018 was $24,455 and there were no securities held by the Company in an unrealized loss position for more than 12 months. As of September 30, 2018, the Company did not intend to sell, and would not be more likely than not required to sell, the securities in an unrealized loss position before recovery of their amortized cost basis. Furthermore, the Company has determined that there was no material change in the credit risk of these securities. As a result, the Company determined it did not hold any securities with any other-than-temporary impairment as of September 30, 2018.

There were no realized gains or losses on available-for-sale securities during the nine month periods ended September 30, 2018 and 2017.

6. Accrued expenses

Accrued expenses consist of the following:


	September 30,		December 31,
	2018		2017
Accrued payroll and related expenses	$	2,482	$	3,041
Accrued preclinical, manufacturing and clinical expenses		6,610		3,183
Accrued professional fees		868		492
Accrued other		552		228
	$	10,512	$	6,944

7. Stockholders’ equity

The following table presents the changes in the separate accounts comprising stockholders’ equity for the year ended December 31, 2017 and the nine months ended September 30, 2018, respectively.


				Additional		Accumulated				Stockholders’
	Common Stock			Paid-in		Other Comprehensive		Accumulated		Equity
	Shares	Amount		Capital		Income (Loss)		Deficit		(Deficit)
Balance at December 31, 2016	1,294,352	$	1	$	3,551	$	—	$	(59,171)	$	(55,619)
Change	21,470,665		2		164,467		(149)		(38,707)		125,613
Balance at December 31, 2017	22,765,017		3		168,018		(149)	$	(97,878)		69,994
Change	395,858		—		3,609		107		(43,856)		(40,140)
Balance at September 30, 2018	23,160,875	$	3	$	171,627	$	(42)	$	(141,734)	$	29,854

Preferred stock

As of September 30, 2018, the Company had 25,000,000 shares of authorized preferred stock. No shares of preferred stock have been issued.

Common stock

The holders of the common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors (the Board).

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

At September 30, 2018 and December 31, 2017, there were 3,781,045 and 3,315,850 shares of common stock, respectively, reserved for the exercise of outstanding stock options and warrants (in common stock equivalent shares).


	September 30,	December 31,
	2018	2017
Warrants	110,365	110,365
Stock options	3,670,680	3,205,485
	3,781,045	3,315,850

At-the-market equity offering program

On July 2, 2018, the Company established an at-the-market equity offering program (ATM) pursuant to which it is able to offer and sell up to $75,000 of its common stock from time to time at prevailing market prices. As of September 30, 2018, the Company had not sold any shares under the ATM.

Warrants

In connection with a 2013 Series A-1 Preferred Stock issuance, the Company granted to certain investors warrants to purchase 129,491 shares of common stock. The warrants have a $0.05 per share exercise price and a contractual life of 10 years. The fair value of these warrants was recorded as a component of equity at the time of issuance. As of September 30, 2018, warrants to purchase 110,365 shares of common stock were outstanding.

8. Stock options

Stock option plans

In June 2017 the Company’s shareholders approved the 2017 Stock Incentive Plan (the 2017 Plan or the Plan). Under the 2017 Plan, up to 2,255,000 shares of common stock may be granted to the Company's employees, officers, directors, consultants and advisors in the form of options, restricted stock awards or other stock-based awards. The number of shares of common stock issuable under the Plan will be cumulatively increased annually by 4% of the outstanding shares or such lesser amount specified by the Board. The terms of the awards are determined by the Board, subject to the provisions of the Plan. As of the adoption date of the 2017 Plan, there were 3,141,625 options outstanding under the Company’s 2007 Stock Incentive Plan (the 2007 Plan). Any cancellations under the 2007 Plan would increase the number of shares that could be granted under the 2017 Plan. On January 1, 2018, the number of shares of common stock issuable under the Plan was increased by 910,600 shares. As of September 30, 2018 there were 1,288,227 shares available for future issuance under the Plan.

With respect to incentive stock options, the option price per share will equal the fair market value of the common stock on the date of grant, as determined by the Board, and the vesting period is generally four years. Nonqualified stock options will be granted at an exercise price established by the Board at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Options granted under the Plan expire no later than 10 years from the date of grant. The Board may accelerate vesting or extend the expiration of granted options in the case of a merger, consolidation, dissolution, or liquidation of the Company.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

A summary of the activity under the Plans is as follows:


		Weighted-		Remaining
	Number	Average		Contractual Life	Aggregate
	of Shares	Exercise Price		(in years)	Intrinsic Value

Options outstanding at January 1, 2018	3,205,485	$	3.44	7.8	$	41,709
Granted	1,121,415		14.36
Exercised	(395,858)		2.17
Cancelled	(260,362)		7.86
Options outstanding at September 30, 2018	3,670,680	$	6.61	7.8	$	17,688

Options exercisable at September 30, 2018	1,822,435	$	3.24	6.9	$	12,873

The weighted-average grant date fair value of options granted during the nine months ended September 30, 2018 and 2017, was $9.45 and $5.27 per share, respectively.

Cash received from the exercise of stock options was $853 and $431 for the nine months ended September 30, 2018 and 2017, respectively.

Stock-based compensation

The Company uses the provisions of ASC 718, Stock Compensation, to account for stock-based awards.

The measurement date for employee awards is generally the date of grant. Stock-based compensation expense is recognized over the requisite service period, which is generally the vesting period, using the straight-line method.

For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company recorded stock-based compensation expense of $1,053, $373, $2,756 and $990, respectively. The Company had an aggregate of $11,129 of unrecognized stock compensation cost as of September 30, 2018 remaining to be amortized over the weighted-average period of 2.9 years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:


	Three months ended				Nine months ended
	September 30,				September 30,
	2018		2017		2018		2017
Risk-free interest rate	2.9	%	1.9	%	2.7	%	2.2	%
Expected dividend yield	—	%	—	%	—	%	—	%
Expected term (years)	5.85		6.01		6.06		6.22
Expected stock price volatility	73	%	65	%	73	%	67	%

Employee Stock Purchase Plan

In connection with the IPO, the Board adopted and the Company's stockholders approved the 2017 employee stock purchase plan (the 2017 ESPP), which became effective upon the closing of the IPO in July 2017. The Company has reserved 225,000 shares of common stock for issuance under the 2017 ESPP. The Company has not issued any shares under the 2017 ESPP.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(unaudited)

(in thousands, except share and per share data)

9. Commitments

Operating leases

The Company leases office space in Cambridge, MA under an operating lease, which was last amended in January 2018, which is effective through March 2021. The lease also provided the Company with a tenant improvement allowance of up to $356. The Company fully utilized the allowance and recorded the assets acquired with the allowance as leasehold improvements. The Company recorded the tenant improvement allowance as a deferred lease incentive and is amortizing the deferred lease incentive through a reduction of rent expense ratably over the lease term.

In connection with the office lease, the Company has a letter of credit agreement for the benefit of its landlord in the amount of $321 as of each of September 30, 2018 and December 31, 2017, respectively, collateralized by a money market account. The Company classified this amount as restricted cash in the accompanying unaudited condensed consolidated balance sheets.

For the three months ended September 30, 2018 and 2017 and for the nine months ended September 30, 2018 and 2017, rent expense was $504, $419, $1,482 and $1,256, respectively.

The Company is recording rent expense on a straight-line basis over the term of the lease and has recorded deferred rent in the unaudited condensed consolidated balance sheets, accordingly.

License agreements

Through September 30, 2018, the Company has licensed intellectual property from two biotechnology companies. The consideration included upfront payments and a commitment to pay annual license fees, milestone payments, and, upon product commercialization, royalties on revenue generated from the sale of products covered by the licenses. The Company recorded milestone payments of $0 and $2,250 during the nine months ended September 30, 2018 and 2017, respectively.

Manufacturing services agreement

As of September 30, 2018, the Company had a commitment of approximately $5,700 related to manufacturing services that is expected to be incurred during the three months ending December 31, 2018.

10. Subsequent events

For the purposes of the unaudited financial statements as of September 30, 2018 and the period then ended, the Company has evaluated subsequent events through November 13, 2018, the date the unaudited interim financial statements were issued. There were no items requiring adjustment or disclosure in the consolidated financial statements.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC) on March 28, 2018.

Our actual results and the timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods.

The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, including those risks identified under Part II, Item 1A. Risk Factors, and under Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 28, 2018.

We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Overview

We are a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs), that offer a clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged 20 years of industry learning in the ADC field to develop proprietary technologies that enable us to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies. Our most advanced platform, Dolaflexin, has been used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not currently amenable to treatment with traditional ADC-based therapies. Our first product candidate, XMT‑1522, is a HER2‑antigen targeted ADC currently in a Phase 1 dose escalation study primarily in breast cancer patients as well as non‑small cell lung cancer (NSCLC) and gastric cancer. Upon the completion of dose escalation, we will evaluate the data to inform the expansion of clinical development of XMT‑1522. The expansion cohorts will be designed to gather data on the safety and efficacy profile of the product candidate in HER2-expressing patient populations, which are not adequately addressed by existing HER2 therapies. Our second product candidate, XMT-1536, is an ADC targeting NaPi2b, an antigen broadly expressed in ovarian cancer, NSCLC and other, rare tumors. XMT-1536 entered clinical development in late 2017 and is currently in a Phase 1 dose escalation study. Beyond our two clinical stage product candidates, we continue to invest in our earlier stage product candidates and in our ADC technologies. In addition, we have established a strategic partnership with Takeda Pharmaceutical Company Limited (Takeda) under which they obtained rights to XMT-1522 outside of the United States and Canada. We have also established strategic research and development partnerships with Takeda and Merck KGaA for the development and commercialization of additional ADC product candidates against a limited number of targets selected by our partners based on our Dolaflexin platform. We believe the potential of our ADC technologies, supported by our world-class management team and protected by our robust intellectual property portfolio, will allow us to develop targeted and highly tailored therapies to help cancer patients become cancer survivors.

On September 17, 2018, we announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold that had been imposed on the Phase 1 study of XMT-1522 that was announced on July 19, 2018. As part of our plan to resume dosing in the study, we made changes to the study protocol, including a once-every-four-week dosing regimen, increased monitoring and exclusion of patients with advanced hepatic impairment. The partial clinical hold, the protocol changes and the approval process for the protocol changes have resulted in a change in the expected timeline for clinical results for XMT-1522. Selection of a recommended Phase 2 dose is expected in mid-2019.

Table of Contents

On July 3, 2017 we closed our IPO of 5,000,000 shares at a price of $15.00 per share for gross proceeds of $75.0 million. We received approximately $67.4 million after deducting underwriting discounts and commissions and offering costs of approximately $7.6 million. On August 2, 2017, we issued and sold 51,977 shares of common stock at $15.00 per share for gross proceeds of $0.78 million upon the partial exercise of the underwriters’ overallotment option. We received net proceeds of $0.73 million after deducting $0.05 million in underwriting discounts and commissions.

Since inception, our operations have focused on building our platform, identifying potential product candidates, producing drug substance and drug product material for use in preclinical studies, conducting preclinical studies, including Good Laboratory Practice (GLP), toxicology studies, manufacturing clinical trial material and conducting clinical trials, establishing and protecting our intellectual property, staffing our company and raising capital. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations primarily through our strategic partnerships, private placements of our convertible preferred stock and the IPO.

Since inception, we have incurred significant operating losses. Our net losses were $41.8 million and $24.7 million for the nine months ended September 30, 2018 and 2017, respectively. As of September 30, 2018, we had an accumulated deficit of $141.7 million. We expect to continue to incur significant expenses and operating losses over the next several years. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

continue clinical development activities for our clinical stage product candidates XMT-1522 and XMT-1536;

continue activities to discover, validate and develop additional product candidates;

maintain, expand and protect our intellectual property portfolio;

hire additional research, development and general and administrative personnel; and

continue to incur additional costs associated with operating as a public company.

Financial operations overview

Revenue

Effective January 1, 2018, the Company adopted the requirements of Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) using the modified retrospective method as discussed above in Note 2 to our unaudited condensed consolidated financial statements. All amounts and disclosures set forth in this Quarterly Report on Form 10-Q reflect these changes.

To date, all of our revenue has been generated from strategic partnerships. We have not generated any revenue from product sales, and we do not expect to generate any revenue from product sales for the foreseeable future.

In March 2014, we entered into a collaboration agreement with Takeda for the development and commercialization of ADC product candidates utilizing Fleximer. Under this agreement, as amended, Takeda may select up to seven target antigens and has selected four target antigens to date. Takeda is responsible for generating antibodies against the target antigens and we are responsible for generating Fleximer and our proprietary payloads and conjugating this to the antibody to create the ADC product candidates. Takeda then has the exclusive right to and is responsible for the further development, manufacture and commercialization of these ADC product candidates, except that we have an option to co-develop and co-commercialize one product targeting one of Takeda's third through seventh target antigens and may exercise such option with respect to an applicable product no later than 30 days after initiation of a Phase 2 clinical study for such product or at an earlier time if Takeda intends to grant rights to such product to a third party.

In addition, in January 2016, we entered into a collaboration agreement with Takeda for the development and commercialization of XMT-1522. Under this agreement, Takeda is granted the exclusive right and responsibility to commercialize XMT-1522 outside the United States and Canada.

Table of Contents

For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, we recognized revenue of $0.1 million, $5.8 million, $4.7 million and $12.1 million, respectively, related to the Takeda agreements.

In June 2014, we entered into a collaboration agreement with Merck KGaA for the development and commercialization of ADC product candidates utilizing Fleximer for up to six target antigens. Merck KGaA is responsible for generating antibodies against the target antigens and we are responsible for generating Fleximer and our proprietary payloads and conjugating this to the antibody to create the ADC product candidates. Merck KGaA then has the exclusive right to and is responsible for the further development and commercialization of these ADC product candidates.

For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, we recognized revenue of $1.5 million, $0.5 million, $2.4 million and $2.1 million, respectively, related to the Merck KGaA agreement.

The Company has provided limited services for Asana BioSciences. For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, we recorded revenue of $0.6 million, $0.0 million, $0.8 million and $0.1 million, respectively, related to these services. In addition, the Company recognized revenue of $1.5 million related to a milestone achieved during the nine months ended September 30, 2018.

For the foreseeable future, we expect substantially all of our revenue to be generated from our collaboration agreements with Takeda and Merck KGaA and any other collaboration agreements we may enter into. Given the schedule of potential milestone payments and the uncertain nature and timing of clinical development, we cannot predict when or whether we will receive further milestone payments or any royalty payments under these collaborations.

For information about our revenue recognition policy, see Note 2 to unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Operating expenses

Research and development expenses

Research and development expenses consist primarily of costs incurred for our research and development activities, including our drug discovery efforts, and the development of our product candidates, which include:

employee-related expenses, including salaries, bonus, benefits, and stock-based compensation expense;

costs of funding research and development performed by third parties that conduct research, preclinical activities, manufacturing and clinical trials on our behalf;

laboratory supplies;

facility costs, including rent, depreciation and maintenance expenses; and

upfront and milestone payments under our third-party licensing agreements.

Research and development costs are expensed as incurred. Costs of certain activities, such as manufacturing, preclinical studies and clinical trials, are generally recognized based on an evaluation of the progress to completion of specific tasks. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.

We expect research and development costs to increase significantly for the foreseeable future as our product candidate development programs progress. There are numerous factors associated with the successful development and commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at our current stage of development. Additionally, future commercial and regulatory factors beyond our control may impact our clinical development programs and plans.

Table of Contents

A significant portion of our research and development costs have been external costs, which we track on a program-by-program basis following nomination as a product candidate. Our internal research and development costs are primarily personnel-related costs, facility costs, including depreciation and lab consumables. We have not historically tracked all of our internal research and development expenses on a program-by-program basis as they are deployed across multiple projects under development. The following table summarizes our external research and development expenses, by program following nomination as a development candidate. Pre-development candidate expenses, unallocated costs and internal research and development costs have been stated separately.


	Three months ended				Nine months ended
	September 30,				September 30,
(in thousands)	2018		2017		2018		2017
XMT-1522 external costs	$	4,646	$	3,515	$	11,347	$	9,048
XMT-1536 external costs		3,106		2,130		7,739		6,449
External costs for discovery stage programs and platform development		1,590		765		3,434		1,933
Internal research and development costs		5,838		5,002		17,578		14,715
Total research and development costs	$	15,180	$	11,412	$	40,098	$	32,145

The successful development of our product candidates is highly uncertain. As such, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from the development efforts associated with our product candidates. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:

successful completion of preclinical studies and IND-enabling studies;

successful enrollment in and completion of clinical trials;

receipt of marketing approvals from applicable regulatory authorities;

establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;

obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;

commercializing the product candidates, if and when approved, whether alone or in collaboration with others; and

continued acceptable safety profile of the drugs following approval.

A change in the outcome of any of these variables with respect to the development, manufacture or commercialization of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate.

General and administrative expenses

General and administrative expenses consist primarily of salaries and other employee-related costs, including stock-based compensation, for personnel in executive, finance, accounting, information technology, business development, legal operations and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters and fees for accounting and consulting services.

We anticipate that our general and administrative expenses will increase in the future to support continued research and development activities. This will likely include increased costs related to the hiring of additional personnel, fees to outside consultants and patent costs, among other expenses.

Table of Contents

Other income

Other income consists primarily of interest income earned on cash equivalents and marketable securities.

Critical accounting policies and estimates

Our management's discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of change in estimates.

We believe that our most critical accounting policies are those relating to revenue recognition, accrued research and development expenses and stock-based compensation, discussed in the notes to condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Results of Operations

Comparison of the three months ended September 30, 2018 and 2017

The following table summarizes our results of operations for the three months ended September 30, 2018 and 2017:


	Three months ended
	September 30,
(in thousands)	2018		2017		Dollar Change
Collaboration revenue	$	2,151	$	6,267	$	(4,116)
Operating expenses:
Research and development		15,180		11,412		3,768
General and administrative		4,380		2,905		1,475
Total operating expenses		19,560		14,317		5,243
Other income:
Interest income		340		318		22
Total other income		340		318		22
Net loss	$	(17,069)	$	(7,732)	$	(9,337)

Collaboration Revenue

Collaboration revenue was $2.2 million during the three months ended September 30, 2018, compared to $6.3 million during the three months ended September 30, 2017, a decrease of $4.1 million, or 66%, primarily the result of a decrease in efforts to support partner programs and a decrease in revenue due to an increase in projected efforts, associated with the change in timeline, used to measure XMT-1522 revenue during the quarter ended September 30, 2018. In addition, the quarter ended September 30, 2017 included a $4.0 million increase in revenue relating to changes in estimates of the costs to complete services under the Takeda agreements.

Research and Development Expense

Research and development expense increased by $3.8 million from $11.4 million for the three months ended September 30, 2017 to $15.2 million for the three months ended September 30, 2018, an increase of 33%. The increase in research and development expense was primarily attributable to the following:

approximately $0.3 million in increased employee compensation primarily due to an increase in headcount as our programs progress in clinical and preclinical studies;

Table of Contents

approximately $0.8 million due to in increased external clinical and regulatory expenses due to the progress of XMT‑1522 and XMT-1536;

approximately $0.4 million in increased lab consumables and facilities costs; and

approximately $1.9 million in increased external research and development expenses related to our platform development, target evaluation and manufacturing activities for our two clinical stage programs.

We expect our research and development expenses to increase as we continue our clinical development of XMT‑1522 and XMT-1536 and continue to advance our preclinical product candidate pipeline and invest in improvements in our ADC technologies.

General and Administrative Expense

General and administrative expense increased by $1.5 million from $2.9 million during the three months ended September 30, 2017 to $4.4 million for the three months ended September 30, 2018, an increase of 51%. The increase in general and administrative expense was primarily attributable to the following:

approximately $0.8 million in increased employee compensation primarily due to additional headcount as we build the infrastructure to support the growth of the research and development organization; and

approximately $0.7 million in increased consulting and professional fees, including external legal fees, corporate communications and public relations costs.

We expect that our general and administrative expense will increase in future periods as we expand our operations. These increases will likely include legal, auditing and filing fees, additional insurance premiums and general compliance and consulting expenses.

Other Income

Other income was $0.3 million for each of the three months ended September 30, 2018 and September 30, 2017. Other income consists primarily of interest income on cash equivalents and marketable securities.

Comparison of the nine months ended September 30, 2018 and 2017

The following table summarizes our results of operations for the nine months ended September 30, 2018 and 2017:


	Nine months ended
	September 30,
(in thousands)	2018		2017		Dollar Change
Collaboration revenue	$	9,405	$	14,284	$	(4,879)
Operating expenses:
Research and development		40,098		32,145		7,953
General and administrative		12,181		7,406		4,775
Total operating expenses		52,279		39,551		12,728
Other income:
Interest income		1,049		527		522
Total other income		1,049		527		522
Net loss	$	(41,825)	$	(24,740)	$	(17,085)

Table of Contents

Collaboration Revenue

Collaboration revenue was $9.4 million during the nine months ended September 30, 2018, compared to $14.3 million during the nine months ended September 30, 2017, a decrease of $4.9 million, or 34%, primarily the result of a decrease in efforts to support partner programs and a decrease in revenue due to an increase in projected efforts, associated with the change in timeline, used to measure XMT-1522 revenue during the nine months ended September 30, 2018. In addition, the nine months ended September 30, 2017 included a $4.0 million increase in revenue relating to changes in estimates of the costs to complete services under the Takeda agreements. The net decrease was partially offset by the receipt of a $1.5 million milestone during the nine months ended September 30, 2018.

Research and Development Expense

Research and development expense increased by $8.0 million from $32.1 million for the nine months ended September 30, 2017 to $40.1 million for the nine months ended September 30, 2018, an increase of 25%. The increase in research and development expense was primarily attributable to the following:

approximately $2.0 million in increased employee compensation primarily due to an increase in headcount as our programs progress in clinical and preclinical studies;

approximately $3.2 million in increased external research and development expenses related to our platform development, target evaluation and manufacturing activities for our two clinical stage programs;

approximately $3.2 million due to in increased external clinical and regulatory expenses due to the progress of XMT‑1522 and XMT-1536; and

approximately $0.3 in increased lab consumables and facilities costs, partially offset by;

approximately $1.5 million due to milestone payment made in the comparable period of 2017.

General and Administrative Expense

General and administrative expense increased by $4.8 million from $7.4 million during the nine months ended September 30, 2017 to $12.2 million for the nine months ended September 30, 2018, an increase of 65%. The increase in general and administrative expense was primarily attributable to the following:

approximately $2.2 million in increased employee compensation primarily due to additional headcount as we build the infrastructure to support the growth of the research and development organization;

approximately $1.6 million in increased consulting and professional fees, including external legal fees, corporate communications and public relations costs; and

approximately $0.9 million in increased other costs, including taxes, insurance and software.

Table of Contents

Other Income

Other income was $1.0 million for the nine months ended September 30, 2018, compared to $0.5 million for the nine months ended September 30, 2017. The increase in other income was primarily related to the recognition of interest income during the period ended September 30, 2018 due to higher cash, cash equivalents and marketable securities balances.

Liquidity and Capital Resources

Sources of Liquidity

Prior to our IPO, we financed our operations primarily through private placements of our convertible preferred stock and strategic partnerships.

On July 3, 2017, we closed our IPO of 5,000,000 shares at $15.00 per share with gross proceeds of $75.0 million and net proceeds $67.4 million after deducting offering costs of $7.6 million. On August 2, 2017, we issued and sold 51,977 shares of common stock at $15.00 per share for gross proceeds of $0.78 million upon the partial exercise of the underwriters’ overallotment option. We received net proceeds of $0.73 million after deducting $0.05 million in underwriting discounts and commissions.

As of September 30, 2018, we had cash, cash equivalents and short-term marketable securities of $86.1 million. On July 2, 2018, we established an ATM pursuant to which we are able to offer and sell up to $75.0 million of our common stock from time to time at prevailing market prices. As of September 30, 2018, we had not sold any shares under the ATM and had $75.0 million of availability under the program.

Cash Flows

The following table provides information regarding our cash flows for the nine months ended September 30, 2018 and 2017:


	Nine months ended
	September 30,
(in thousands)	2018		2017
Net cash used in operating activities	$	(39,312)	$	(31,683)
Net cash provided by (used in) investing activities		73,472		(86,434)
Net cash provided by financing activities		853		68,576
Increase (decrease) in cash, cash equivalents and restricted cash	$	35,013	$	(49,541)

Net Cash Used in Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2018 was $39.3 million as compared to $31.7 million during the nine months ended September 30, 2017. The increase was due primarily to an increase in operating expenses for 2018 and timing of payments made to vendors.

Net Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities was $73.4 million during the nine months ended September 30, 2018 and consisted primarily of maturities of marketable securities. Net cash used in investing activities was $86.4 million during the nine months ended September 30, 2017 and consisted primarily of purchases of marketable securities.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was $0.9 million during the nine months ended September 30, 2018 as compared to net cash provided by financing activities of $68.6 million during the nine months ended September 30, 2017. During the nine month ended September 30, 2018 cash provided by financing activities consisted primarily of the proceeds from exercises of stock options. During the nine months ended September 30, 2017, cash provided by financing activities resulted primarily from the net proceeds from our IPO.

Table of Contents

Funding Requirements

We expect our cash expenditures to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

We expect that our existing cash, cash equivalents and marketable securities will enable us to fund our current operating plan for at least the next twelve months. Our future capital requirements will depend on many factors, including:

the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates;

the scope, prioritization and number of our research and development programs;

the costs, timing and outcome of reviews of our product candidates by regulatory agencies;

our ability to establish and maintain collaborations on favorable terms, if at all;

the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we obtain;

the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any;

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property‑related claims;

the extent to which we acquire or in‑license other product candidates and technologies;

the costs of securing manufacturing arrangements for clinical and commercial production; and

the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates.

Identifying potential product candidates and conducting preclinical testing and clinical trials is a time‑consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve drug sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, strategic partnerships and licensing arrangements. We do not have any committed external source of funds outside of those to be earned in connection with our agreements with Merck KGaA and Takeda, if development activities are successful under those agreements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we raise funds through additional strategic partnerships or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to

Table of Contents

grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Off‑Balance Sheet Arrangements

We did not have, during the periods presented, and we do not currently have, any off‑balance sheet arrangements, as defined under applicable SEC rules.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash and cash equivalents and, short-term marketable securities are in a money market fund that invests in U.S. Treasury obligations. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.

We are currently not exposed to market risk related to changes in foreign currency exchange rates, but we may contract with vendors that are located in Asia and Europe and may be subject to fluctuations in foreign currency rates at that time.

Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the three or nine months ended September 30, 2018 and 2017.

Item 4. Controls and Procedures

Management’s Evaluation of our Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act), that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2018, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the end of the period covered by this report, we did not believe we were party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors

Risk Factors

Other than as disclosed below, there have been no material changes to the Company’s risk factors as set forth in Part I, Item 1A of the Company’s Annual Report on Form 10-K, as filed with the SEC on March 28, 2018.

Events that may delay or prevent successful commencement, enrollment or completion of clinical studies of our ADC product candidates could result in increased costs to us as well as a delay in obtaining, or failure to obtain, regulatory approval, or cause us to terminate a clinical trial, which could prevent us from commercializing our ADC product candidates on a timely basis, or at all.

We cannot guarantee that clinical studies, including our ongoing Phase 1 clinical studies and anticipated additional clinical studies for XMT‑1522 and XMT-1536, will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing, and other events may cause us to temporarily or permanently cease a clinical study. Events that may prevent successful or timely commencement, enrollment or completion of clinical development include, among others:

delays by us in reaching a consensus with regulatory agencies on study design;

delays in reaching, or failing to reach, agreement on acceptable terms with prospective clinical research organizations (CROs) and clinical study sites;

difficulties in obtaining required Institutional Review Board (IRB) approval at each clinical study site;

challenges in recruiting and enrolling suitable patients to participate in clinical studies that meet the criteria of the protocol for the clinical study;

imposition of a clinical hold by regulatory agencies or IRBs for any reason, including safety concerns or after an inspection of clinical operations or study sites;

failure by CROs, other third parties or us to adhere to clinical study requirements;

failure to perform in accordance with the FDA’s good clinical practices (GCP) or applicable regulatory guidelines in other countries;

inadequate quantity or quality of a product candidate or other materials necessary to conduct clinical studies, including, for example, delays in the testing, validation, manufacturing and delivery of the ADC product candidates to the clinical sites;

patients not completing participation in a study or not returning for post‑treatment follow‑up;

clinical study sites or patients dropping out of a study;

Table of Contents

safety issues, including occurrence of serious adverse events (SAEs) in clinical studies that are associated with the ADC product candidates that are viewed to outweigh their potential benefits or unforeseen safety issues in our ongoing preclinical studies;

changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; or

lack of adequate funding to continue the clinical study.

For example, in July 2018, the FDA placed a partial clinical hold on the Phase 1 study of XMT-1522 following our

report to the FDA of a Grade 5 SAE (patient death) in dose level 7 of the XMT-1522 Phase 1 trial, which was classified

by the investigator as possibly drug-related. On September 17, 2018, the Company announced that the FDA lifted this partial clinical hold. As part of its plan to resume dosing in the study, the Company made changes to the study protocol, including a once-every-four-week dosing regimen, increased monitoring and exclusion of patients with advanced hepatic impairment. The partial clinical hold, the protocol changes and the approval process for the protocol changes have resulted in a change in the expected timeline for clinical results for XMT-1522.

Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to complete a clinical study. If we or our partners are not able to successfully complete clinical studies, we or they will not be able to obtain regulatory approval and will not be able to commercialize our ADC product candidates or our partners’ ADC product candidates based on our technology.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Use of Proceeds from the Sale of Registered Securities

On July 3, 2017, we closed our IPO, in which we issued and sold 5,000,000 shares of our common stock at a public offering price of $15.00 per share, for aggregate gross proceeds of $75.0 million. On August 2, 2017, we issued and sold an additional 51,977 shares of common stock at $15.00 per share for gross proceeds of $0.78 million. All of the shares issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No. 333-218412), which was declared effective by the SEC on June 27, 2017.

The net offering proceeds to us upon the initial closing were, after deducting underwriting discounts and offering costs payable by us totaling $7.5 million, were approximately $67.5 million. Upon the exercise of the overallotment option by the underwriters, we received an additional $0.73 million after $0.05 million of underwriting discounts. No material offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10.0% or more of any class of our equity securities or to any other affiliates.

As of September 30, 2018, we estimate that we have used approximately $51.0 million of the net proceeds from the IPO to fund manufacturing and clinical development activities for XMT-1522 and XMT-1536 and other research activities in support of our preclinical programs, and for working capital and other general corporate purposes. We have invested the unused proceeds from the offering in marketable securities and money market accounts. There has been no material change in our planned use of the net proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on June 29, 2017.

Table of Contents

Item 6. Exhibits.


EXHIBIT 3.1	-	Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on July 10, 2017).

EXHIBIT 3.2	-	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed on July 10, 2017).

EXHIBIT 31.1	-	Rule 13a—14(a) / 15d—14(a) Certifications — Chief Executive Officer.

EXHIBIT 31.2	-	Rule 13a—14(a) / 15d—14(a) Certifications — Chief Financial Officer.

EXHIBIT 32.1	-	Section 1350 Certifications.

EXHIBIT 101.INS	-	XBRL Instance Document.

EXHIBIT 101.SCH	-	XBRL Taxonomy Extension Schema Document.

EXHIBIT 101.CAL	-	XBRL Taxonomy Extension Calculation Linkbase Document.

EXHIBIT 101.DEF	-	XBRL Taxonomy Extension Definition Linkbase Document.

EXHIBIT 101.LAB	-	XBRL Taxonomy Extension Label Linkbase Document.

EXHIBIT 101.PRE	-	XBRL Taxonomy Extension Presentation Linkbase Document.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Mersana Therapeutics, Inc.

Dated: November 13, 2018	By:	/s/ Anna Protopapas
		Anna Protopapas
		President and Chief Executive Officer

Dated: November 13, 2018	By:	/s/ David A. Spellman
		David A. Spellman
		Chief Financial Officer

EX-31.1 2 mrsn-20180930ex311d9cf54.htm EX-31.1 mrsn_Ex_31_1

Exhibit 31.1

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a)

and 15d-14(a), as adopted pursuant to Section 302 of Sarbanes-Oxley Act of 2002

I, Anna Protopapas, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Mersana Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report), that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Mersana Therapeutics, Inc.

/s/ Anna Protopapas

Anna Protopapas

President and Chief Executive Officer

(Principal Executive Officer)

Dated: November 13, 2018

EX-31.2 3 mrsn-20180930ex312ffe10c.htm EX-31.2 mrsn_Ex_31_2

Exhibit 31.2

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a)

and 15d-14(a), as adopted pursuant to Section 302 of Sarbanes-Oxley Act of 2002

I, David A. Spellman, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Mersana Therapeutics, Inc.;

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



	Mersana Therapeutics, Inc. /s/ David A. Spellman
	David A. Spellman
	Chief Financial Officer (Principal Financial Officer)

Dated: November 13, 2018

EX-32.1 4 mrsn-20180930ex3214238b5.htm EX-32.1 mrsn_Ex_32_1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Mersana Therapeutics, Inc. (the “Company”) for the quarter ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that to the best of her knowledge:

1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: November 13, 2018		/s/ Anna Protopapas
		Anna Protopapas
		President and Chief Executive Officer (Principal Executive Officer)



Dated: November 13, 2018		/s/ David A. Spellman
		David A. Spellman
		Chief Financial Officer (Principal Financial Officer)

EX-101.INS 5 mrsn-20180930.xml EX-101.INS 0001442836 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001442836 mrsn:AtMarketEquityOfferingProgramMember 2018-07-01 2018-09-30 0001442836 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001442836 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001442836 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001442836 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001442836 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001442836 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001442836 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001442836 2017-06-15 2017-06-15 0001442836 us-gaap:RetainedEarningsMember 2018-09-30 0001442836 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001442836 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001442836 us-gaap:RetainedEarningsMember 2017-12-31 0001442836 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001442836 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001442836 us-gaap:RetainedEarningsMember 2016-12-31 0001442836 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001442836 us-gaap:CommonStockMember 2018-09-30 0001442836 us-gaap:CommonStockMember 2017-12-31 0001442836 us-gaap:CommonStockMember 2016-12-31 0001442836 us-gaap:OverAllotmentOptionMember 2017-08-02 0001442836 us-gaap:IPOMember 2017-07-03 0001442836 mrsn:StockIncentivePlan2017Member 2017-06-01 2017-06-30 0001442836 mrsn:StockIncentivePlan2007Member 2017-06-30 0001442836 mrsn:StockIncentivePlan2017Member 2018-09-30 0001442836 mrsn:StockIncentivePlan2017Member 2017-06-30 0001442836 mrsn:StockIncentivePlan2017Member 2018-01-01 2018-01-01 0001442836 mrsn:StockIncentivePlan2017Member us-gaap:MaximumMember 2018-01-01 2018-09-30 0001442836 mrsn:StockIncentivePlan2017Member 2018-01-01 2018-09-30 0001442836 mrsn:LimitedServicesMember mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember 2018-07-01 2018-09-30 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-07-01 2018-09-30 0001442836 mrsn:ServiceMilestoneMember mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember 2018-01-01 2018-09-30 0001442836 mrsn:LimitedServicesMember mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember 2018-01-01 2018-09-30 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-01-01 2018-09-30 0001442836 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member mrsn:LimitedServicesMember mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember 2017-07-01 2017-09-30 0001442836 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2017-07-01 2017-09-30 0001442836 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2017-07-01 2017-09-30 0001442836 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member mrsn:LimitedServicesMember mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember 2017-01-01 2017-09-30 0001442836 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2017-01-01 2017-09-30 0001442836 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2017-01-01 2017-09-30 0001442836 mrsn:TakedaPharmaceuticalCompanyLimitedMember 2017-01-01 2017-12-31 0001442836 us-gaap:OverAllotmentOptionMember 2017-01-01 2017-09-30 0001442836 us-gaap:IPOMember 2017-01-01 2017-09-30 0001442836 mrsn:ManufacturingServicesAgreementMember 2018-09-30 0001442836 2017-01-01 2017-12-31 0001442836 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-07-01 2018-09-30 0001442836 mrsn:CostsToCompleteResearchServicesMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-07-01 2018-09-30 0001442836 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-09-30 0001442836 mrsn:CostsToCompleteResearchServicesMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-01-01 2018-09-30 0001442836 2018-06-30 0001442836 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0001442836 us-gaap:WarrantMember 2018-09-30 0001442836 us-gaap:EmployeeStockOptionMember 2018-09-30 0001442836 mrsn:WarrantAndEmployeeStockOptionMember 2018-09-30 0001442836 mrsn:EmployeeStockPurchasePlanMember 2018-09-30 0001442836 us-gaap:WarrantMember 2017-12-31 0001442836 us-gaap:EmployeeStockOptionMember 2017-12-31 0001442836 mrsn:WarrantAndEmployeeStockOptionMember 2017-12-31 0001442836 2017-09-30 0001442836 2016-12-31 0001442836 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001442836 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001442836 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001442836 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001442836 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001442836 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001442836 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001442836 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001442836 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2017-12-31 0001442836 us-gaap:USTreasurySecuritiesMember 2018-09-30 0001442836 us-gaap:USTreasurySecuritiesMember 2017-12-31 0001442836 us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001442836 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001442836 us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001442836 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001442836 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001442836 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001442836 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001442836 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001442836 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001442836 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001442836 us-gaap:WarrantMember 2017-07-01 2017-09-30 0001442836 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001442836 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001442836 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001442836 2017-07-01 2017-09-30 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda20142015And2016AgreementsMember 2017-12-31 0001442836 mrsn:AtMarketEquityOfferingProgramMember 2018-07-02 0001442836 mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-07-01 2018-09-30 0001442836 mrsn:RightsToFutureTechnologicalImprovementsMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:ResearchLicenseToSecondDesignatedTargetAndResearchServicesMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:MaterialRightRelatedToSecondReplacementRightDesignatedTargetMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:MaterialRightRelatedToLicenseSixthDesignatedTargetAndResearchServicesMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:MaterialRightRelatedToLicenseSeventhDesignatedTargetAndResearchServicesMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:MaterialRightRelatedToLicenseFifthDesignatedTargetAndResearchServicesMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:MaterialRightRelatedToFirstReplacementRightDesignatedTargetMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:MaterialRightRelatedToExclusiveLicenseSecondDesignatedTargetMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:LicenseAndRelatedServicesXmt1522Member mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:JointResearchCommitteeServicesXmt1522Member mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:JointResearchCommitteeServicesTakedaMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:ExclusiveLicenseToThirdDesignatedTargetAndResearchServicesMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:ExclusiveLicenseToFourthDesignatedTargetAndResearchServicesMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:ExclusiveLicenseToFirstDesignatedTargetAndResearchServicesMember mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:RightsToFutureTechnologicalImprovementsMember mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 0001442836 mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeMember mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 0001442836 mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 0001442836 mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetSixMember mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 0001442836 mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 0001442836 mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 0001442836 mrsn:JointResearchCommitteeServicesMember mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 0001442836 mrsn:LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember 2018-09-30 0001442836 mrsn:RightsToFutureTechnologicalImprovementsMember

2018-01-01

mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 2018-09-30 0001442836 mrsn:LicenseAndRelatedServicesXmt1522Member

2018-01-01

mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-01-01 2018-09-30 0001442836 mrsn:JointResearchCommitteeServicesXmt1522Member

2018-01-01

mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 2018-09-30 0001442836 mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-07-01 2018-09-30 0001442836 mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-01-01 2018-09-30 0001442836 mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2017-07-01 2017-09-30 0001442836 mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2017-01-01 2017-09-30 0001442836 us-gaap:OverAllotmentOptionMember 2017-08-02 2017-08-02 0001442836 us-gaap:IPOMember 2017-07-03 2017-07-03 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-01-01 0001442836 mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 0001442836 mrsn:LicenseAgreementsMember 2018-01-01 2018-09-30 0001442836 mrsn:LicenseAgreementsMember 2017-01-01 2017-09-30 0001442836 us-gaap:MaximumMember 2018-09-30 0001442836 2018-07-01 2018-09-30 0001442836 mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2014-06-01 2014-06-30 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda20142015And2016AgreementsMember 2014-03-01 2018-03-31 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2015And2016AgreementsMember 2016-01-31 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda20142015And2016AgreementsMember 2016-01-31 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2014AgreementMember 2014-03-31 0001442836 mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2017-12-31 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember 2016-01-31 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember 2016-01-01 2016-01-31 0001442836 mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2016-01-01 2016-01-31 0001442836 mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember 2018-09-30 0001442836 mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-01-01 2018-09-30 0001442836 mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2015-01-01 2017-12-31 0001442836 mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember 2016-01-31 2016-01-31 0001442836 us-gaap:MaximumMember mrsn:UnitedStatesEuropeanUnionAndJapanMember mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2016-01-31 0001442836 mrsn:LocationsOtherThanUnitedStatesEuropeanUnionAndJapanMember mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2016-01-31 0001442836 mrsn:UnitedStatesEuropeanUnionAndJapanMember mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2016-01-31 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda20142015And2016AgreementsMember 2018-09-30 0001442836 mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2014-06-30 0001442836 mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2016-01-31 0001442836 2013-01-01 2013-12-31 0001442836 2017-01-01 2017-09-30 0001442836 mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember 2018-09-30 0001442836 mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember 2018-09-30 0001442836 2018-09-30 0001442836 2017-12-31 0001442836 2018-11-12 0001442836 2018-01-01 2018-09-30 iso4217:USD xbrli:shares mrsn:Vote mrsn:security xbrli:pure mrsn:item iso4217:USD xbrli:shares false --12-31 Q3 2018 2018-09-30 10-Q 0001442836 23182472 Yes Non-accelerated Filer Mersana Therapeutics, Inc. 3183000 6610000 22070000 86429000 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2017 </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26,591 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,604 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 100,297 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 50,756 </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted cash included in other assets </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash, cash equivalents and restricted cash per statement of cash flows </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26,962 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,975 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 100,668 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 51,127 </td> </tr> </table></div>   <div /></div> </div> -115000 77000 129491 1 9 4 3 3 6 6 4 5 14 8 3 2 4 1 73000000 271500000 84000000 87000000 50250000 500000 12000000 750000 3000000 0 780000000 474750000 288000000 2500000 158250000 3 P90D P30D P45D P60D 15000000 1.00 0.50 0.50 0.30 1 264000000 128000000 153000000 432000000 6 6 4 2 6 7 5 2 24800000 20000000 1300000 12000000 26500000 500000 P10Y 7906000 2151000 2373000 849000 0 24455000 0 0 0 0 7 -9193000 -5532000 356000 2250000 0 0 0 2 1 <div> <div> Patent Costs The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. <div /></div> </div> 75000000 780000 0 0 2959000 1165000 7875000 14023000 7070000 9755000 P30D 3000000 1 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Allocated </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Performance obligations </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Transaction Price </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> XMT-1522 license and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 49,828 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Joint research committee services for XMT-1522 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 449 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exclusive license to the first designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,611 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research license to the second designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,017 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Material right related to the exclusive license to the second designated target </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 526 </td> </tr> <tr> <td valign="top" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exclusive license to the third designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,974 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exclusive license to the fourth designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,678 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Material right related to the license to the fifth designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,506 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Material right related to the license to the sixth designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,506 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Material right to license to the seventh designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,506 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Material right related to first replacement right for a designated target </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,506 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Material right related to the second replacement right to a designated target </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,116 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Rights to future technological improvements </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,750 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Joint research committee services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 150 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 86,123 </td> </tr> </table></div>   <div /></div> </div> P5Y P6Y P10Y P10Y 1 22875000 86123000 242000 3439000 3439000 3439000 4226000 3439000 425000 86123000 6611000 3678000 4974000 150000 449000 49828000 526000 3506000 3506000 3506000 3506000 3116000 1017000 1750000 -805000 -805000 7580000 55000 75000000

<div> <div> 6. Accrued expenses<a name="a6AccruedExpenses_953062"></a> Accrued expenses consist of the following: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued payroll and related expenses </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,482 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,041 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued preclinical, manufacturing and clinical expenses </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,610 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,183 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued professional fees </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 868 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 492 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued other </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 552 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 228 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,512 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,944 </td> </tr> </table></div>   <div /></div> </div>

3070000

6729000

530000

784000

330000

454000

586000

391000

163000

32000

118000

288000

6944000

10512000

492000

868000

-149000

-42000

168018000

171627000

990000

373000

2756000

1053000

3335205

3205714

129491

3335205

3205714

129491

3781045

3670680

110365

3781045

3670680

110365

130715000

94378000

117543000

90049000

125216000

89231000

35985000

86059000

149000

12000

137000

42000

98774000

24931000

11066000

62777000

24497000

98625000

24931000

11054000

62640000

24931000

11054000

62640000

24931000

11054000

62640000

24455000

88143000

24455000

10482000

82000

75000

100297000

50756000

26591000

61604000

26591000

61604000

<div> <div> Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value. <a name="_Hlk513720952"></a>The following amounts were presented as cash, cash equivalents and restricted cash: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2017 </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26,591 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,604 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 100,297 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 50,756 </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted cash included in other assets </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash, cash equivalents and restricted cash per statement of cash flows </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26,962 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,975 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 100,668 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 51,127 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <a name="_Hlk513720937"></a>Other Assets The Company recorded other assets of $1,804 and $371 as of September 30, 2018 and December 31, 2017, respectively. The September 30, 2018 amount is comprised of restricted cash of $371 held as security deposits for a standby letter of credit related to a facility lease and a corporate credit card program and $1,433 held by a service provider. The December 31, 2017 amount is comprised of restricted cash. <div /></div> </div>

100668000

51127000

26962000

61975000

-49541000

35013000

0.05

110365

<div> <div> 3. Collaboration agreements Takeda XMT-1522 strategic partnership In January 2016, the Company entered into a Development Collaboration and Commercial License Agreement with Takeda through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc. for the development and commercialization of XMT-1522 (the XMT-1522 Agreement). Under the XMT-1522 Agreement, Takeda was granted the exclusive right to commercialize XMT-1522 outside of the United States and Canada. Under the XMT-1522 Agreement, the Company is responsible for conducting certain Phase 1 development activities for XMT-1522, including the ongoing Phase 1 clinical study, at its own expense. Takeda has the option to conduct Phase 1 development activities at its own expense within its territory. The parties agreed to collaborate on the further development of XMT-1522 in accordance with a global development plan (Post-Phase 1 Development). The parties agreed to share equally all clinical stage manufacturing costs and any Post-Phase 1 Development costs incurred in the performance of activities for the purpose of obtaining regulatory approval in either the United States or Canada and in certain other major markets in the rest of the world. Each party will be responsible for all Post-Phase 1 Development costs incurred in the performance of activities solely for the purpose of obtaining regulatory approval in such party's territory. Each party may conduct independent development of XMT-1522, subject to certain restrictions. The Company received an upfront payment of $26,500 upon execution of the XMT-1522 Agreement. In addition, the Company was entitled to a milestone payment of $20,000 upon achievement of the IND Clearance Date (as defined therein). The Company achieved the IND Clearance Date in October 2016. In addition to the milestone payment upon achievement of the IND Clearance Date, the Company is entitled to receive future development, regulatory and commercial milestones of up to $288,000, consisting of $87,000 of development milestones, $128,000 of regulatory milestones and $73,000 of commercial milestones, as well as royalties in the low to mid teens on net sales of XMT-1522 in Takeda’s territory during the applicable royalty term. There are development milestones payable upon the achievement of nine separate events: the initiation of Phase 2 clinical trials and Phase 3 clinical trials for four separate specified patient populations and the initiation of a Phase 3 clinical trial for one additional unspecified patient population. There are 14 regulatory milestones, which are payable upon regulatory submissions, regulatory approvals and pricing approvals, as applicable, for the U.S., European Union and Japanese markets for up to four separate patient populations and multiple label indications. In addition, a regulatory milestone is payable upon the receipt of regulatory and pricing approval in two specified markets other than the United States, the European Union or Japan. There are three individual commercial milestones, which are payable upon the attainment of certain thresholds for annual net sales. The next potential milestone the Company will be eligible to receive is a development milestone of $12,000 related to the initiation of a Phase 2 clinical trial. The XMT-1522 Agreement expires upon the expiration of the royalty term for XMT-1522, after which time, Takeda will have a perpetual, royalty-free license. However, Takeda may terminate the XMT-1522 Agreement in its entirety for convenience upon 30 days' prior written notice at any time up to the initiation of the first Phase 2 clinical study of XMT-1522 or upon 90 days' prior written notice following the initiation of the first Phase 2 clinical study of XMT-1522. Each party may terminate the XMT-1522 Agreement in its entirety upon bankruptcy or similar proceedings of the other party and in its entirety or on a country-by-country basis upon an uncured material breach of the agreement by the other party. Following termination, XMT-1522 will revert to the Company for further development and commercialization. Takeda strategic research and development partnership In March 2014, the Company entered into a Research Collaboration and Commercial License Agreement with Takeda through Takeda’s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (the 2014 Agreement). The 2014 Agreement was amended in January 2015 and amended and restated in January 2016 (the 2016 Restated Agreement). The agreements initially provided Takeda with the right to develop ADCs directed to a total of seven exclusive targets, designated by Takeda, over a specified period of time. Takeda will be responsible for the product development and marketing of any products resulting from this collaboration.  To date, the Company has received $24,800 in non-refundable upfront fees, technology access fees or option exercise fees.  For the two targets initially under the 2014 Agreement, the Company initially granted a research license upon designation of a target.  To receive a development and commercialization license for these designated targets, Takeda was required to pay an additional option exercise fee of $1,300.  For the remaining five targets, the Company grants a research, development and commercialization license upon the designation of a target. For each designated target, the Company and Takeda develop research plans to evaluate Takeda's antibodies as ADCs incorporating the Company's technology. The Company receives service fees for its efforts under the research plans. The goal of the research plans is to provide Takeda with sufficient information to formally nominate a development candidate and begin Investigational New Drug Application (IND), enabling studies or cease development on the designated target.  As of September 30, 2018, Takeda had designated four targets and received development and commercialization licenses for the first, third and fourth designated targets and a research license for the second designated target.  Takeda has limited replacement rights for two designated targets, subject to certain contractual restrictions.  Takeda is required to pay $500 to utilize the second limited replacement right. As of September 30, 2018, if products are successfully developed and commercialized, the Company would be entitled to receive aggregate milestones of up to $474,750 for all eligible designated targets consisting of $50,250 in development milestones, $153,000 in regulatory milestones, and $271,500 in commercial milestones. The total milestones payable on each of the remaining eligible three targets are $158,250. There are four individual development milestones per target, which are payable upon the filing of an IND application and the initiation of Phase 1 through Phase 3 clinical trials. There are eight individual regulatory milestones per target. These are payable upon regulatory submissions, regulatory approvals and pricing approvals, as applicable, for the U.S., European Union and Japanese markets and regulatory approvals for both a second and third indication. There are six individual commercial milestones, which are payable upon the first commercial sale in each of the U.S., European Union and Japanese markets and upon the attainment of three separate defined thresholds for annual net sales. The next potential milestone payment the Company will be eligible to receive is a development milestone of $750 related to the filing of an IND. The Company is also entitled to receive royalties on product sales, if any, during the applicable royalty term. Royalties payable on the remaining designated targets are in the mid to high single digits. The Company may elect to exercise an option to co-develop and co-commercialize one product incorporating either Takeda's fifth, sixth or seventh target in the United States for a payment of $15,000. If the Company elects to exercise the option to co-develop and co-commercialize a product, the Company will share in 50% of the profits related to the United States. The Company will be responsible for 50% of costs incurred specifically for the United States and 30% of global development costs. Any costs incurred specifically for a foreign country will be borne 100% by Takeda. If the Company elects to co-develop and co-commercialize a product, certain regulatory milestones and royalties related to the United States for that target would not be paid by Takeda. Unless earlier terminated, the 2016 Restated Agreement will expire upon the expiration of the last royalty term for a product under the agreement, after which time, Takeda will have a perpetual, royalty-free license. Except with respect to the target antigen of a product for which the Company exercised its option to co-develop and co-commercialize in the United States, Takeda may terminate the 2016 Restated Agreement in its entirety or with respect to any target for convenience upon 45 days' prior written notice. Each party may terminate the 2016 Restated Agreement in its entirety upon bankruptcy or similar proceedings of the other party or upon an uncured material breach of the agreement by the other party. However, if such breach only relates to one target, the agreement may only be terminated with respect to such target. Accounting Analysis <a name="_Hlk513711417"></a>For periods prior to January 1, 2018, the Company applied the provisions of ASC 605 in accounting for these arrangements.  Refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 28, 2018 for the accounting analysis under these provisions. Under ASC 605 and Topic 606, the Company has concluded that the 2016 Restated Agreement and the XMT-1522 Agreement should be accounted for as one arrangement due in part because the agreements are with the same party and were negotiated and executed contemporaneously. Further, in applying the contract modification practical expedient, the Company has aggregated the effect of all modifications through the initial date of application of Topic 606 for the purposes of (i) identifying the satisfied and unsatisfied performance obligations, (ii) determining the transaction price and (iii) allocating the transaction price to the satisfied and unsatisfied performance obligations.  The performance obligations and the allocated transaction price as of the date of initial application of Topic 606 are as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Allocated </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Performance obligations </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Transaction Price </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> XMT-1522 license and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 49,828 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Joint research committee services for XMT-1522 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 449 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exclusive license to the first designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,611 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research license to the second designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,017 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Material right related to the exclusive license to the second designated target </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 526 </td> </tr> <tr> <td valign="top" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exclusive license to the third designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,974 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exclusive license to the fourth designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,678 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Material right related to the license to the fifth designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,506 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Material right related to the license to the sixth designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,506 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Material right to license to the seventh designated target and research services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,506 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Material right related to first replacement right for a designated target </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,506 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Material right related to the second replacement right to a designated target </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,116 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Rights to future technological improvements </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,750 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Joint research committee services </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 150 </td> </tr> <tr> <td valign="bottom" style="width:83.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 86,123 </td> </tr> </table></div> The Company has concluded the license related to each of the designated targets is not distinct from the research services performed related to each of the designated targets as Takeda cannot obtain the benefit of the license without the related research services.  Each license to a designated target and the related services performance obligation is considered distinct from every other license to a designated target and related services performance obligation as each research plan is pursued independent of the any other research plans for other designated targets.  Further, the material rights provided in the agreement provide Takeda incremental rights for either no additional consideration or for additional fees that contain a significant discount.  The material rights are distinct from the other performance obligations in the arrangement as they are options in the contract and are not required for Takeda to obtain the benefit of the other promised goods or services in the arrangement.  Similarly, the Company concluded that the XMT-1522 license and the related research and development services, including the Phase 1 development and the transfer certain materials and know how related to the Company's manufacturing processes are one performance obligation. The license to the Company's intellectual property is not distinct from the research and related development services that the Company is obligated to perform. Takeda would not have the ability to realize the value of the license without the Company performing the related services. The Company has concluded that the Post-Phase 1 Development activities under the XMT-1522 Agreement represent joint operating activities in which both parties are active participants and of which both parties are exposed to significant risks and rewards that are dependent on the commercial success of the activities. Accordingly, the Company is accounting for the Post-Phase 1 Development activities in accordance with ASC 808 and they are not considered revenue elements under Topic 606. For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company was billed approximately $2,210,  $924,  $5,013 and $1,719, respectively, from Takeda representing the Company's share of Post-Phase 1 Development costs incurred by Takeda. These amounts have been reflected as research and development costs in the consolidated statement of operations. The Company did not perform any Post-Phase 1 Development activities or incur any associated costs prior to January 1, 2018.   During the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company billed Takeda $1,165,  $0,  $2,959 and $0, respectively, related to ASC 808 costs. As of the date of initial application of Topic 606, the total transaction price for the 2016 Restated Agreement and the XMT-1522 Agreement was $86,123, which included approximately $14,023 of fees associated with research and development activities which had been or were expected to be provided.  The Company utilizes the expected value approach to estimate the amount of consideration related to the fees associated with development and research services.  The Company utilizes the most likely amount approach to estimate any development and regulatory milestone payments to be received.  As of the date of initial application of Topic 606, there were no milestone payments, which had not been received, included in the estimated transaction price.  The Company considered the stage of development and the remaining risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Takeda.  The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be achieved.  The Company has determined that any commercial milestones and sales based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price.  The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. <a name="_Hlk528582654"></a>In the third quarter of 2018, the Company revised its estimate for fees associated with research and development activities under the XMT-1522 Agreement to $9,755. The revised total transaction price for the 2016 Restated Agreement and the XMT-1522 Agreement is $86,429.  <a name="_Hlk511829003"></a>The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation or, in the case of certain variable consideration, to one or more performance obligations.  The estimated standalone selling prices for performance obligations which include a license and research services, was developed using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an estimated market rate for research services. The estimated standalone selling price of the licenses was established based on comparable transactions.  The estimated standalone selling price for the material rights and rights to future technological improvements were developed based on the estimated selling prices of a license or rights received and any fees payable upon exercise of the associated option, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology or exercise the option. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees. The Company will recognize revenue related to the performance obligations, which include research licenses or an exclusive development and commercialization license and the related research services, over the estimated period of the research and development services using a proportional performance model. The Company measures proportional performance based on the costs incurred relative to the total estimated costs of the research.  To the extent that the Company receives fees for the research services as they are performed, these amounts are recorded as deferred revenue. Revenue related to material rights will be recognized when the option is exercised, unless there are additional research services that the Company is required to perform related to the designated target (in which case revenue will be recognized based on the proportional performance model) or at the time the option right lapses. To the extent that the Company receives a fee upon exercise of the option, such amounts are recorded as deferred revenue. Revenue related to the material rights related to replacement rights will be recognized over the research term of the replacement target once the replacement right is exercised or at the time the right lapses unused. To the extent that the Company receives a fee upon exercise of the replacement right, such amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the performance period (which in the case of the joint research committee services approximates the time and cost incurred), which is expected to be ten years and six years, respectively. The Company will reassess the estimated remaining term at each subsequent reporting period. For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company recorded total revenue of $82,  $5,768,  $4,697 and $12,052, respectively, related to its efforts under the 2016 Restated Agreement and the XMT-1522 Agreement. Included in accounts receivable as of September 30, 2018 and December 31, 2017 was $32 and $454, respectively, related to the Takeda agreements. Included in accounts payable as of September 30, 2018 was $530 related to the Takeda agreements. During the quarter ended September 30, 2018, the Company revised its estimate of the total costs to complete research services under the 2016 Restated Agreement and the XMT-1522 Agreement, which changed the total consideration to be received under the agreements and the amount of revenue recognized in the three months and nine months ended September 30, 2018. The Company recognized approximately $1,380 less for the three months and nine months ended September 30, 2018 as a result of the Company’s change in estimate. The change in estimate increased the net loss by $1,380 for the three months and nine months ended September 30, 2018, or $0.06 per common share.  As of September 30, 2018, the Company had $41,104 of deferred revenue related to the Takeda agreements that will be recognized over the remaining performance periods for the applicable obligations. Takeda invested $10,000 as part of the Company’s IPO. Merck KGaA In June 2014, the Company entered into a Collaboration and Commercial License Agreement with Merck KGaA (the Merck KGaA Agreement). Upon the execution of the agreement, Merck KGaA paid the Company a nonrefundable technology access fee of $12,000 for the right to develop ADCs directed to six exclusive targets over a specified period of time. No additional fees are due when a target is designated and the commercial license to the target is granted. Merck KGaA will be responsible for the product development and marketing of any products resulting from this collaboration.  All six targets were designated prior to 2018. Under the terms of the agreement, the Company and Merck KGaA develop research plans to evaluate Merck KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives fees for its efforts under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to formally nominate a development candidate and begin IND-enabling studies or cease development on the designated target. In addition to the payments received for research and development activities performed on behalf of Merck KGaA, the Company is also eligible to receive up to a total of $780,000 in future milestones related to all targets under the agreement, plus low to mid single digit royalties on the commercial sales of any resulting products during the applicable royalty term. The total milestones are categorized as follows: development milestones—$84,000; regulatory milestones—$264,000; and sales milestones—$432,000. There are six individual development milestones per target, payable upon the completion of various activities from the delivery of ADCs meeting defined specifications, through the dosing in a Phase 3 clinical trial. There are five regulatory milestones, which are payable upon regulatory approvals for a first indication in each of the U.S., European Union and Japanese markets and regulatory approvals for both a second and a third indication in the United States. There are three individual commercial milestones, which are payable upon the attainment of certain defined thresholds for annual net sales. <a name="_Hlk513724998"></a>Prior to 2018, the Company had received $3,000 related to development milestones under the agreement.   There have been no additional milestone payments in the nine months ended September 30, 2018.  The next potential milestone payment the Company will be eligible to receive will be a development milestone of $500 on Merck KGaA's designation of a preclinical development candidate for any target. Revenue will be recognized upon achievement of the milestone. The Company and Merck KGaA may also enter into a future supply agreement to provide clinical study material should Merck KGaA pursue clinical development of any candidates nominated under the agreement. Unless earlier terminated, the agreement will expire upon the expiration of the last royalty term for a product under the agreement, after which time, Merck KGaA will have a perpetual, royalty-free license, or if Merck KGaA does not designate any ADC product candidates produced by the Company under the agreement as preclinical development candidates, upon the expiration of the last to expire research program. Merck KGaA may terminate the agreement in its entirety or with respect to any target for convenience upon 60 days' prior written notice. Each party may terminate the Merck KGaA Agreement in its entirety upon bankruptcy or similar proceedings of the other party or upon an uncured material breach of the agreement by the other party. However, if such breach only relates to one target, the agreement may only be terminated with respect to such target. In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the Merck KGaA Supply Agreement). Under the terms of the agreement, the Company will provide Merck KGaA preclinical non-GMP ADC Drug Substance and clinical GMP Drug Substance for use in clinical trials associated with one of the antibodies designated under the Merck KGaA Agreement. The Company receives fees for its efforts under the Merck KGaA Supply Agreement and reimbursement equal to the supply cost. Accounting Analysis For periods prior to January 1, 2018, the Company applied the provisions of ASC 605 in accounting for this arrangement.  Refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 28, 2018 for the accounting analysis under these provisions. By applying the contract modification practical expedient, the Company has aggregated the effect of all modifications through the initial date of application of Topic 606 for the purposes of (i) identifying the satisfied and unsatisfied performance obligations, (ii) determining the transaction price and (iii) allocating the transaction price to the satisfied and unsatisfied performance obligations.  The Company identified the following performance obligations under the agreement: (i) exclusive license and research services for six designated targets, (ii) rights to future technological improvements and (iii) participation of project team leaders and providing joint research committee services. The Company has concluded that each license for a designated target is not distinct from the research services performed related to the designated target as Merck KGaA cannot obtain the benefit of the license without the related research services.  Each license for a designated target and the related services performance obligation is considered distinct from every other license for a designated target and related services performance obligation as each research plan is pursued independent of every other research plans for other designated targets.  As of the date of initial application of Topic 606, the total transaction price for the Merck KGaA Agreement was $22,875, which included approximately $7,875 fees for research and development activities which have been or were expected to be received and $3,000 of milestone payments previously earned.  The Company utilizes the expected value approach to estimate the amount of consideration related to the payment of fees associated with development and research services.  The Company utilizes the most likely amount approach to estimate any development and regulatory milestone payments to be received.  As of the date of initial application of Topic 606, there were no milestones payments that had not already been received, included in the estimated transaction price.  The Company considered the stage of development and the remaining risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Merck KGaA.  The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be achieved.  The Company has determined that any commercial milestones and sales based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price.  The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.  For each of the three and nine months ended September 30, 2018, the transaction price decreased $805 to $22,070 due to a decrease in fees for research and development activities expected to be received, as the Company revised its estimate for fees associated with research and development activities under the Merck KGaA Agreement in the third quarter of 2018 to $7,070. The revised total transaction price for the Merck KGaA Agreement is $22,070. The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation or in the case of certain variable consideration to one or more performance obligations.  The estimated standalone selling prices for performance obligations, that include a license and research services, were developed using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an estimated market rate for research services. The estimated standalone selling price of the licenses was established based on comparable transactions.  The estimated standalone selling price for the rights to future technological improvements was developed based on the estimated selling prices of a license or rights received, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees. The transaction price of $22,875 was allocated to the performance obligations as follows: approximately $4,226 for each of the license and corresponding research and development services units of account for the first and second designated targets; $3,439 for each of the license and corresponding research and development services units of account for the third, fourth,  fifth and sixth designated target; $425 for rights to future technological improvements; and $242 for joint research committee services. The Company is recognizing revenue related to the exclusive license and research and development services performance obligation over the estimated period of the research and development services using a proportional performance model.  The Company measures proportional performance based on the costs incurred relative to the total costs expected to be incurred.  To the extent that the Company receives fees for the research services as they are preformed, these amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the performance period (which in the case of the joint research committee services approximate the time and cost incurred each period), which are 10 and 5 years, respectively.  The Company is continuing to reassess the estimated remaining term at each subsequent reporting period. During the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company recorded revenue of $1,482,  $499,  $2,426 and $2,107, respectively, related to its efforts under the collaboration agreement. Included in accounts receivable as of September 30, 2018 and December 31, 2017 was $163 and $330, respectively, related to the Merck KGaA Agreement. As of September 30, 2018, the Company had recorded $5,480 in deferred revenue related to the Merck KGaA Agreement that will be recognized over the remaining performance period. Summary of Contract Assets and Liabilities The following table presents changes in the balances of our contract assets and liabilities during the three and nine months ended September 30, 2018:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of Period </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Deductions </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Three months ended September 30, 2018 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contract assets </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Contract liabilities: </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 48,208 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 849 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,151 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 46,906 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of Period </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Deductions </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Nine months ended September 30, 2018 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contract assets </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Contract liabilities: </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 52,439 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,373 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,906 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 46,906 </td> </tr> </table></div> The impact of the adoption of the new revenue recognition guidance is reflected within the beginning of period balance. During the three months and nine months ended September 30, 2018, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.20%;"> <tr> <td valign="bottom" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Revenue recognized in the period from: </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Amounts included in the contract liability at the beginning of the period </td> <td valign="middle" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,760 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,515 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Performance obligations satisfied in previous periods </td> <td valign="middle" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div> Other Revenue The Company has provided limited services for a collaboration partner, Asana BioSciences. For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company recorded revenue of $587,  $0,  $782 and $125, respectively, related to these services. In addition, during the nine months ended September 30, 2018, the Company recognized revenue of $1,500 related to a milestone achieved upon the completion of a GLP toxicology study by Asana BioSciences. The next potential milestone the Company is eligible to receive is $2,500 upon dosing the fifth patient in a Phase 1 clinical study by Asana BioSciences. Included in accounts receivable as of September 30, 2018 was $391 related to the Asana agreement. <div /></div> </div>

<div> <div> 9. Commitments<a name="a12Commitments_987935"></a> Operating leases The Company leases office space in Cambridge, MA under an operating lease, which was last amended in January 2018, which is effective through March 2021. The lease also provided the Company with a tenant improvement allowance of up to $356. The Company fully utilized the allowance and recorded the assets acquired with the allowance as leasehold improvements. The Company recorded the tenant improvement allowance as a deferred lease incentive and is amortizing the deferred lease incentive through a reduction of rent expense ratably over the lease term. In connection with the office lease, the Company has a letter of credit agreement for the benefit of its landlord in the amount of $321 as of each of September 30, 2018 and December 31, 2017, respectively, collateralized by a money market account. The Company classified this amount as restricted cash in the accompanying unaudited condensed consolidated balance sheets. For the three months ended September 30, 2018 and 2017 and for the nine months ended September 30, 2018 and 2017, rent expense was $504,  $419,  $1,482 and $1,256, respectively. The Company is recording rent expense on a straight-line basis over the term of the lease and has recorded deferred rent in the unaudited condensed consolidated balance sheets, accordingly. License agreements Through September 30, 2018, the Company has licensed intellectual property from two biotechnology companies. The consideration included upfront payments and a commitment to pay annual license fees, milestone payments, and, upon product commercialization, royalties on revenue generated from the sale of products covered by the licenses. The Company recorded milestone payments of $0 and $2,250 during the nine months ended September 30, 2018 and 2017, respectively. Manufacturing services agreement As of September 30, 2018, the Company had a commitment of approximately $5,700 related to manufacturing services that is expected to be incurred during the three months ending December 31, 2018. <div /></div> </div>

3315850

3205485

110365

225000

3781045

3670680

110365

0.0001

175000000

22765017

23160875

22765017

23160875

3000

-24755000

-7738000

-41718000

-17021000

<div> <div> The following table presents changes in the balances of our contract assets and liabilities during the three and nine months ended September 30, 2018:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of Period </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Deductions </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Three months ended September 30, 2018 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contract assets </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Contract liabilities: </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 48,208 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 849 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,151 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 46,906 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of Period </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Deductions </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Nine months ended September 30, 2018 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contract assets </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Contract liabilities: </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 52,439 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,373 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,906 </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 46,906 </td> </tr> </table></div> The impact of the adoption of the new revenue recognition guidance is reflected within the beginning of period balance. During the three months and nine months ended September 30, 2018, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.20%;"> <tr> <td valign="bottom" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Revenue recognized in the period from: </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Amounts included in the contract liability at the beginning of the period </td> <td valign="middle" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,760 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,515 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:69.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Performance obligations satisfied in previous periods </td> <td valign="middle" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

52439000

2031000

48208000

46906000

5480000

41104000

21635000

14151000

28773000

32756000

7515000

1760000

94450000

2031000

232000

48000

67000

328000

1433000

673000

907000

<div> <div> 8. Stock options<a name="a9StockOptions_965195"></a> Stock option plans In June 2017 the Company’s shareholders approved the 2017 Stock Incentive Plan (the 2017 Plan or the Plan).  Under the 2017 Plan, up to 2,255,000 shares of common stock may be granted to the Company's employees, officers, directors, consultants and advisors in the form of options, restricted stock awards or other stock-based awards. The number of shares of common stock issuable under the Plan will be cumulatively increased annually by 4% of the outstanding shares or such lesser amount specified by the Board. The terms of the awards are determined by the Board, subject to the provisions of the Plan. As of the adoption date of the 2017 Plan, there were 3,141,625 options outstanding under the Company’s 2007 Stock Incentive Plan (the 2007 Plan). Any cancellations under the 2007 Plan would increase the number of shares that could be granted under the 2017 Plan. On January 1, 2018, the number of shares of common stock issuable under the Plan was increased by 910,600 shares. As of September 30, 2018 there were 1,288,227 shares available for future issuance under the Plan. With respect to incentive stock options, the option price per share will equal the fair market value of the common stock on the date of grant, as determined by the Board, and the vesting period is generally four years. Nonqualified stock options will be granted at an exercise price established by the Board at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Options granted under the Plan expire no later than 10 years from the date of grant. The Board may accelerate vesting or extend the expiration of granted options in the case of a merger, consolidation, dissolution, or liquidation of the Company. A summary of the activity under the Plans is as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Life </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of Shares </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in years) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Options outstanding at January 1, 2018 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,205,485 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.44 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.8 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,709 </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,121,415 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14.36 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (395,858) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.17 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cancelled </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (260,362) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7.86 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Options outstanding at September 30, 2018 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,670,680 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.61 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.8 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 17,688 </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Options exercisable at September 30, 2018 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,822,435 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.9 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12,873 </td> </tr> <tr> <td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> The weighted-average grant date fair value of options granted during the nine months ended September 30, 2018 and 2017, was $9.45 and $5.27 per share, respectively. Cash received from the exercise of stock options was $853 and $431 for the nine months ended September 30, 2018 and 2017, respectively. Stock-based compensation The Company uses the provisions of ASC 718, Stock Compensation, to account for stock-based awards. The measurement date for employee awards is generally the date of grant. Stock-based compensation expense is recognized over the requisite service period, which is generally the vesting period, using the straight-line method. For the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, the Company recorded stock-based compensation expense of $1,053,  $373,  $2,756 and $990, respectively. The Company had an aggregate of $11,129 of unrecognized stock compensation cost as of September 30, 2018 remaining to be amortized over the weighted-average period of 2.9 years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="3" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="3" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="3" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.9 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.9 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.7 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.2 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (years) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.85 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.01 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.06 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.22 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected stock price volatility </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 73 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 65 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 73 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 67 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> Employee Stock Purchase Plan In connection with the IPO, the Board adopted and the Company's stockholders approved the 2017 employee stock purchase plan (the 2017 ESPP), which became effective upon the closing of the IPO in July 2017. The Company has reserved 225,000 shares of common stock for issuance under the 2017 ESPP. The Company has not issued any shares under the 2017 ESPP. <div /></div> </div>

-2.94

-0.35

-1.82

-0.06

-0.02

-0.74

-0.06

0.00

<div> <div> Net Loss per Share Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, warrants to purchase common stock and options to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares): <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.56%;"> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110,365 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 129,491 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110,365 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 129,491 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,670,680 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,205,714 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,670,680 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,205,714 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,781,045 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,335,205 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,781,045 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,335,205 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

3041000

2482000

P2Y10M24D

11129000

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in Active </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Markets </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61,604 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61,604 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. Treasuries </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,455 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,455 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 86,059 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 86,059 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in Active </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Markets </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 26,591 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 26,591 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. Treasuries </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,640 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,640 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,931 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,931 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,054 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,054 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 125,216 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 89,231 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 35,985 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 4. Fair value measurements<a name="a4FairValueMeasurements_936112"></a> The following table presents information about the Company's assets and liabilities regularly measured and carried at a fair value and indicates the level within fair value hierarchy of the valuation techniques utilized to determine such value as of September 30, 2018 and December 31, 2017: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in Active </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Markets </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61,604 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61,604 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. Treasuries </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,455 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,455 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 86,059 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 86,059 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in Active </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Markets </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 26,591 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 26,591 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. Treasuries </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,640 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,640 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,931 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,931 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,054 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,054 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 125,216 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 89,231 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 35,985 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div> There were no changes in valuation techniques or transfers between fair value measurement levels during the nine months ended September 30, 2018 and 2017. As of September 30, 2018 and December 31, 2017, cash and cash equivalents were comprised of cash and money market funds. <div /></div> </div>

-20000

7406000

2905000

12181000

4380000

1112000

3619000

-320000

-198000

1132000

3568000

-47000

1433000

1791000

1379000

527000

318000

1049000

340000

60721000

64524000

130715000

94378000

31881000

31440000

<div> <div> Marketable Securities Short-term marketable securities consist of investments with maturities greater than three months and less than one year from the balance sheet date. Long-term marketable securities consist of investments with maturities greater than one year that are not expected to be used to fund current operations. The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Amortization and accretion of discounts and premiums are recorded as interest income within other income. Unrealized gains and losses on available-for-sale securities are included in other comprehensive loss as a component of stockholders’ equity until realized. <div /></div> </div>

<div> <div> 5. Marketable securities The following table summarizes marketable securities held at September 30, 2018 and December 31, 2017: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. Treasuries </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,497 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (42) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,455 </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,497 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,455 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <a name="_Hlk513215406"></a>  </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. Treasuries </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,777 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (137) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,640 </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,931 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,931 </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,066 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (12) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,054 </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 98,774 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (149) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 98,625 </td> </tr> </table></div> As of September 30, 2018, the Company held 7 securities that were in an unrealized loss position. The aggregate fair value of securities held by the Company in an unrealized loss position for less than 12 months at September 30, 2018 was $24,455 and there were no securities held by the Company in an unrealized loss position for more than 12 months. As of September 30, 2018, the Company did not intend to sell, and would not be more likely than not required to sell, the securities in an unrealized loss position before recovery of their amortized cost basis. Furthermore, the Company has determined that there was no material change in the credit risk of these securities. As a result, the Company determined it did not hold any securities with any other-than-temporary impairment as of September 30, 2018. There were no realized gains or losses on available-for-sale securities during the nine month periods ended September 30, 2018 and 2017. <div /></div> </div>

68576000

853000

-86434000

73472000

-31683000

-39312000

-38707000

-41825000

-24740000

-7732000

-41825000

-17069000

-24740000

-7732000

-41825000

-17069000

527000

318000

1049000

340000

39551000

14317000

52279000

19560000

1256000

419000

1482000

504000

228000

552000

371000

1804000

5700000

-15000

-6000

107000

48000

111321000

433000

1093000

0.0001

25000000

2025000

3404000

67420000

725000

10000000

67420000

725000

25320000

74565000

431000

853000

-24740000

-7732000

-41825000

-1380000

-570000

-17069000

-1380000

2000

2319000

2525000

32145000

1719000

11412000

924000

40098000

5013000

15180000

2210000

us-gaap:OtherAssetsNoncurrent

371000

-97878000

-141734000

14284000

2107000

12052000

125000

6267000

499000

5768000

9405000

2426000

4697000

-1380000

782000

1500000

-570000

2151000

1482000

82000

-1380000

587000

2000

true

<div> <div> Revenue Recognition Effective January 1, 2018, the Company adopted the provisions of Topic 606, using the modified retrospective transition method.  Under this method, the Company recorded the cumulative effect of initially applying the new standard to all contracts in process as of the date of adoption.  This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.  <a name="_Hlk529518541"></a>The adoption of the new revenue recognition guidance resulted in increases of $2,031 in deferred revenue and accumulated deficit as of January 1, 2018. For the three months ended September 30, 2018, revenue increased by $2, net loss decreased by $2 and basic and diluted net loss per share decreased by $0.00, based on revenue recognition under Topic 606 as compared to the Company’s prior revenue recognition methodology under ASC 605 Revenue Recognition. For the nine months ended September 30, 2018, revenue decreased by $570, net loss increased by $570 and basic and diluted net loss per share increased by $0.02, based on revenue recognition under Topic 606 as compared to the Company’s prior revenue recognition methodology under ASC 605 Revenue Recognition. These changes were primarily caused by the differences in determining and allocating transaction price under Topic 606. The Company enters into collaboration agreements which are within the scope of Topic 606, under which the Company licenses rights to its technology and certain of the Company’s product candidates and performs research and development services for third parties.  The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.   Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.   The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.  The promised good or services in the Company’s arrangement typically consist of license rights to the Company’s intellectual property and research and development services.  The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.  Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.  Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.  In assessing whether promised good or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.  The consideration may include both fixed consideration or variable consideration.  At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.  The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method better predicts the amount expected to be received.  If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services or any significant difference is due to factors other than financing; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract. The Company’s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is not probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.  Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are not included in the transaction price.  At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).  To date, the Company has not recognized any royalty revenue resulting from any of the Company’s collaboration arrangements. The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.  The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.  The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.  Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.    For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.  If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30 day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional. Collaborative Arrangements The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808, Collaborative Arrangements (ASC 808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company considers the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606. <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued payroll and related expenses </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,482 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,041 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued preclinical, manufacturing and clinical expenses </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,610 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,183 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued professional fees </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 868 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 492 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued other </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 552 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 228 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,512 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,944 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares): <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.56%;"> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110,365 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 129,491 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110,365 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 129,491 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,670,680 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,205,714 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,670,680 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,205,714 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,781,045 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,335,205 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,781,045 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,335,205 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. Treasuries </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,497 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (42) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,455 </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,497 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,455 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. Treasuries </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,777 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (137) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,640 </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,931 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,931 </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,066 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (12) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,054 </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 98,774 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (149) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 98,625 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.42%;"> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110,365 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110,365 </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,670,680 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,205,485 </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,781,045 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,315,850 </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additional </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Accumulated </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stockholders’ </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:20.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Common Stock </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Paid-in </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other Comprehensive </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Accumulated </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Equity </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amount </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Capital </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Income (Loss) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Deficit </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Deficit) </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2016 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,294,352 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,551 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (59,171) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (55,619) </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,470,665 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  2 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 164,467 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (149) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (38,707) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 125,613 </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2017 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 22,765,017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 168,018 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (149) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (97,878) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 69,994 </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 395,858 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,609 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 107 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (43,856) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (40,140) </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at September 30, 2018 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 23,160,875 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 171,627 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (141,734) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 29,854 </td> </tr> </table></div>   <div /></div> </div>

321000

990000

2756000

P4Y

P10Y

P6Y2M19D

P6Y4D

P6Y22D

P5Y10M6D

0.67

0.65

0.73

0.022

0.019

0.027

0.029

910600

2255000

1288227

12873000

1822435

3.24

P6Y10M24D

260362

1121415

41709000

17688000

3141625

3205485

3670680

3.44

6.61

P7Y9M18D

5.27

9.45

0.04

2.17

7.86

14.36

<div> <div> Accounting for Stock-based Compensation The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation—Stock Compensation (ASC 718). ASC 718 requires all stock-based payments to employees and directors to be recognized as expense in the statements of operations based on their grant date fair values. Expense related to stock awards to non-employees is required to be recognized in the statement of operations based on the awards' vesting date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate and (iv) the expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the IPO and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so. There were significant judgments and estimates inherent in the determination of the fair value of our common stock prior to the closing of the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an IPO or sale. In the first quarter of 2017, the Company made an accounting policy election to recognize forfeitures as they occur upon adoption of guidance per ASU No. 2016-09. The adoption of this ASU did not have a material impact on the Company's financial statements. <div /></div> </div>

15.00

1294352

22765017

23160875

<div> <div> <a name="_Hlk529279245"></a>2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include those of the Company and its subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, management’s judgments with respect to the performance obligations and estimated selling prices within its revenue arrangements, accrued expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates. The Company utilized significant estimates and assumptions in determining the fair value of its common stock prior to the Company’s IPO. The Company has utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately‑Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company's chief operating decision-maker, the Company's chief executive officer, view the Company's operations and manage its business as a single operating segment, which is the business of discovering and developing ADCs. Research and Development The Company expenses all costs incurred in performing research and development activities. Research and development expenses include salaries and benefits, materials and supplies, preclinical expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. Costs of certain development activities, such as manufacturing, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs associated with collaboration agreements are included in research and development expense. Revenue Recognition Effective January 1, 2018, the Company adopted the provisions of Topic 606, using the modified retrospective transition method.  Under this method, the Company recorded the cumulative effect of initially applying the new standard to all contracts in process as of the date of adoption.  This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.  <a name="_Hlk529518541"></a>The adoption of the new revenue recognition guidance resulted in increases of $2,031 in deferred revenue and accumulated deficit as of January 1, 2018. For the three months ended September 30, 2018, revenue increased by $2, net loss decreased by $2 and basic and diluted net loss per share decreased by $0.00, based on revenue recognition under Topic 606 as compared to the Company’s prior revenue recognition methodology under ASC 605 Revenue Recognition. For the nine months ended September 30, 2018, revenue decreased by $570, net loss increased by $570 and basic and diluted net loss per share increased by $0.02, based on revenue recognition under Topic 606 as compared to the Company’s prior revenue recognition methodology under ASC 605 Revenue Recognition. These changes were primarily caused by the differences in determining and allocating transaction price under Topic 606. The Company enters into collaboration agreements which are within the scope of Topic 606, under which the Company licenses rights to its technology and certain of the Company’s product candidates and performs research and development services for third parties.  The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.   Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.   The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.  The promised good or services in the Company’s arrangement typically consist of license rights to the Company’s intellectual property and research and development services.  The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.  Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.  Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.  In assessing whether promised good or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.  The consideration may include both fixed consideration or variable consideration.  At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.  The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method better predicts the amount expected to be received.  If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services or any significant difference is due to factors other than financing; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract. The Company’s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is not probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.  Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are not included in the transaction price.  At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).  To date, the Company has not recognized any royalty revenue resulting from any of the Company’s collaboration arrangements. The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.  The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.  The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.  Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.    For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.  If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30 day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional. Collaborative Arrangements The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808, Collaborative Arrangements (ASC 808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company considers the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606. Fair Value Measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820 Fair Value Measurement (ASC 820) establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows: Level 1—Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2—Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level 3—Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value. <a name="_Hlk513720952"></a>The following amounts were presented as cash, cash equivalents and restricted cash: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2017 </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of period </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26,591 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,604 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 100,297 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 50,756 </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted cash included in other assets </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 371 </td> </tr> <tr> <td valign="bottom" style="width:53.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash, cash equivalents and restricted cash per statement of cash flows </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26,962 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,975 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 100,668 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 51,127 </td> </tr> </table></div>   Marketable Securities Short-term marketable securities consist of investments with maturities greater than three months and less than one year from the balance sheet date. Long-term marketable securities consist of investments with maturities greater than one year that are not expected to be used to fund current operations. The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Amortization and accretion of discounts and premiums are recorded as interest income within other income. Unrealized gains and losses on available-for-sale securities are included in other comprehensive loss as a component of stockholders’ equity until realized. <a name="_Hlk513720937"></a>Other Assets The Company recorded other assets of $1,804 and $371 as of September 30, 2018 and December 31, 2017, respectively. The September 30, 2018 amount is comprised of restricted cash of $371 held as security deposits for a standby letter of credit related to a facility lease and a corporate credit card program and $1,433 held by a service provider. The December 31, 2017 amount is comprised of restricted cash. Accounting for Stock-based Compensation The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation—Stock Compensation (ASC 718). ASC 718 requires all stock-based payments to employees and directors to be recognized as expense in the statements of operations based on their grant date fair values. Expense related to stock awards to non-employees is required to be recognized in the statement of operations based on the awards' vesting date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate and (iv) the expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the IPO and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so. There were significant judgments and estimates inherent in the determination of the fair value of our common stock prior to the closing of the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an IPO or sale. In the first quarter of 2017, the Company made an accounting policy election to recognize forfeitures as they occur upon adoption of guidance per ASU No. 2016-09. The adoption of this ASU did not have a material impact on the Company's financial statements. Net Loss per Share Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, warrants to purchase common stock and options to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares): <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.56%;"> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110,365 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 129,491 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110,365 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 129,491 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,670,680 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,205,714 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,670,680 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,205,714 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,781,045 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,335,205 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,781,045 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,335,205 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Patent Costs The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. Income Taxes The Company accounts for income taxes using the liability method.  The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Comprehensive Income (Loss) Comprehensive income (loss) is comprised of net loss and other comprehensive income (loss). For the three and nine months ended September 30, 2018 and 2017, other comprehensive loss consisted of unrealized gain (loss) on marketable securities. Concentration of Credit Risk and Off-Balance Sheet Risk The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. Cash, cash equivalents, and marketable securities are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. Recently Issued Accounting Pronouncements In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments (ASU No. 2016-01) related to the recording of financial assets and financial liabilities. Under the amended guidance, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) are to be measured at fair value with changes in fair value recognized in net income (loss). However, an entity has the option to measure equity investments without readily determinable fair values either (i) at fair value or (ii) at cost, adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative will be recognized in net income (loss). The amended guidance became effective January 1, 2018. The Company adopted the new standard effective January 1, 2018. Based on the Company’s current investment holdings, the adoption of this new standard did not have a material impact on its consolidated financial position or results of operations. In February 2016, the FASB issued ASU No. 2016-02, Leases (ASU No. 2016-02), which will replace the existing guidance in ASC 840, Leases. The updated standard aims to increase transparency and comparability among organizations by requiring lessees to recognize lease assets and lease liabilities on the balance sheet and requiring disclosure of key information about leasing arrangements. This standard is effective for the Company in the fiscal year beginning after December 15, 2018, but early adoption is permissible. The Company is currently evaluating the potential impact that ASU No. 2016-02 may have on its financial position and results of operations. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of contingent consideration payments made after a business combination and several other clarifications not currently applicable to the Company. The new standard also clarifies that an entity should determine each separately identifiable source or use within cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The Company adopted the new standard effective January 1, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated statement of cash flows. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows: Restricted Cash (ASU No. 2016-18). The amendments in this update require that amounts generally described as restricted cash and restricted cash equivalents be included within cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The Company adopted the new standard effective January 1, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated statement of cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting. This guidance is intended to provide clarity and reduce diversity in practice as to when changes to the terms or conditions of share-based payments are accounted for as modifications. Under this new guidance, entities will apply modification accounting if the fair value, vesting conditions or classification of the award changes. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2017-09 is to be adopted prospectively to an award modified on or after the adoption date. The Company adopted the new standard effective January 1, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated statement of cash flows. In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808):Clarifying the Interaction between Topic 808 and Topic 606. The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-18 is to be adopted retrospectively to the date of initial application of Topic 606. The Company is currently evaluating the potential impact that ASU No. 2018-18 may have on its financial position and results of operations.   <div /></div> </div>

-55619000

3551000

1000

-59171000

69994000

-149000

168018000

3000

-97878000

29854000

-42000

171627000

3000

-141734000

<div> <div> 7. Stockholders’ equity <a name="a8StockholdersDeficitEquity_454186"></a> The following table presents the changes in the separate accounts comprising stockholders’ equity for the year ended December 31, 2017 and the nine months ended September 30, 2018, respectively. <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additional </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Accumulated </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stockholders’ </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:20.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Common Stock </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Paid-in </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other Comprehensive </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Accumulated </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Equity </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amount </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Capital </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Income (Loss) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Deficit </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Deficit) </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2016 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,294,352 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,551 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (59,171) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (55,619) </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,470,665 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  2 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 164,467 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (149) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (38,707) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 125,613 </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2017 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 22,765,017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 168,018 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (149) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (97,878) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 69,994 </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 395,858 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,609 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 107 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (43,856) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (40,140) </td> </tr> <tr> <td valign="bottom" style="width:23.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at September 30, 2018 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 23,160,875 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 171,627 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (141,734) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 29,854 </td> </tr> </table></div> Preferred stock As of September 30, 2018, the Company had 25,000,000 shares of authorized preferred stock. No shares of preferred stock have been issued. Common stock The holders of the common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors (the Board). At September 30, 2018 and December 31, 2017, there were 3,781,045 and 3,315,850 shares of common stock, respectively, reserved for the exercise of outstanding stock options and warrants (in common stock equivalent shares). <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.42%;"> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <a name="iSkippedRange_30774"></a>  </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110,365 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110,365 </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,670,680 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,205,485 </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,781,045 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,315,850 </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div> At-the-market equity offering program On July 2, 2018, the Company established an at-the-market equity offering program (ATM) pursuant to which it is able to offer and sell up to $75,000 of its common stock from time to time at prevailing market prices. As of September 30, 2018, the Company had not sold any shares under the ATM. Warrants In connection with a 2013 Series A-1 Preferred Stock issuance, the Company granted to certain investors warrants to purchase 129,491 shares of common stock. The warrants have a $0.05 per share exercise price and a contractual life of 10 years. The fair value of these warrants was recorded as a component of equity at the time of issuance. As of September 30, 2018, warrants to purchase 110,365 shares of common stock were outstanding. <div /></div> </div>

0.2222

125613000

-149000

164467000

2000

-38707000

-40140000

107000

3609000

-43856000

5000000

51977

21470665

395858

<div> <div> 10. Subsequent events<a name="a14SubsequentEvents_583350"></a> For the purposes of the unaudited financial statements as of September 30, 2018 and the period then ended, the Company has evaluated subsequent events through November 13, 2018, the date the unaudited interim financial statements were issued. There were no items requiring adjustment or disclosure in the consolidated financial statements.   <div /></div> </div>

false

8407541

22242129

22979516

23152019

EX-101.SCH 6 mrsn-20180930.xsd EX-101.SCH 00100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of significant accounting policies - Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of significant accounting policies - Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Collaboration agreements - Takeda partnership (Details) link:presentationLink link:calculationLink link:definitionLink 40306 - Disclosure - Collaboration agreements - Merck KGaA Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Fair value measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Marketable securities (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of business and basis of presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Collaboration agreements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Marketable securities link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Stockholders' equity (deficit) link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock options link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Collaboration Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Marketable securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accrued expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Stockholders' equity (deficit) (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Stock options (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of business and basis of presentation - IPO (Details) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - Nature of business and basis of presentation - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of significant accounting policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Summary of significant accounting policies - Antidilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 40205 - Disclosure - Summary of significant accounting policies - Risks (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Collaboration agreements - XMT-1522 Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Accounting (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Performance obligations (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Additional Accounting (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Additional Accounting Default (Details) link:presentationLink link:calculationLink link:definitionLink 40307 - Disclosure - Collaboration agreements - Merck KGaA Agreement - Accounting (Details) link:presentationLink link:calculationLink link:definitionLink 40307 - Disclosure - Collaboration agreements - Merck KGaA Agreement - Accounting Default (Details) link:presentationLink link:calculationLink link:definitionLink 40308 - Disclosure - Collaboration Agreements - Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40309 - Disclosure - Collaboration Agreements - Other Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Stockholders' Equity - Statement (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Stockholders' Equity - Stock and warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Stockholders' Equity - At-the-market equity offering program (Details) link:presentationLink link:calculationLink link:definitionLink 40704 - Disclosure - Stockholders' Equity - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock options - Plans (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Stock options - Activity under stock option plan (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Stock options - Stock based compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Stock options - Fair value of each option award (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Stock options - Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Commitments - Operating leases (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Commitments - License agreements (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mrsn-20180930_cal.xml EX-101.CAL EX-101.DEF 8 mrsn-20180930_def.xml EX-101.DEF EX-101.LAB 9 mrsn-20180930_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Condensed Consolidated Balance Sheets Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Debt Securities, Available-for-sale, Current Short-term marketable securities Accounts Receivable, Net, Current Accounts receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Debt Securities, Available-for-sale, Noncurrent Long-term marketable securities Other Assets, Noncurrent Other assets Other assets Assets Total assets abilities and Equity [Abstract] Liabilities and stockholders’ equity Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Deferred Rent Credit, Current Deferred rent Contract with Customer, Liability, Current Deferred revenue Deferred revenue, current Liabilities, Current Total current liabilities Deferred Rent Credit, Noncurrent Deferred rent, net of current portion Contract with Customer, Liability, Noncurrent Deferred revenue, net of current portion Liabilities Total liabilities Commitments and Contingencies. Commitments (Note 9) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity Preferred Stock, Value, Issued Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Common stock, $0.0001 par value; 175,000,000 shares authorized; 23,160,875 and 22,765,017 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance at end of period Balance at beginning of period Total stockholders’ equity Liabilities and Equity Total liabilities and stockholders’ equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations and Comprehensive Loss Revenue from Contract with Customer, Excluding Assessed Tax Collaboration revenue Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Other income: Interest Income (Expense), Nonoperating, Net Interest income Nonoperating Income (Expense) Total other income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net loss Net income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive loss: Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gain (loss) on marketable securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders - basic Net Income (Loss) Available to Common Stockholders, Diluted Net loss attributable to common stockholders - diluted Earnings Per Share, Basic and Diluted Net loss per share attributable to common stockholders — basic and diluted Basic and diluted net income (loss) per share (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted Condensed Consolidated Statements of Cash Flows Adjustments for New Accounting Pronouncements [Axis] Type Of Adoption [Member] Type of Adoption [Domain] Accounting Standards Update201409 [Member] ASU 2014-09 Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] I P O [Member] IPO Over Allotment Option [Member] Over allotment option Cash flows from operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of fixed assets Accretion (Amortization) of Discounts and Premiums, Investments Net amortization of premiums and discounts on investments Share-based Compensation. Stock-based compensation The amount of change in deferred rent during the reporting period. Change in Deferred Rent Change in deferred rent Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. Increase (Decrease) in Contract with Customer, Liability Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Cash flows from investing activities Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Maturities of marketable securities Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Payments to Acquire Available-for-sale Securities, Debt Purchase of marketable securities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash provided by (used in) investing activities Cash flows from financing activities Proceeds from Issuance Initial Public Offering Net proceeds from issuance of stock Proceeds from IPO Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options Cash received from the exercise of stock options (in dollars) Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, beginning of period Total cash, cash equivalents and restricted cash per statement of cash flows Supplemental disclosures of non-cash activities: Conversion of Stock, Amount Converted Conversion of preferred stock to common stock upon closing of initial public offering Capital Expenditures Incurred but Not yet Paid Purchases of property and equipment included in accounts payable and accrued expenses Cumulative Effect on Retained Earnings, Net of Tax Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606 Nature of business and basis of presentation Business Description and Basis of Presentation [Text Block] Nature of business and basis of presentation Summary of significant accounting policies Significant Accounting Policies [Text Block] Summary of significant accounting policies No definition available. Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Collaboration agreements Fair value measurements Fair Value, Measurement Inputs, Disclosure [Text Block] Fair value measurements Marketable securities Marketable Securities [Table Text Block] Marketable securities Accrued expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued expenses Stockholders' equity (deficit) Stockholders' Equity Note Disclosure [Text Block] Stockholders' deficit Stock options Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock options Commitments Commitments Disclosure [Text Block] Commitments Subsequent events Subsequent Events [Text Block] Subsequent events Consolidation, Policy [Policy Text Block] Principles of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Segment Reporting, Policy [Policy Text Block] Segment Information Research and Development Expense, Policy [Policy Text Block] Research and Development Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Marketable Securities, Policy [Policy Text Block] Marketable Securities Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Other Assets Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Accounting for Stock-based Compensation Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Disclosure of accounting policy for patent costs. Patent Costs [Policy Text Block] Patent Costs Income Tax, Policy [Policy Text Block] Income Taxes Comprehensive Income, Policy [Policy Text Block] Comprehensive Income (Loss) Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk and Off-balance Sheet Risk New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Tabular disclosure of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] Schedule of cash, cash equivalents and restricted cash Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share Tabular disclosure of allocated transaction price of performance obligations. Revenue, Remaining Performance Obligation, Allocated Transaction Price [Table Text Block] Schedule of allocated transaction price of performance obligations Contract with Customer, Asset and Liability [Table Text Block] Schedule of changes in the balances of our contract assets and liabilities and recognized revenue Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of assets and liabilities measured and carried at fair value Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of reconciliation of marketable securities from cost basis to fair value Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accrued expenses Schedule of Stockholders Equity [Table Text Block] Schedule of stockholder's equity Schedule of Stock by Class [Table Text Block] Schedule for number of common stock reserved for conversion of outstanding Preferred Stock and for the exercise of outstanding stock options and warrants Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of stock option activity under Plan Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted average assumptions for estimating fair value of option awards Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Initial public offering Stock Issued During Period, Shares, New Issues Issuance of stock (in shares) Number of shares sold Shares Issued, Price Per Share Share price (in dollars per share) The gross proceeds associated with the entity's first offering of stock to the public. Proceeds from Issuance Initial Public Offering, Gross Gross proceeds Discounts and commissions deducted from cash proceeds received on stock transaction. Stock issuance, Discounts And Commissions On Transaction Underwriting discounts and commissions and other offering costs Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split Net Income (Loss) Attributable to Parent Net loss Substantial Doubt about Going Concern, within One Year Substantial doubt about going concern, within twelve months Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference Between Revenue Guidance In Effect Before And After Topic606 [Member] Difference between Revenue Guidance in Effect before and after Topic 606 Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaboration agreements Offering program Contract with Customer, Liability Deferred revenue, Balance at End of Period Deferred revenue, Balance at Beginning of Period Deferred revenue Period over which entity receives payment upon billing. Revenue, Collection Period Billing term Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Cash, cash equivalents and restricted cash Restricted Cash, Noncurrent Restricted cash included in other assets Restricted Cash, Asset, Statement of Financial Position [Extensible List] Restricted cash, Balance Sheet Location Schedule of Restricted Cash and Cash Equivalents [Table] Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Investments [Abstract] Other Assets Deposit Assets Held by service provider Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants Employee Stock Option [Member] Stock options. Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities Concentration and risks Concentration of Credit Risk and Off-balance Sheet Risk Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure Financial instruments with off-balance sheet risk Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Represents information pertaining to the Development Collaboration and Commercial License Agreement for the development and commercialization of XMT-1522 with Takeda Pharmaceutical Company Limited. Development Collaboration And Commercial License Agreement Takeda [Member] XMT-1522 Agreement Range [Axis] Range [Member] Range [Domain] Maximum [Member] Maximum Geographical [Axis] EX-101.PRE 10 mrsn-20180930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 12, 2018
Document and Entity Information
Entity Registrant Name	Mersana Therapeutics, Inc.
Entity Central Index Key	0001442836
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		23,182,472
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 61,604	$ 26,591
Short-term marketable securities	24,455	88,143
Accounts receivable	586	784
Prepaid expenses and other current assets	3,404	2,025
Total current assets	90,049	117,543
Property and equipment, net	2,525	2,319
Long-term marketable securities		10,482
Other assets	1,804	371
Total assets	94,378	130,715
Current liabilities:
Accounts payable	6,729	3,070
Accrued expenses	10,512	6,944
Deferred rent	48	232
Deferred revenue	14,151	21,635
Total current liabilities	31,440	31,881
Deferred rent, net of current portion	328	67
Deferred revenue, net of current portion	32,756	28,773
Total liabilities	64,524	60,721
Commitments (Note 9)
Stockholders' equity
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
Common stock, $0.0001 par value; 175,000,000 shares authorized; 23,160,875 and 22,765,017 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	3	3
Additional paid-in capital	171,627	168,018
Accumulated other comprehensive loss	(42)	(149)
Accumulated deficit	(141,734)	(97,878)
Total stockholders’ equity	29,854	69,994
Total liabilities and stockholders’ equity	$ 94,378	$ 130,715

XML 13 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Condensed Consolidated Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	175,000,000
Common stock, shares issued	23,160,875	22,765,017
Common stock, shares outstanding	23,160,875	22,765,017

XML 14 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Condensed Consolidated Statements of Operations and Comprehensive Loss
Collaboration revenue	$ 2,151	$ 6,267	$ 9,405	$ 14,284
Operating expenses:
Research and development	15,180	11,412	40,098	32,145
General and administrative	4,380	2,905	12,181	7,406
Total operating expenses	19,560	14,317	52,279	39,551
Other income:
Interest income	340	318	1,049	527
Total other income	340	318	1,049	527
Net loss	(17,069)	(7,732)	(41,825)	(24,740)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	48	(6)	107	(15)
Comprehensive loss	(17,021)	(7,738)	(41,718)	(24,755)
Net loss attributable to common stockholders - basic	(17,069)	(7,732)	(41,825)	(24,740)
Net loss attributable to common stockholders - diluted	$ (17,069)	$ (7,732)	$ (41,825)	$ (24,740)
Net loss per share attributable to common stockholders — basic and diluted	$ (0.74)	$ (0.35)	$ (1.82)	$ (2.94)
Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted	23,152,019	22,242,129	22,979,516	8,407,541

XML 15 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities
Net loss	$ (41,825)	$ (24,740)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	907	673
Loss on disposal of fixed assets	20
Net amortization of premiums and discounts on investments	(288)	(118)
Stock-based compensation	2,756	990
Change in deferred rent	77	(115)
Changes in operating assets and liabilities:
Accounts receivable	198	320
Prepaid expenses and other current assets	(1,379)	(1,791)
Other assets	(1,433)	47
Accounts payable	3,619	1,112
Accrued expenses	3,568	1,132
Deferred revenue	(5,532)	(9,193)
Net cash used in operating activities	(39,312)	(31,683)
Cash flows from investing activities
Maturities of marketable securities	74,565	25,320
Purchase of property and equipment	(1,093)	(433)
Purchase of marketable securities		(111,321)
Net cash provided by (used in) investing activities	73,472	(86,434)
Cash flows from financing activities
Proceeds from exercise of stock options	853	431
Net cash provided by financing activities	853	68,576
Increase (decrease) in cash, cash equivalents and restricted cash	35,013	(49,541)
Cash, cash equivalents and restricted cash, beginning of period	26,962	100,668
Cash, cash equivalents and restricted cash, end of period	61,975	51,127
Supplemental disclosures of non-cash activities:
Conversion of preferred stock to common stock upon closing of initial public offering		94,450
Purchases of property and equipment included in accounts payable and accrued expenses	75	82
Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606	$ 2,031
IPO
Cash flows from financing activities
Net proceeds from issuance of stock		67,420
Over allotment option
Cash flows from financing activities
Net proceeds from issuance of stock		$ 725

XML 16 R6.htm IDEA: XBRL DOCUMENT

Nature of business and basis of presentation	9 Months Ended
Nature of business and basis of presentation	Sep. 30, 2018
Nature of business and basis of presentation
Nature of business and basis of presentation	1. Nature of business and basis of presentation Mersana Therapeutics, Inc. is a clinical stage company located in Cambridge, Massachusetts. The Company is advancing a proprietary pipeline of targeted oncology therapeutics leveraging multiple proprietary platforms, including its Dolaflexin® antibody drug conjugate (ADC) platform. The Company’s first product candidate, XMT-1522, an ADC designed to address a much broader population of patients with HER2-antigen expressing tumors than served by currently approved HER2 therapies, is currently in a Phase 1 dose escalation study. The Company’s second clinical stage product candidate, XMT-1536, an ADC targeting NaPi2b, an antigen broadly expressed in certain types of cancer, is also in a Phase 1 dose escalation study. In addition, the Company has established a strategic partnership with Takeda Pharmaceutical Company Limited (Takeda) under which Takeda obtained rights to XMT‑1522 outside of the United States and Canada. The Company has also established strategic research and development partnerships with Takeda and Merck KGaA for the development and commercialization of additional ADC product candidates against a limited number of targets selected by the Company’s partners based on the Company’s Dolaflexin platform. The Company has other earlier stage platforms, including Dolasynthen and Alkymer and is developing an ADC platform for immuno-oncology indications. The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products. On September 17, 2018, the Company announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold that had been imposed on the Phase 1 study of XMT-1522 that was announced on July 19, 2018. As part of its plan to resume dosing in the study, the Company made changes to the study protocol, including a once-every-four-week dosing regimen, increased monitoring and exclusion of patients with advanced hepatic impairment. The partial clinical hold, the protocol changes and the approval process for the protocol changes have resulted in a change in the expected timeline for clinical results for XMT-1522. Selection of a recommended Phase 2 dose is expected in mid-2019. On July 3, 2017, the Company completed an initial public offering (IPO), in which the Company issued and sold 5,000,000 shares of its common stock at a public offering price of $15.00 per share, for aggregate gross proceeds of $75,000. The Company received $67,420 in net proceeds after deducting $7,580 of underwriting discounts and commissions and offering costs. On August 2, 2017, the Company issued and sold 51,977 shares of common stock at $15.00 per share for gross proceeds of $780 upon the partial exercise of the underwriters’ overallotment option. The Company received net proceeds of $725 after deducting $55 in underwriting discounts and commissions. In connection with preparing for the IPO, the Company effected a 1-for-4.5 reverse stock split of the Company’s common stock. The reverse stock split became effective on June 15, 2017. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. All share and per share amounts in the financial statements and the notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. The Company has incurred net losses since inception. The Company’s net loss was $41,825 for the nine months ended September 30, 2018 and $38,707 for the year ended December 31, 2017. The Company expects to continue to incur operating losses for at least the next several years. As of September 30, 2018, the Company had an accumulated deficit of $141,734. The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. The Company’s net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company’s stockholders' deficit and working capital. The Company believes that its existing cash, cash equivalents and marketable securities as of September 30, 2018, will enable it to fund its current operating plan for at least the next twelve months, which the Company expects will allow it to achieve initial clinical data readouts for its two clinical stage development programs, select recommended Phase 2 doses and continue to advance its earlier assets. The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2017 and the notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 28, 2018. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of September 30, 2018, the results of its operations for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017. Such adjustments are of a normal and recurring nature, other than the adjustments associated with the adoption of ASC Topic 606, Revenue from Contracts with Customers (Topic 606). The results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results for the year ending December 31, 2018, or for any future period. Effective January 1, 2018, the Company adopted the requirements of Topic 606 using the modified retrospective method as discussed below in Note 2: Summary of Significant Accounting Policies. All 2018 amounts and disclosures set forth in this Quarterly Report on Form 10-Q reflect these changes.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies

9 Months Ended

Sep. 30, 2018

Summary of significant accounting policies

Summary of significant accounting policies

2. Summary of Significant Accounting Policies

Principles of Consolidation

Use of Estimates

Segment Information

Research and Development

Revenue Recognition

Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.

Collaborative Arrangements

Fair Value Measurements

Level 1—Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 3—Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Cash and Cash Equivalents

The following amounts were presented as cash, cash equivalents and restricted cash:


	Nine months ended				Nine months ended
	September 30, 2018				September 30, 2017
	Beginning		End		Beginning		End
	of period		of period		of period		of period
Cash and cash equivalents	$	26,591	$	61,604	$	100,297	$	50,756
Restricted cash included in other assets		371		371		371		371
Total cash, cash equivalents and restricted cash per statement of cash flows	$	26,962	$	61,975	$	100,668	$	51,127

Marketable Securities

Other Assets

Accounting for Stock-based Compensation

Net Loss per Share


	Three months ended		Nine months ended
	September 30,		September 30,
	2018	2017	2018	2017
Warrants	110,365	129,491	110,365	129,491
Stock options	3,670,680	3,205,714	3,670,680	3,205,714
	3,781,045	3,335,205	3,781,045	3,335,205

Patent Costs

Income Taxes

Comprehensive Income (Loss)

Concentration of Credit Risk and Off-Balance Sheet Risk

Recently Issued Accounting Pronouncements

XML 18 R8.htm IDEA: XBRL DOCUMENT

Collaboration agreements

9 Months Ended

Sep. 30, 2018

Collaboration Agreements

Collaboration agreements

3. Collaboration agreements

Takeda XMT-1522 strategic partnership

Takeda strategic research and development partnership

Accounting Analysis

The performance obligations and the allocated transaction price as of the date of initial application of Topic 606 are as follows:


	Allocated
Performance obligations	Transaction Price
XMT-1522 license and research services	$	49,828
Joint research committee services for XMT-1522		449
Exclusive license to the first designated target and research services		6,611
Research license to the second designated target and research services		1,017
Material right related to the exclusive license to the second designated target		526
Exclusive license to the third designated target and research services		4,974
Exclusive license to the fourth designated target and research services		3,678
Material right related to the license to the fifth designated target and research services		3,506
Material right related to the license to the sixth designated target and research services		3,506
Material right to license to the seventh designated target and research services		3,506
Material right related to first replacement right for a designated target		3,506
Material right related to the second replacement right to a designated target		3,116
Rights to future technological improvements		1,750
Joint research committee services		150
	$	86,123

The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation or, in the case of certain variable consideration, to one or more performance obligations. The estimated standalone selling prices for performance obligations which include a license and research services, was developed using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an estimated market rate for research services. The estimated standalone selling price of the licenses was established based on comparable transactions. The estimated standalone selling price for the material rights and rights to future technological improvements were developed based on the estimated selling prices of a license or rights received and any fees payable upon exercise of the associated option, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology or exercise the option. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees.

As of September 30, 2018, the Company had $41,104 of deferred revenue related to the Takeda agreements that will be recognized over the remaining performance periods for the applicable obligations.

Takeda invested $10,000 as part of the Company’s IPO.

Merck KGaA

Accounting Analysis

The Company has concluded that each license for a designated target is not distinct from the research services performed related to the designated target as Merck KGaA cannot obtain the benefit of the license without the related research services. Each license for a designated target and the related services performance obligation is considered distinct from every other license for a designated target and related services performance obligation as each research plan is pursued independent of every other research plans for other designated targets.

As of September 30, 2018, the Company had recorded $5,480 in deferred revenue related to the Merck KGaA Agreement that will be recognized over the remaining performance period.

Summary of Contract Assets and Liabilities

The following table presents changes in the balances of our contract assets and liabilities during the three and nine months ended September 30, 2018:


	Balance at
	Beginning						Balance at
	of Period		Additions		Deductions		End of Period
Three months ended September 30, 2018
Contract assets	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	48,208	$	849	$	2,151	$	46,906


	Balance at
	Beginning						Balance at
	of Period		Additions		Deductions		End of Period
Nine months ended September 30, 2018
Contract assets	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	52,439	$	2,373	$	7,906	$	46,906

The impact of the adoption of the new revenue recognition guidance is reflected within the beginning of period balance.


	Three months ended		Nine months ended
	September 30, 2018		September 30, 2018
Revenue recognized in the period from:
Amounts included in the contract liability at the beginning of the period	$	1,760	$	7,515
Performance obligations satisfied in previous periods	$	—	$	—

Other Revenue

XML 19 R9.htm IDEA: XBRL DOCUMENT

Fair value measurements

9 Months Ended

Sep. 30, 2018

Fair value measurements

Fair value measurements

4. Fair value measurements


					Significant
			Quoted Prices		Other		Significant
			in Active		Observable		Unobservable
	Fair		Markets		Inputs		Inputs
	Value		(Level 1)		(Level 2)		(Level 3)
September 30, 2018
Cash and cash equivalents	$	61,604	$	61,604	$	—	$	—
Marketable securities:
U.S. Treasuries		24,455		24,455		—		—
	$	86,059	$	86,059	$	—	$	—


					Significant
			Quoted Prices		Other		Significant
			in Active		Observable		Unobservable
	Fair		Markets		Inputs		Inputs
	Value		(Level 1)		(Level 2)		(Level 3)
December 31, 2017
Cash and cash equivalents	$	26,591	$	26,591	$	—	$	—
Marketable securities:
U.S. Treasuries		62,640		62,640		—		—
Commercial paper		24,931		—		24,931		—
Corporate bonds		11,054		—		11,054		—
	$	125,216	$	89,231	$	35,985	$	—

XML 20 R10.htm IDEA: XBRL DOCUMENT

Marketable securities

9 Months Ended

Sep. 30, 2018

Marketable securities

Marketable securities

5. Marketable securities

The following table summarizes marketable securities held at September 30, 2018 and December 31, 2017:


			Gross		Gross
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
September 30, 2018
U.S. Treasuries	$	24,497	$	—	$	(42)	$	24,455
	$	24,497	$	—	$	(42)	$	24,455


			Gross		Gross
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
December 31, 2017
U.S. Treasuries	$	62,777	$	—	$	(137)	$	62,640
Commercial paper		24,931		—		—		24,931
Corporate bonds		11,066		—		(12)		11,054
	$	98,774	$	—	$	(149)	$	98,625

There were no realized gains or losses on available-for-sale securities during the nine month periods ended September 30, 2018 and 2017.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Accrued expenses

9 Months Ended

Sep. 30, 2018

Accrued expenses

Accrued expenses

6. Accrued expenses

Accrued expenses consist of the following:


	September 30,		December 31,
	2018		2017
Accrued payroll and related expenses	$	2,482	$	3,041
Accrued preclinical, manufacturing and clinical expenses		6,610		3,183
Accrued professional fees		868		492
Accrued other		552		228
	$	10,512	$	6,944

XML 22 R12.htm IDEA: XBRL DOCUMENT

Stockholders' equity (deficit)

9 Months Ended

Sep. 30, 2018

Stockholders' equity (deficit)

Stockholders' deficit

7. Stockholders’ equity

The following table presents the changes in the separate accounts comprising stockholders’ equity for the year ended December 31, 2017 and the nine months ended September 30, 2018, respectively.


				Additional		Accumulated				Stockholders’
	Common Stock			Paid-in		Other Comprehensive		Accumulated		Equity
	Shares	Amount		Capital		Income (Loss)		Deficit		(Deficit)
Balance at December 31, 2016	1,294,352	$	1	$	3,551	$	—	$	(59,171)	$	(55,619)
Change	21,470,665		2		164,467		(149)		(38,707)		125,613
Balance at December 31, 2017	22,765,017		3		168,018		(149)	$	(97,878)		69,994
Change	395,858		—		3,609		107		(43,856)		(40,140)
Balance at September 30, 2018	23,160,875	$	3	$	171,627	$	(42)	$	(141,734)	$	29,854

Preferred stock

As of September 30, 2018, the Company had 25,000,000 shares of authorized preferred stock. No shares of preferred stock have been issued.

Common stock

The holders of the common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors (the Board).


	September 30,	December 31,
	2018	2017
Warrants	110,365	110,365
Stock options	3,670,680	3,205,485
	3,781,045	3,315,850

At-the-market equity offering program

Warrants

XML 23 R13.htm IDEA: XBRL DOCUMENT

Stock options

9 Months Ended

Sep. 30, 2018

Stock options

Stock options

8. Stock options

Stock option plans

A summary of the activity under the Plans is as follows:


		Weighted-		Remaining
	Number	Average		Contractual Life	Aggregate
	of Shares	Exercise Price		(in years)	Intrinsic Value

Options outstanding at January 1, 2018	3,205,485	$	3.44	7.8	$	41,709
Granted	1,121,415		14.36
Exercised	(395,858)		2.17
Cancelled	(260,362)		7.86
Options outstanding at September 30, 2018	3,670,680	$	6.61	7.8	$	17,688

Options exercisable at September 30, 2018	1,822,435	$	3.24	6.9	$	12,873

The weighted-average grant date fair value of options granted during the nine months ended September 30, 2018 and 2017, was $9.45 and $5.27 per share, respectively.

Cash received from the exercise of stock options was $853 and $431 for the nine months ended September 30, 2018 and 2017, respectively.

Stock-based compensation

The Company uses the provisions of ASC 718, Stock Compensation, to account for stock-based awards.


	Three months ended				Nine months ended
	September 30,				September 30,
	2018		2017		2018		2017
Risk-free interest rate	2.9	%	1.9	%	2.7	%	2.2	%
Expected dividend yield	—	%	—	%	—	%	—	%
Expected term (years)	5.85		6.01		6.06		6.22
Expected stock price volatility	73	%	65	%	73	%	67	%

Employee Stock Purchase Plan

XML 24 R14.htm IDEA: XBRL DOCUMENT

Commitments	9 Months Ended
Commitments	Sep. 30, 2018
Commitments
Commitments	9. Commitments Operating leases The Company leases office space in Cambridge, MA under an operating lease, which was last amended in January 2018, which is effective through March 2021. The lease also provided the Company with a tenant improvement allowance of up to $356. The Company fully utilized the allowance and recorded the assets acquired with the allowance as leasehold improvements. The Company recorded the tenant improvement allowance as a deferred lease incentive and is amortizing the deferred lease incentive through a reduction of rent expense ratably over the lease term. In connection with the office lease, the Company has a letter of credit agreement for the benefit of its landlord in the amount of $321 as of each of September 30, 2018 and December 31, 2017, respectively, collateralized by a money market account. The Company classified this amount as restricted cash in the accompanying unaudited condensed consolidated balance sheets. For the three months ended September 30, 2018 and 2017 and for the nine months ended September 30, 2018 and 2017, rent expense was $504, $419, $1,482 and $1,256, respectively. The Company is recording rent expense on a straight-line basis over the term of the lease and has recorded deferred rent in the unaudited condensed consolidated balance sheets, accordingly. License agreements Through September 30, 2018, the Company has licensed intellectual property from two biotechnology companies. The consideration included upfront payments and a commitment to pay annual license fees, milestone payments, and, upon product commercialization, royalties on revenue generated from the sale of products covered by the licenses. The Company recorded milestone payments of $0 and $2,250 during the nine months ended September 30, 2018 and 2017, respectively. Manufacturing services agreement As of September 30, 2018, the Company had a commitment of approximately $5,700 related to manufacturing services that is expected to be incurred during the three months ending December 31, 2018.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Subsequent events	9 Months Ended
Subsequent events	Sep. 30, 2018
Subsequent events
Subsequent events	10. Subsequent events For the purposes of the unaudited financial statements as of September 30, 2018 and the period then ended, the Company has evaluated subsequent events through November 13, 2018, the date the unaudited interim financial statements were issued. There were no items requiring adjustment or disclosure in the consolidated financial statements.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies (Policies)

9 Months Ended

Sep. 30, 2018

Summary of significant accounting policies

Principles of Consolidation

Use of Estimates

Segment Information

Research and Development

Revenue Recognition

Collaborative Arrangements

Fair Value Measurements

Level 1—Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 3—Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Cash and Cash Equivalents

The following amounts were presented as cash, cash equivalents and restricted cash:


	Nine months ended				Nine months ended
	September 30, 2018				September 30, 2017
	Beginning		End		Beginning		End
	of period		of period		of period		of period
Cash and cash equivalents	$	26,591	$	61,604	$	100,297	$	50,756
Restricted cash included in other assets		371		371		371		371
Total cash, cash equivalents and restricted cash per statement of cash flows	$	26,962	$	61,975	$	100,668	$	51,127

Marketable Securities

Other Assets

Accounting for Stock-based Compensation

Net Loss per Share


	Three months ended		Nine months ended
	September 30,		September 30,
	2018	2017	2018	2017
Warrants	110,365	129,491	110,365	129,491
Stock options	3,670,680	3,205,714	3,670,680	3,205,714
	3,781,045	3,335,205	3,781,045	3,335,205

Patent Costs

Income Taxes

Comprehensive Income (Loss)

Concentration of Credit Risk and Off-balance Sheet Risk

Concentration of Credit Risk and Off-Balance Sheet Risk

Recently Issued Accounting Pronouncements

XML 27 R17.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies (Tables)

9 Months Ended

Sep. 30, 2018

Summary of significant accounting policies

Schedule of cash, cash equivalents and restricted cash


	Nine months ended				Nine months ended
	September 30, 2018				September 30, 2017
	Beginning		End		Beginning		End
	of period		of period		of period		of period
Cash and cash equivalents	$	26,591	$	61,604	$	100,297	$	50,756
Restricted cash included in other assets		371		371		371		371
Total cash, cash equivalents and restricted cash per statement of cash flows	$	26,962	$	61,975	$	100,668	$	51,127

Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share


	Three months ended		Nine months ended
	September 30,		September 30,
	2018	2017	2018	2017
Warrants	110,365	129,491	110,365	129,491
Stock options	3,670,680	3,205,714	3,670,680	3,205,714
	3,781,045	3,335,205	3,781,045	3,335,205

XML 28 R18.htm IDEA: XBRL DOCUMENT

Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2018

Collaboration Agreements

Schedule of allocated transaction price of performance obligations


	Allocated
Performance obligations	Transaction Price
XMT-1522 license and research services	$	49,828
Joint research committee services for XMT-1522		449
Exclusive license to the first designated target and research services		6,611
Research license to the second designated target and research services		1,017
Material right related to the exclusive license to the second designated target		526
Exclusive license to the third designated target and research services		4,974
Exclusive license to the fourth designated target and research services		3,678
Material right related to the license to the fifth designated target and research services		3,506
Material right related to the license to the sixth designated target and research services		3,506
Material right to license to the seventh designated target and research services		3,506
Material right related to first replacement right for a designated target		3,506
Material right related to the second replacement right to a designated target		3,116
Rights to future technological improvements		1,750
Joint research committee services		150
	$	86,123

Schedule of changes in the balances of our contract assets and liabilities and recognized revenue

The following table presents changes in the balances of our contract assets and liabilities during the three and nine months ended September 30, 2018:


	Balance at
	Beginning						Balance at
	of Period		Additions		Deductions		End of Period
Three months ended September 30, 2018
Contract assets	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	48,208	$	849	$	2,151	$	46,906


	Balance at
	Beginning						Balance at
	of Period		Additions		Deductions		End of Period
Nine months ended September 30, 2018
Contract assets	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	52,439	$	2,373	$	7,906	$	46,906

The impact of the adoption of the new revenue recognition guidance is reflected within the beginning of period balance.


	Three months ended		Nine months ended
	September 30, 2018		September 30, 2018
Revenue recognized in the period from:
Amounts included in the contract liability at the beginning of the period	$	1,760	$	7,515
Performance obligations satisfied in previous periods	$	—	$	—

XML 29 R19.htm IDEA: XBRL DOCUMENT

Fair value measurements (Tables)

9 Months Ended

Sep. 30, 2018

Fair value measurements

Schedule of assets and liabilities measured and carried at fair value


					Significant
			Quoted Prices		Other		Significant
			in Active		Observable		Unobservable
	Fair		Markets		Inputs		Inputs
	Value		(Level 1)		(Level 2)		(Level 3)
September 30, 2018
Cash and cash equivalents	$	61,604	$	61,604	$	—	$	—
Marketable securities:
U.S. Treasuries		24,455		24,455		—		—
	$	86,059	$	86,059	$	—	$	—


					Significant
			Quoted Prices		Other		Significant
			in Active		Observable		Unobservable
	Fair		Markets		Inputs		Inputs
	Value		(Level 1)		(Level 2)		(Level 3)
December 31, 2017
Cash and cash equivalents	$	26,591	$	26,591	$	—	$	—
Marketable securities:
U.S. Treasuries		62,640		62,640		—		—
Commercial paper		24,931		—		24,931		—
Corporate bonds		11,054		—		11,054		—
	$	125,216	$	89,231	$	35,985	$	—

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

Marketable securities (Tables)

9 Months Ended

Sep. 30, 2018

Marketable securities

Schedule of reconciliation of marketable securities from cost basis to fair value


			Gross		Gross
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
September 30, 2018
U.S. Treasuries	$	24,497	$	—	$	(42)	$	24,455
	$	24,497	$	—	$	(42)	$	24,455


			Gross		Gross
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
December 31, 2017
U.S. Treasuries	$	62,777	$	—	$	(137)	$	62,640
Commercial paper		24,931		—		—		24,931
Corporate bonds		11,066		—		(12)		11,054
	$	98,774	$	—	$	(149)	$	98,625

XML 31 R21.htm IDEA: XBRL DOCUMENT

Accrued expenses (Tables)

9 Months Ended

Sep. 30, 2018

Accrued expenses

Schedule of accrued expenses


	September 30,		December 31,
	2018		2017
Accrued payroll and related expenses	$	2,482	$	3,041
Accrued preclinical, manufacturing and clinical expenses		6,610		3,183
Accrued professional fees		868		492
Accrued other		552		228
	$	10,512	$	6,944

XML 32 R22.htm IDEA: XBRL DOCUMENT

Stockholders' equity (deficit) (Tables)

9 Months Ended

Sep. 30, 2018

Stockholders' equity (deficit)

Schedule of stockholder's equity


				Additional		Accumulated				Stockholders’
	Common Stock			Paid-in		Other Comprehensive		Accumulated		Equity
	Shares	Amount		Capital		Income (Loss)		Deficit		(Deficit)
Balance at December 31, 2016	1,294,352	$	1	$	3,551	$	—	$	(59,171)	$	(55,619)
Change	21,470,665		2		164,467		(149)		(38,707)		125,613
Balance at December 31, 2017	22,765,017		3		168,018		(149)	$	(97,878)		69,994
Change	395,858		—		3,609		107		(43,856)		(40,140)
Balance at September 30, 2018	23,160,875	$	3	$	171,627	$	(42)	$	(141,734)	$	29,854

Schedule for number of common stock reserved for conversion of outstanding Preferred Stock and for the exercise of outstanding stock options and warrants


	September 30,	December 31,
	2018	2017
Warrants	110,365	110,365
Stock options	3,670,680	3,205,485
	3,781,045	3,315,850

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21553-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21488-112644

+ Details

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stock options (Tables)

9 Months Ended

Sep. 30, 2018

Stock options

Schedule of stock option activity under Plan


		Weighted-		Remaining
	Number	Average		Contractual Life	Aggregate
	of Shares	Exercise Price		(in years)	Intrinsic Value

Options outstanding at January 1, 2018	3,205,485	$	3.44	7.8	$	41,709
Granted	1,121,415		14.36
Exercised	(395,858)		2.17
Cancelled	(260,362)		7.86
Options outstanding at September 30, 2018	3,670,680	$	6.61	7.8	$	17,688

Options exercisable at September 30, 2018	1,822,435	$	3.24	6.9	$	12,873

Schedule of weighted average assumptions for estimating fair value of option awards


	Three months ended				Nine months ended
	September 30,				September 30,
	2018		2017		2018		2017
Risk-free interest rate	2.9	%	1.9	%	2.7	%	2.2	%
Expected dividend yield	—	%	—	%	—	%	—	%
Expected term (years)	5.85		6.01		6.06		6.22
Expected stock price volatility	73	%	65	%	73	%	67	%

XML 34 R24.htm IDEA: XBRL DOCUMENT

Nature of business and basis of presentation - IPO (Details) $ / shares in Units, $ in Thousands				9 Months Ended
	Aug. 02, 2017 USD ($) $ / shares shares	Jul. 03, 2017 USD ($) $ / shares shares	Jun. 15, 2017	Sep. 30, 2017 USD ($)
Initial public offering
Reverse stock split			0.2222
IPO
Initial public offering
Issuance of stock (in shares) \| shares		5,000,000
Share price (in dollars per share) \| $ / shares		$ 15.00
Gross proceeds		$ 75,000
Net proceeds from issuance of stock		67,420		$ 67,420
Underwriting discounts and commissions and other offering costs		$ 7,580
Over allotment option
Initial public offering
Issuance of stock (in shares) \| shares	51,977
Share price (in dollars per share) \| $ / shares	$ 15.00
Gross proceeds	$ 780
Net proceeds from issuance of stock	725			$ 725
Underwriting discounts and commissions and other offering costs	$ 55

XML 35 R25.htm IDEA: XBRL DOCUMENT

Nature of business and basis of presentation - Liquidity (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Nature of business and basis of presentation
Net loss	$ (41,825)	$ (38,707)
Accumulated deficit	$ (141,734)	$ (97,878)
Substantial doubt about going concern, within twelve months	false

XML 36 R26.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies - Revenue Recognition (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Collaboration agreements
Deferred revenue	$ 46,906		$ 46,906		$ 48,208		$ 52,439
Collaboration revenue	2,151	$ 6,267	9,405	$ 14,284
Net income (loss)	$ (17,069)	$ (7,732)	$ (41,825)	$ (24,740)
Basic and diluted net income (loss) per share (in dollars per share)	$ (0.74)	$ (0.35)	$ (1.82)	$ (2.94)
Billing term			30 days
Difference between Revenue Guidance in Effect before and after Topic 606 \| ASU 2014-09
Collaboration agreements
Deferred revenue						$ 2,031
Collaboration revenue	$ 2		$ (570)
Net income (loss)	$ 2		$ (570)
Basic and diluted net income (loss) per share (in dollars per share)	$ 0.00		$ (0.02)

XML 37 R27.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Cash, cash equivalents and restricted cash
Cash and cash equivalents	$ 61,604	$ 26,591	$ 50,756	$ 100,297
Restricted cash included in other assets	371	371	371	371
Total cash, cash equivalents and restricted cash per statement of cash flows	$ 61,975	$ 26,962	$ 51,127	$ 100,668
Restricted cash, Balance Sheet Location	us-gaap:OtherAssetsNoncurrent	us-gaap:OtherAssetsNoncurrent	us-gaap:OtherAssetsNoncurrent

XML 38 R28.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies - Other Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Other Assets
Other assets	$ 1,804	$ 371
Restricted cash included in other assets	$ 371	$ 371	$ 371	$ 371
Restricted cash, Balance Sheet Location	us-gaap:OtherAssetsNoncurrent	us-gaap:OtherAssetsNoncurrent	us-gaap:OtherAssetsNoncurrent
Held by service provider	$ 1,433

XML 39 R29.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies - Antidilutive securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Anti-dilutive securities
Anti-dilutive securities	3,781,045	3,335,205	3,781,045	3,335,205
Warrants
Anti-dilutive securities
Anti-dilutive securities	110,365	129,491	110,365	129,491
Stock options.
Anti-dilutive securities
Anti-dilutive securities	3,670,680	3,205,714	3,670,680	3,205,714

XML 40 R30.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies - Risks (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018 USD ($)
Concentration of Credit Risk and Off-balance Sheet Risk
Financial instruments with off-balance sheet risk	$ 0

XML 41 R31.htm IDEA: XBRL DOCUMENT

Collaboration agreements - XMT-1522 Agreement (Details) - XMT-1522 Agreement $ in Thousands	1 Months Ended
	Jan. 31, 2016 USD ($) item	Sep. 30, 2018 USD ($)
Collaboration agreements
Upfront payment received \| $	$ 26,500
Milestone payment upon achievement of IND Clearance Date \| $	20,000
Aggregate milestones, excluding milestone payment upon achievement of IND Clearance Date \| $	288,000
Development milestones \| $	87,000
Regulatory milestones \| $	128,000
Commercial milestones \| $	$ 73,000
Number of separate events to be achieved \| item	9
Number of separate specified patient populations \| item	4
Number of additional unspecified patient populations \| item	1
Number of individual commercial milestones \| item	3
Next potential development milestone payment eligible to receive \| $		$ 12,000
Prior written notice for termination, before initiation of clinical study	30 days
Prior written notice for termination, after initiation of clinical study	90 days
United States, European Union and Japan
Collaboration agreements
Number of regulatory milestones \| item	14
Locations other than United States, European Union and Japan
Collaboration agreements
Number of specified markets in which regulatory milestone is payable \| item	2
Maximum \| United States, European Union and Japan
Collaboration agreements
Number of separate patient populations, regulatory milestone \| item	4

XML 42 R32.htm IDEA: XBRL DOCUMENT

Collaboration agreements - Takeda partnership (Details) $ in Thousands		1 Months Ended	49 Months Ended
	Jan. 31, 2016 USD ($) item	Jan. 31, 2016 USD ($) item	Mar. 31, 2018 USD ($)	Sep. 30, 2018 USD ($) item	Mar. 31, 2014 USD ($) item
2014, 2015 and 2016 Takeda Agreements
Collaboration agreements
Number of targets	7	7
Fee payments received \| $			$ 24,800
Number of targets designated				4
Number of targets for which Tokeda has limited replacement rights				2
Amount to be received for second limited replacement right \| $				$ 500
Aggregate milestones \| $				474,750
Development milestones \| $				50,250
Regulatory milestones \| $				153,000
Commercial milestones \| $				$ 271,500
Number of remaining eligible targets				3
Milestone payable on each of the remaining eligible targets \| $				$ 158,250
Number of individual development milestones per target				4
Number of individual regulatory milestones per target				8
Number of individual commercial milestones				6
Number of thresholds for annual net sales				3
Next potential development milestone payment eligible to receive \| $				$ 750
2015 and 2016 Takeda Agreements
Collaboration agreements
Number of targets	5	5
2014 Tokeda Agreement
Collaboration agreements
Number of targets					2
Amount of option exercise fee for designated targets \| $					$ 1,300
2016 Restated Tokeda Agreement
Collaboration agreements
Number of products entity may elect to co-develop and co-commercialize	1	1
Payment for option to co-develop and co-commercialize product \| $	$ 15,000	$ 15,000
Share of profit related to United States (as a percent)	50.00%	50.00%
Costs incurred in United States (as a percent)	50.00%	50.00%
Global development costs (as a percent)	30.00%	30.00%
Costs incurred specifically for a foreign country borne by Takeda (as a percent)	100.00%	100.00%
Prior written notice for termination period		45 days
Number of targets with respect to breach	1

XML 43 R33.htm IDEA: XBRL DOCUMENT

Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Accounting (Details)	9 Months Ended
	Sep. 30, 2018 item
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Revenue, Practical Expedient, Initial Application and Transition, Nonrestatement of Modified Contract	true
2016 Restated Tokeda Agreement and XMT-1522 Agreement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Number of arrangements	1

XML 44 R34.htm IDEA: XBRL DOCUMENT

Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Performance obligations (Details) - 2016 Restated Tokeda Agreement and XMT-1522 Agreement - USD ($) $ in Thousands	Sep. 30, 2018	Jan. 01, 2018
Performance obligations
Allocated Transaction Price	$ 86,123	$ 86,123
XMT-1522 license and research services
Performance obligations
Allocated Transaction Price	49,828
Joint research committee services for XMT-1522
Performance obligations
Allocated Transaction Price	449
Exclusive license to the first designated target and research services
Performance obligations
Allocated Transaction Price	6,611
Research license to the second designated target and research services
Performance obligations
Allocated Transaction Price	1,017
Material right related to the exclusive license to the second designated target
Performance obligations
Allocated Transaction Price	526
Exclusive license to the third designated target and research services
Performance obligations
Allocated Transaction Price	4,974
Exclusive license to the fourth designated target and research services
Performance obligations
Allocated Transaction Price	3,678
Material right related to the license to the fifth designated target and research services
Performance obligations
Allocated Transaction Price	3,506
Material right related to the license to the sixth designated target and research services
Performance obligations
Allocated Transaction Price	3,506
Material right to license to the seventh designated target and research services
Performance obligations
Allocated Transaction Price	3,506
Material right related to first replacement right for a designated target
Performance obligations
Allocated Transaction Price	3,506
Material right related to the second replacement right to a designated target
Performance obligations
Allocated Transaction Price	3,116
Rights to future technological improvements
Performance obligations
Allocated Transaction Price	1,750
Joint research committee services
Performance obligations
Allocated Transaction Price	$ 150

XML 45 R35.htm IDEA: XBRL DOCUMENT

Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Additional Accounting (Details) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018 USD ($) item $ / shares	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2018 USD ($) item $ / shares	Sep. 30, 2017 USD ($) $ / shares	Dec. 31, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jan. 01, 2018 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Research and development	$ 15,180	$ 11,412	$ 40,098	$ 32,145
Collaboration revenue	2,151	6,267	9,405	14,284
Accounts receivable	586		586		$ 784
Accounts payable	6,729		6,729		3,070
Net loss	$ (17,069)	$ (7,732)	$ (41,825)	$ (24,740)
Basic and diluted net income (loss) per share (in dollars per share) \| $ / shares	$ (0.74)	$ (0.35)	$ (1.82)	$ (2.94)
Deferred revenue	$ 46,906		$ 46,906		52,439	$ 48,208
License and related research and development services, including Phase 1 development and transfer certain materials and know how
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Number of performance obligations \| item	1		1
2016 Restated Tokeda Agreement and XMT-1522 Agreement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Allocated Transaction Price	$ 86,123		$ 86,123				$ 86,123
Estimated amount of research and development fees received or expected to be received included in transaction price							14,023
Amount of milestone payments, which had not been received, included in the estimated transaction price							$ 0
Adjusted transaction price	86,429		86,429
Collaboration revenue	82		4,697
2016 Restated Tokeda Agreement and XMT-1522 Agreement \| Revised estimate of costs to complete research services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Collaboration revenue	(1,380)		(1,380)
Net loss	$ (1,380)		$ (1,380)
Basic and diluted net income (loss) per share (in dollars per share) \| $ / shares	$ (0.06)		$ (0.06)
2016 Restated Tokeda Agreement and XMT-1522 Agreement \| Calculated under Revenue Guidance in Effect before Topic 606
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Collaboration revenue		$ 5,768		$ 12,052
2016 Restated Tokeda Agreement and XMT-1522 Agreement \| Rights to future technological improvements
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Allocated Transaction Price	$ 1,750		$ 1,750
2016 Restated Tokeda Agreement and XMT-1522 Agreement \| Joint research committee services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Allocated Transaction Price	150		150
2016 Restated Tokeda Agreement and XMT-1522 Agreement \| XMT-1522 license and research services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Allocated Transaction Price	49,828		49,828
2016 Restated Tokeda Agreement and XMT-1522 Agreement \| Joint research committee services for XMT-1522
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Allocated Transaction Price	449		449
2014, 2015 and 2016 Takeda Agreements
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Accounts receivable	32		32		454
Accounts payable	530		530
Deferred revenue	41,104		41,104
XMT-1522 Agreement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Research and development	2,210	924	5,013	1,719
ASC 808 costs billed to Takeda	1,165	$ 0	2,959	$ 0
Estimated amount of research and development fees received or expected to be received included in transaction price	$ 9,755		$ 9,755
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 \| 2016 Restated Tokeda Agreement and XMT-1522 Agreement \| XMT-1522 license and research services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Expected recognition period			10 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 \| 2016 Restated Tokeda Agreement and XMT-1522 Agreement \| Joint research committee services for XMT-1522
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Expected recognition period			6 years
Takeda
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction
Proceeds from IPO					$ 10,000

XML 46 R36.htm IDEA: XBRL DOCUMENT

Collaboration agreements - Merck KGaA Agreement (Details) - Merck KGaA $ in Thousands	1 Months Ended	9 Months Ended	36 Months Ended
	Jun. 30, 2014 USD ($) item	Sep. 30, 2018 USD ($) item	Dec. 31, 2017 USD ($) item
Collaboration agreements
Upfront payment received	$ 12,000
Number of targets \| item	6
Number of targets designated \| item		6	6
Aggregate milestones	$ 780,000
Development milestones	84,000
Regulatory milestones	264,000
Sales milestones	$ 432,000
Number of individual development milestones per target \| item	6
Number of individual regulatory milestones per target \| item	5
Number of individual commercial milestones \| item	3
Amount of development milestone payment received		$ 0	$ 3,000
Next potential development milestone payment eligible to receive		$ 500
Prior written notice for termination period		60 days

XML 47 R37.htm IDEA: XBRL DOCUMENT

Collaboration agreements - Merck KGaA Agreement - Accounting (Details) $ in Thousands	3 Months Ended		9 Months Ended		36 Months Ended
	Sep. 30, 2018 USD ($) item	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) item	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($) item	Jun. 30, 2018 USD ($)	Jan. 01, 2018 USD ($)
Collaboration agreements
Revenue, Practical Expedient, Initial Application and Transition, Nonrestatement of Modified Contract			true
Collaboration revenue	$ 2,151	$ 6,267	$ 9,405	$ 14,284
Accounts receivable	586		586		$ 784
Deferred revenue	46,906		46,906		52,439	$ 48,208
Deferred revenue, current	$ 14,151		$ 14,151		$ 21,635
Merck KGaA
Collaboration agreements
Number of targets designated \| item	6		6		6
Allocated Transaction Price							$ 22,875
Estimated amount of research and development fees received or expected to be received included in transaction price	$ 7,070		$ 7,070				7,875
Amount of milestone payment earned					$ 3,000
Amount of milestone payments, which had not been received, included in the estimated transaction price							0
Increase (decrease) in transaction price	(805)		(805)
Adjusted transaction price	22,070		22,070
Collaboration revenue	1,482		2,426
Accounts receivable	163		163		$ 330
Deferred revenue	$ 5,480		$ 5,480
License and corresponding research and development services, First and second targets \| Merck KGaA
Collaboration agreements
Allocated Transaction Price							4,226
License and corresponding research and development services, Third target \| Merck KGaA
Collaboration agreements
Allocated Transaction Price							3,439
License and corresponding research and development services, Fourth target \| Merck KGaA
Collaboration agreements
Allocated Transaction Price							3,439
License and corresponding research and development services, Fifth target \| Merck KGaA
Collaboration agreements
Allocated Transaction Price							3,439
License and corresponding research and development services, Sixth target \| Merck KGaA
Collaboration agreements
Allocated Transaction Price							3,439
Rights to future technological improvements \| Merck KGaA
Collaboration agreements
Allocated Transaction Price							425
Joint research committee services \| Merck KGaA
Collaboration agreements
Allocated Transaction Price							$ 242
Calculated under Revenue Guidance in Effect before Topic 606 \| Merck KGaA
Collaboration agreements
Collaboration revenue		$ 499		$ 2,107
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 \| Rights to future technological improvements \| Merck KGaA
Collaboration agreements
Expected recognition period			10 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 \| Joint research committee services \| Merck KGaA
Collaboration agreements
Expected recognition period			5 years

XML 48 R38.htm IDEA: XBRL DOCUMENT

Collaboration Agreements - Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Contract liabilities
Deferred revenue, Balance at Beginning of Period	$ 48,208	$ 52,439
Deferred revenue, Additions	849	2,373
Deferred revenue, Deductions	2,151	7,906
Deferred revenue, Balance at End of Period	46,906	46,906
Revenue recognized in the period from:
Amounts included in the contract liability at the beginning of the period	$ 1,760	$ 7,515

XML 49 R39.htm IDEA: XBRL DOCUMENT

Collaboration Agreements - Other Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Collaboration agreements
Collaboration revenue	$ 2,151	$ 6,267	$ 9,405	$ 14,284
Accounts receivable	586		586		$ 784
Asana BioSciences
Collaboration agreements
Next potential milestone payment eligible to receive	2,500		2,500
Accounts receivable	391		391
Asana BioSciences \| Limited services
Collaboration agreements
Collaboration revenue	$ 587		782
Asana BioSciences \| Milestone
Collaboration agreements
Collaboration revenue			$ 1,500
Asana BioSciences \| Calculated under Revenue Guidance in Effect before Topic 606 \| Limited services
Collaboration agreements
Collaboration revenue		$ 0		$ 125

XML 50 R40.htm IDEA: XBRL DOCUMENT

Fair value measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Fair value measurements
Marketable securities	$ 24,455	$ 98,625
Transfers between fair value measurement level 1 to level 2	0	0	$ 0
Transfers between fair value measurement level 2 to level 1	0	0	$ 0
Recurring basis
Fair value measurements
Cash and cash equivalents	61,604	26,591
Total assets	86,059	125,216
U.S. Treasuries \| Recurring basis
Fair value measurements
Marketable securities	24,455	62,640
Commercial paper \| Recurring basis
Fair value measurements
Marketable securities		24,931
Corporate bonds \| Recurring basis
Fair value measurements
Marketable securities		11,054
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring basis
Fair value measurements
Cash and cash equivalents	61,604	26,591
Total assets	86,059	89,231
Quoted Prices in Active Markets for Identical Assets (Level 1) \| U.S. Treasuries \| Recurring basis
Fair value measurements
Marketable securities	$ 24,455	62,640
Significant Other Observable Inputs (Level 2) \| Recurring basis
Fair value measurements
Total assets		35,985
Significant Other Observable Inputs (Level 2) \| Commercial paper \| Recurring basis
Fair value measurements
Marketable securities		24,931
Significant Other Observable Inputs (Level 2) \| Corporate bonds \| Recurring basis
Fair value measurements
Marketable securities		$ 11,054

XML 51 R41.htm IDEA: XBRL DOCUMENT

Marketable securities (Details) $ in Thousands	9 Months Ended
Marketable securities (Details) $ in Thousands	Sep. 30, 2018 USD ($) security	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Marketable securities
Amortized Cost	$ 24,497		$ 98,774
Gross Unrealized Losses	(42)		(149)
Marketable securities	$ 24,455		98,625
Number of securities in an unrealized loss position \| security	7
Aggregate fair value of securities in an unrealized loss position for less than 12 months	$ 24,455
Securities in an unrealized loss position for more than 12 months	0
Realized gains on available-for-sale securities	0	$ 0
Realized losses on available-for-sale securities	0	$ 0
U.S. Treasuries
Marketable securities
Amortized Cost	24,497		62,777
Gross Unrealized Losses	(42)		(137)
Marketable securities	$ 24,455		62,640
Commercial paper
Marketable securities
Amortized Cost			24,931
Marketable securities			24,931
Corporate bonds
Marketable securities
Amortized Cost			11,066
Gross Unrealized Losses			(12)
Marketable securities			$ 11,054

XML 52 R42.htm IDEA: XBRL DOCUMENT

Accrued expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accrued expenses
Accrued payroll and related expenses	$ 2,482	$ 3,041
Accrued preclinical, manufacturing and clinical expenses	6,610	3,183
Accrued professional fees	868	492
Accrued other	552	228
Total	$ 10,512	$ 6,944

XML 53 R43.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Statement (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Increase (Decrease) in Stockholders' Equity
Balance at beginning of period	$ 69,994	$ (55,619)
Change	(40,140)	125,613
Balance at end of period	$ 29,854	$ 69,994
Common stock
Increase (Decrease) in Stockholders' Equity
Balance at beginning of period (in shares)	22,765,017	1,294,352
Balance at beginning of period	$ 3	$ 1
Change (in shares)	395,858	21,470,665
Change		$ 2
Balance at end of period (in shares)	23,160,875	22,765,017
Balance at end of period	$ 3	$ 3
Additional paid-in capital
Increase (Decrease) in Stockholders' Equity
Balance at beginning of period	168,018	3,551
Change	3,609	164,467
Balance at end of period	171,627	168,018
Accumulated other comprehensive income/(loss)
Increase (Decrease) in Stockholders' Equity
Balance at beginning of period	(149)
Change	107	(149)
Balance at end of period	(42)	(149)
Accumulated deficit
Increase (Decrease) in Stockholders' Equity
Balance at beginning of period	(97,878)	(59,171)
Change	(43,856)	(38,707)
Balance at end of period	$ (141,734)	$ (97,878)

XML 54 R44.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Stock and warrants (Details)	9 Months Ended	12 Months Ended
Stockholders' Equity - Stock and warrants (Details)	Sep. 30, 2018 Vote $ / shares shares	Dec. 31, 2013 shares	Dec. 31, 2017 shares
Preferred stock
Preferred stock, shares authorized	25,000,000		25,000,000
Preferred stock, shares issued	0		0
Common stock
Number of votes for each shares held \| Vote	1
Warrants
Number of shares into which warrant issued during period may be converted		129,491
Warrant exercise price per share (in dollars per share) \| $ / shares	$ 0.05
Contractual life of warrants	10 years
Number of shares of common stock into which warrants may be converted	110,365
Stock options.
Common stock
Number of shares reserved for future issuance	3,670,680		3,205,485
Warrants
Common stock
Number of shares reserved for future issuance	110,365		110,365
Warrants and options
Common stock
Number of shares reserved for future issuance	3,781,045		3,315,850

XML 55 R45.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - At-the-market equity offering program (Details) - ATM - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Jul. 02, 2018
Offering program
Amount of shares authorized to be offered and sold		$ 75,000
Number of shares sold	0

XML 56 R46.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
Stockholders' Equity - Warrants (Details) - $ / shares	Sep. 30, 2018	Dec. 31, 2013
Warrants
Number of shares into which warrant issued during period may be converted		129,491
Warrant exercise price per share (in dollars per share)	$ 0.05
Contractual life of warrants	10 years
Number of shares of common stock into which warrants may be converted	110,365

XML 57 R47.htm IDEA: XBRL DOCUMENT

Stock options - Plans (Details) - shares		1 Months Ended	9 Months Ended
Stock options - Plans (Details) - shares	Jan. 01, 2018	Jun. 30, 2017	Sep. 30, 2018	Dec. 31, 2017
Stock options
Number of shares outstanding			3,670,680	3,205,485
2007 Plan
Stock options
Number of shares outstanding		3,141,625
2017 Plan
Stock options
Number of shares authorized		2,255,000
Cumulative increase in number of shares issuable (as a percent)		4.00%
Additional shares authorized	910,600
Number of shares available for future issuance			1,288,227
Vesting period (in years)			4 years
2017 Plan \| Maximum
Stock options
Expiration period			10 years

XML 58 R48.htm IDEA: XBRL DOCUMENT

Stock options - Activity under stock option plan (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Number of Shares
Outstanding at beginning of period (in shares)	3,205,485
Granted (in shares)	1,121,415
Exercised (in shares)	(395,858)
Cancelled (in shares)	(260,362)
Outstanding at end of period (in shares)	3,670,680		3,205,485
Options exercisable, at end of period (in shares)	1,822,435
Weighted- Average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 3.44
Granted (in dollars per share)	14.36
Exercised (in dollars per share)	2.17
Cancelled (in dollars per share)	7.86
Outstanding at end of period (in dollars per share)	6.61		$ 3.44
Options exercisable, at end of period (in dollars per share)	$ 3.24
Additional Disclosures
Remaining Contractual Life, Options outstanding	7 years 9 months 18 days		7 years 9 months 18 days
Remaining Contractual Life, Options exercisable	6 years 10 months 24 days
Aggregate Intrinsic Value, Options outstanding (in dollars)	$ 17,688		$ 41,709
Aggregate Intrinsic Value, Options exercisable (in dollars)	$ 12,873
Weighted-average grant date fair value of options granted (in dollars per share)	$ 9.45	$ 5.27
Cash received from the exercise of stock options (in dollars)	$ 853	$ 431

XML 59 R49.htm IDEA: XBRL DOCUMENT

Stock options - Stock based compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock options
Share-based compensation charge	$ 1,053	$ 373	$ 2,756	$ 990
Unrecognized stock compensation cost	$ 11,129		$ 11,129
Weighted-average amortization period of unrecognized stock compensation cost			2 years 10 months 24 days

XML 60 R50.htm IDEA: XBRL DOCUMENT

Stock options - Fair value of each option award (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Weighted average fair value assumptions
Risk-free interest rate (as a percent)	2.90%	1.90%	2.70%	2.20%
Expected term	5 years 10 months 6 days	6 years 4 days	6 years 22 days	6 years 2 months 19 days
Expected stock price volatility (as a percent)	73.00%	65.00%	73.00%	67.00%

XML 61 R51.htm IDEA: XBRL DOCUMENT

Stock options - Employee Stock Purchase Plan (Details)	Sep. 30, 2018 shares
Employee Stock Purchase Plan
Employee Stock Purchase Plan
Number of shares reserved for future issuance	225,000

XML 62 R52.htm IDEA: XBRL DOCUMENT

Commitments - Operating leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Operating leases
Letter of credit for security deposit	$ 321		$ 321		$ 321
Rent expense	504	$ 419	1,482	$ 1,256
Maximum
Operating leases
Tenant improvement allowance	$ 356		$ 356

XML 63 R53.htm IDEA: XBRL DOCUMENT

Commitments - License agreements (Details) $ in Thousands	9 Months Ended
Commitments - License agreements (Details) $ in Thousands	Sep. 30, 2018 USD ($) item	Sep. 30, 2017 USD ($)
License agreements
Commitments
Number of biotechnology companies where Company has licensed intellectual property \| item	2
Milestone payments	$ 0	$ 2,250
Manufacturing services agreement
Commitments
Amount of commitment	$ 5,700

EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
&PO=V]R M:W-H965T&UL M4$L! A0#% @ \(EM3=^OJ^K= @ + L !D ( !3'P M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M\(EM3:FT'-!T @ [@@ !D ( !MX, 'AL+W=O P &0 @ '' MC@ >&PO=V]R:W-H965T0 !X;"]W;W)K&UL4$L! A0#% @ \(EM3135T;<6 @ \ 4 !D M ( !-I, 'AL+W=O&PO&POX! !4( &@ @ %=) $ >&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #PB6U-C*-T4=$! M C( $P @ &#)@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 /@ ^ .00 "%* $ ! end XML 65 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 156 243 1 false 66 0 false 7 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.mersana.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://www.mersana.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.mersana.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.mersana.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00300 - Statement - Consolidated Statements of Cash Flows Sheet http://www.mersana.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 10101 - Disclosure - Nature of business and basis of presentation Sheet http://www.mersana.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation Nature of business and basis of presentation Notes 6 false false R7.htm 10201 - Disclosure - Summary of significant accounting policies Sheet http://www.mersana.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 7 false false R8.htm 10301 - Disclosure - Collaboration agreements Sheet http://www.mersana.com/role/DisclosureCollaborationAgreements Collaboration agreements Notes 8 false false R9.htm 10401 - Disclosure - Fair value measurements Sheet http://www.mersana.com/role/DisclosureFairValueMeasurements Fair value measurements Notes 9 false false R10.htm 10501 - Disclosure - Marketable securities Sheet http://www.mersana.com/role/DisclosureMarketableSecurities Marketable securities Notes 10 false false R11.htm 10601 - Disclosure - Accrued expenses Sheet http://www.mersana.com/role/DisclosureAccruedExpenses Accrued expenses Notes 11 false false R12.htm 10701 - Disclosure - Stockholders' equity (deficit) Sheet http://www.mersana.com/role/DisclosureStockholdersEquityDeficit Stockholders' equity (deficit) Notes 12 false false R13.htm 10801 - Disclosure - Stock options Sheet http://www.mersana.com/role/DisclosureStockOptions Stock options Notes 13 false false R14.htm 10901 - Disclosure - Commitments Sheet http://www.mersana.com/role/DisclosureCommitments Commitments Notes 14 false false R15.htm 11001 - Disclosure - Subsequent events Sheet http://www.mersana.com/role/DisclosureSubsequentEvents Subsequent events Notes 15 false false R16.htm 20202 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.mersana.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 16 false false R17.htm 30203 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://www.mersana.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of significant accounting policies (Tables) Tables http://www.mersana.com/role/DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 30303 - Disclosure - Collaboration Agreements (Tables) Sheet http://www.mersana.com/role/DisclosureCollaborationAgreementsTables Collaboration Agreements (Tables) Tables 18 false false R19.htm 30403 - Disclosure - Fair value measurements (Tables) Sheet http://www.mersana.com/role/DisclosureFairValueMeasurementsTables Fair value measurements (Tables) Tables http://www.mersana.com/role/DisclosureFairValueMeasurements 19 false false R20.htm 30503 - Disclosure - Marketable securities (Tables) Sheet http://www.mersana.com/role/DisclosureMarketableSecuritiesTables Marketable securities (Tables) Tables http://www.mersana.com/role/DisclosureMarketableSecurities 20 false false R21.htm 30603 - Disclosure - Accrued expenses (Tables) Sheet http://www.mersana.com/role/DisclosureAccruedExpensesTables Accrued expenses (Tables) Tables http://www.mersana.com/role/DisclosureAccruedExpenses 21 false false R22.htm 30703 - Disclosure - Stockholders' equity (deficit) (Tables) Sheet http://www.mersana.com/role/DisclosureStockholdersEquityDeficitTables Stockholders' equity (deficit) (Tables) Tables http://www.mersana.com/role/DisclosureStockholdersEquityDeficit 22 false false R23.htm 30803 - Disclosure - Stock options (Tables) Sheet http://www.mersana.com/role/DisclosureStockOptionsTables Stock options (Tables) Tables http://www.mersana.com/role/DisclosureStockOptions 23 false false R24.htm 40101 - Disclosure - Nature of business and basis of presentation - IPO (Details) Sheet http://www.mersana.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationIpoDetails Nature of business and basis of presentation - IPO (Details) Details http://www.mersana.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation 24 false false R25.htm 40102 - Disclosure - Nature of business and basis of presentation - Liquidity (Details) Sheet http://www.mersana.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails Nature of business and basis of presentation - Liquidity (Details) Details 25 false false R26.htm 40201 - Disclosure - Summary of significant accounting policies - Revenue Recognition (Details) Sheet http://www.mersana.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails Summary of significant accounting policies - Revenue Recognition (Details) Details 26 false false R27.htm 40202 - Disclosure - Summary of significant accounting policies - Cash and Cash Equivalents (Details) Sheet http://www.mersana.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails Summary of significant accounting policies - Cash and Cash Equivalents (Details) Details 27 false false R28.htm 40203 - Disclosure - Summary of significant accounting policies - Other Assets (Details) Sheet http://www.mersana.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails Summary of significant accounting policies - Other Assets (Details) Details 28 false false R29.htm 40204 - Disclosure - Summary of significant accounting policies - Antidilutive securities (Details) Sheet http://www.mersana.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetails Summary of significant accounting policies - Antidilutive securities (Details) Details 29 false false R30.htm 40205 - Disclosure - Summary of significant accounting policies - Risks (Details) Sheet http://www.mersana.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksDetails Summary of significant accounting policies - Risks (Details) Details http://www.mersana.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 40301 - Disclosure - Collaboration agreements - XMT-1522 Agreement (Details) Sheet http://www.mersana.com/role/DisclosureCollaborationAgreementsXmt1522AgreementDetails Collaboration agreements - XMT-1522 Agreement (Details) Details 31 false false R32.htm 40302 - Disclosure - Collaboration agreements - Takeda partnership (Details) Sheet http://www.mersana.com/role/DisclosureCollaborationAgreementsTakedaPartnershipDetails Collaboration agreements - Takeda partnership (Details) Details 32 false false R33.htm 40303 - Disclosure - Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Accounting (Details) Sheet http://www.mersana.com/role/DisclosureCollaborationAgreements2016TakedaAndXmt1522AgreementsAccountingDetails Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Accounting (Details) Details 33 false false R34.htm 40304 - Disclosure - Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Performance obligations (Details) Sheet http://www.mersana.com/role/DisclosureCollaborationAgreements2016TakedaAndXmt1522AgreementsPerformanceObligationsDetails Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Performance obligations (Details) Details 34 false false R35.htm 40305 - Disclosure - Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Additional Accounting (Details) Sheet http://www.mersana.com/role/DisclosureCollaborationAgreements2016TakedaAndXmt1522AgreementsAdditionalAccountingDetails Collaboration agreements - 2016 Takeda and XMT-1522 Agreements - Additional Accounting (Details) Details 35 false false R36.htm 40306 - Disclosure - Collaboration agreements - Merck KGaA Agreement (Details) Sheet http://www.mersana.com/role/DisclosureCollaborationAgreementsMerckKgaaAgreementDetails Collaboration agreements - Merck KGaA Agreement (Details) Details 36 false false R37.htm 40307 - Disclosure - Collaboration agreements - Merck KGaA Agreement - Accounting (Details) Sheet http://www.mersana.com/role/DisclosureCollaborationAgreementsMerckKgaaAgreementAccountingDetails Collaboration agreements - Merck KGaA Agreement - Accounting (Details) Details 37 false false R38.htm 40308 - Disclosure - Collaboration Agreements - Contract Assets and Liabilities (Details) Sheet http://www.mersana.com/role/DisclosureCollaborationAgreementsContractAssetsAndLiabilitiesDetails Collaboration Agreements - Contract Assets and Liabilities (Details) Details 38 false false R39.htm 40309 - Disclosure - Collaboration Agreements - Other Revenue (Details) Sheet http://www.mersana.com/role/DisclosureCollaborationAgreementsOtherRevenueDetails Collaboration Agreements - Other Revenue (Details) Details 39 false false R40.htm 40401 - Disclosure - Fair value measurements (Details) Sheet http://www.mersana.com/role/DisclosureFairValueMeasurementsDetails Fair value measurements (Details) Details http://www.mersana.com/role/DisclosureFairValueMeasurementsTables 40 false false R41.htm 40501 - Disclosure - Marketable securities (Details) Sheet http://www.mersana.com/role/DisclosureMarketableSecuritiesDetails Marketable securities (Details) Details http://www.mersana.com/role/DisclosureMarketableSecuritiesTables 41 false false R42.htm 40601 - Disclosure - Accrued expenses (Details) Sheet http://www.mersana.com/role/DisclosureAccruedExpensesDetails Accrued expenses (Details) Details http://www.mersana.com/role/DisclosureAccruedExpensesTables 42 false false R43.htm 40701 - Disclosure - Stockholders' Equity - Statement (Details) Sheet http://www.mersana.com/role/DisclosureStockholdersEquityStatementDetails Stockholders' Equity - Statement (Details) Details 43 false false R44.htm 40702 - Disclosure - Stockholders' Equity - Stock and warrants (Details) Sheet http://www.mersana.com/role/DisclosureStockholdersEquityStockAndWarrantsDetails Stockholders' Equity - Stock and warrants (Details) Details 44 false false R45.htm 40703 - Disclosure - Stockholders' Equity - At-the-market equity offering program (Details) Sheet http://www.mersana.com/role/DisclosureStockholdersEquityAtMarketEquityOfferingProgramDetails Stockholders' Equity - At-the-market equity offering program (Details) Details 45 false false R46.htm 40704 - Disclosure - Stockholders' Equity - Warrants (Details) Sheet http://www.mersana.com/role/DisclosureStockholdersEquityWarrantsDetails Stockholders' Equity - Warrants (Details) Details 46 false false R47.htm 40801 - Disclosure - Stock options - Plans (Details) Sheet http://www.mersana.com/role/DisclosureStockOptionsPlansDetails Stock options - Plans (Details) Details 47 false false R48.htm 40802 - Disclosure - Stock options - Activity under stock option plan (Details) Sheet http://www.mersana.com/role/DisclosureStockOptionsActivityUnderStockOptionPlanDetails Stock options - Activity under stock option plan (Details) Details 48 false false R49.htm 40803 - Disclosure - Stock options - Stock based compensation (Details) Sheet http://www.mersana.com/role/DisclosureStockOptionsStockBasedCompensationDetails Stock options - Stock based compensation (Details) Details 49 false false R50.htm 40804 - Disclosure - Stock options - Fair value of each option award (Details) Sheet http://www.mersana.com/role/DisclosureStockOptionsFairValueOfEachOptionAwardDetails Stock options - Fair value of each option award (Details) Details 50 false false R51.htm 40805 - Disclosure - Stock options - Employee Stock Purchase Plan (Details) Sheet http://www.mersana.com/role/DisclosureStockOptionsEmployeeStockPurchasePlanDetails Stock options - Employee Stock Purchase Plan (Details) Details 51 false false R52.htm 40901 - Disclosure - Commitments - Operating leases (Details) Sheet http://www.mersana.com/role/DisclosureCommitmentsOperatingLeasesDetails Commitments - Operating leases (Details) Details 52 false false R53.htm 40902 - Disclosure - Commitments - License agreements (Details) Sheet http://www.mersana.com/role/DisclosureCommitmentsLicenseAgreementsDetails Commitments - License agreements (Details) Details 53 false false All Reports Book All Reports mrsn-20180930.xml mrsn-20180930.xsd mrsn-20180930_cal.xml mrsn-20180930_def.xml mrsn-20180930_lab.xml mrsn-20180930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 70 0001558370-18-009290-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-18-009290-xbrl.zip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�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